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AND SUBSTANDARD MEDICINES 
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Major Professor:  Muhammad H. Zaman, Ph.D. Professor of Biomedical Engineering,  
     Professor, Howard Hughes Medical Institute 
ABSTRACT 
The World Health Organization estimates that about 10-30% of pharmaceuticals in the 
world are either substandard or counterfeit. The number is even higher in the developing 
countries. From a public health perspective, a key contributor to the development and 
proliferation drug resistant strains of infections, including tuberculosis (TB), malaria and 
other infections that are leading killers in resource limited settings is poor quality 
medicines. Most of the main causes are profit driven corruption in many pharmaceutical 
companies, the poor manufacture and quality control, and/or the inappropriate storage 
conditions. Poor quality drugs lead to loss of life, create morbidity, strain the financial 
structure of the health system and lead to long-term drug resistance that affects us all. 
 The current technology for screening poor quality drugs can be divided into 2 categories: 
the high end, precise and high cost technologies (such as High Performance Liquid 
Chromatography) and lower cost and qualitative technologies (such as Thin-Layered 
Chromatography). The high-end methods can give a precise measurement of active 
pharmaceutical ingredient (API) concentration and the presence of impurities in the 
  viii 
tablets, but require trained personnel, advanced machine and lab set up, not suitable for 
field testing where most of poor quality pharmaceuticals have been found. The lower cost 
techniques require little training and simple equipment to operate at a relatively 
inexpensive price, but only gives qualitative results. In addition, most of current methods 
do not look at the dissolution profile of the tablets simultaneously with the concentration 
of API. Therefore, we propose to develop an assay that can quantify the concentrations of 
multiple APIs simultaneously and measure dissolution rates.  
In order to address current gaps in knowledge, my research proposal has three main parts 
in the assay development: 1) Development of an fluorescent/luminescent assay for 
detection of counterfeit/substandard antimalarial using small-molecules-based methods 
and field testing in Ghana; 2) Development of a fluorescent assay for detection of water-
soluble pharmaceuticals using SELEX; and 3) Design a detection platform using 
microfluidic chips for real time quantification of multiple active pharmaceutical 
ingredients. For proof-of-concept, an antimalarial drug (artesunate and amodiaquine) and 
antibacterial antibiotics (sulfamethoxazole and trimethoprim) are selected to demonstrate 
the probe development and test the chip performance. Overall, the assay will be rapid, 
robust, portable, inexpensive, multiplexed, quantitative, specific, and sensitive. At a big 
picture level, emphasizing drug quality and creating robust mechanisms of drug testing 
will improve health outcomes and enhance treatment efficacy in resource limited settings.   
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Chapter 1: Introduction 
1.1 POOR-QUALITY MEDICINE AND PROBLEMS 
Globally, it is estimated that about 10–30% of pharmaceuticals are of poor quality. 
Poor-quality drugs lead to long-term drug resistance, create morbidity, and strain the 
financial structure of the health system. The problem of bad medicines is more severe in 
Africa and Southeast Asia since the patients can buy smuggled drugs easily of market 
like in Figure 1.1. In those low and medium incomes countries, one of the key factors to 
the development and proliferation of drug resistant strains of infections, including 
tuberculosis (TB), malaria and other infections is the use of poor quality medicines. 
It is difficult to track down and identify these substandard and counterfeit medicines 
since they can be found everywhere from pharmacy, clinical center, hospitals to illegal 
markets and unregulated websites (World Health Organization, 2016). 
One of the main causes was the increase in drug-resistant cases of infectious 
disease like tuberculosis. In 2013, Roger Bate did a study on the quality of anti-
tuberculosis around the globe. The results turned out that 9.1% of the samples globally 
failed the analysis and 16.6% of the medicines collected in Africa did not pass the 
chemical analysis tests (Bate, Jensen, Hess, Mooney, & Milligan, 2013). Moreover, the 
penalties for manufacturing counterfeit drugs were too low compared to the profit. For 
examples, in 2009, five tons of medicines in Uganda were found to be counterfeit, but 
only 5 people were convicted and had to pay only a fine of $520 (Putze, Conway, Reilly, 
& Madrid, 2008). Weak drug regulation and licensing together with corruption and lack 
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of manpower has made Africa become a profitable market for counterfeit and 
substandard medicines (Sambria, 2013). 
The presence of counterfeit and substandard medicines is an even more serious 
issue in Asia since this is where most of the factories of fake drugs coming from. It has 
been estimated that about 20% of generic drugs and 40% of the API in all medications in 
the United States are from India and China (Kaufman, 2007). In China, an investigation 
on fake drugs in 2008 showed that 66% of pharmacies sold counterfeit drugs (Qi, 2008). 
In India, according to a study conducted by Associated Chambers of Commerce and 
Industry of India, 20% of drugs sold in India were of poor quality. Among those, 60% of 
them did not have enough active ingredients, 19% did not have correct active ingredients, 
and 16% had inappropriate ingredients (Press Trust Of India, 2008). In Southeast Asia, 
about 15% of the drugs in the market were of poor quality and the most common 
counterfeit and substandard medicines were antimalarial, anti-tuberculosis, antibiotics, 
etc., due to the high prevalence of the infectious diseases in the areas. This led to drug-
resistance developing in the region (Raymond, 2009). It has been reported that about 38-
53% of artesunate found in the pharmacies and shops were counterfeit (Day, 2006). 
In the United States, the authorities have been catching and reporting multiple 
cases of counterfeit drugs in weight loss, Botox, and hair loss treatments. Other 
medicines like AIDS medications, high-cholesterol drugs (Lipitor), and common 
medicine like aspirin were found to be counterfeit across the United States (Appleby, 
2003; The Associated Press, 2003). Recently, an investigation in the pharmacies in New 
York State on the herbal supplements led by New York Attorney General Eric 
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Schneiderman showed that only 21% of the herbal supplement collected at Target, GNC, 
Walmart, and Walgreen Co contained DNA belonged to the plant stated on the label 
(CBS, 2015). 
In Europe, a report conducted by Pfizer in 2010 showed that the market for counterfeit 
and substandard here was worth $14.3 billion a year (Putze et al., 2008). Most of those 
poor-quality drugs were from China, India, Pakistan, and other Asian countries. About 11 
million medications in Europe were fake in 2009 (Myers, 2010). The most common way 
to purchase those fake drugs was from the internet pharmacies where the prices were 
cheaper than the registered drugs at the authorized distribution channels.  
These facts above showed that counterfeit and substandard medicines are 
problems that every country in the world has to face. To combat against this problem, 
stricter regulations (regular drug quality testing/inspection) and penalties within the 
country combining with the international agreement about border control and 
import/export policies has to be established. 
1.2 SUBSTANDARD VERSUS COUNTERFEIT 
Poor quality medicines are classified into two different categories. The first one is 
called “counterfeit”. In 1992, WHO together with the pharmaceutical industry have 
defined “counterfeit” as: 
“A counterfeit medicine is one which is deliberately and fraudulently mislabeled 
with respect to identity and/or source. Counterfeiting can apply to both branded 
and generic products and counterfeit products may include products with the 
correct ingredients or with the wrong ingredients, without active ingredients, with 
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insufficient active ingredients or with fake packaging.”(World Health 
Organization, 1999a) 
This implied that any products in the pharmaceutical markets with falsified label 
either packages or the content of the active pharmaceutical ingredients (API) would be 
identified as counterfeit. Most of the counterfeit medicines are produced due to profitable 
corruption with the intent to deceive the consumers. Different countries may have 
modified the definition to adapt to their own regulations.  
On the other hands, substandard medicine is defined by WHO as medicines with 
poor quality due to many reasons: 
“…genuine medicines produced by manufacturers authorized by the NMRA 
[national medicines regulatory authorities] which do not meet the quality 
specifications set for them by national standards.”(World Health Organization, 
2005) 
One of the causes is poor manufacturing practices and quality control at the 
pharmaceutical companies. The medicines may not have correct doses or contaminate 
with other pharmaceuticals produced in the same production line or are pressed 
incorrectly into tablets that cause the API to release inefficiently when taken by patients. 
The other cause is due to the inappropriate storage conditions (temperature, humidity,..) 
at the distribution channels along supply chains. 
1.3 INTERNATIONAL RESPONSE 
There are two ways to approaches to prevent the spread of fake drugs: to stop the 
production of the poor-quality pharmaceuticals in the countries where those drugs are 
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manufactured and to stop the distribution channels of these drugs. In the first approach, a 
strict regulation and severe penalties for committing the distribution of counterfeit drugs. 
For examples, in China, the Chinese State Food and Drug Administration recommended 
that depending on the severity of the drug counterfeiting crime, the convicted person 
could be charged of the life imprisonment or death penalty (Huang, 2007). In 2011, due 
to Memorandum of Understanding between India and Nigeria, the Indian government 
started to enforce the life sentence penalty to Indian person who committed the supply 
and transfer of counterfeit drug to Nigeria (Edomaruse, 2011). On the other hand, to stop 
the distribution channel of the fake drugs, the United Kingdom, like many other countries 
in Europe, warned people to stop buying certain brands of drug that were inspected and 
confirmed to be counterfeit or substandard. In the United States, the Food and Drug 
Administration is cooperating with the U.S supply chain stakeholder to develop a strategy 
to track down and inspect the counterfeit drugs while informing and educating the 
consumers about the risk and the potential spread of certain counterfeit drugs 
(Sklamberg, 2014). In 1992, the United State Pharmacopeia partnered with United States 
Agency of International Development to establish the Promoting the Quality of 
Medicines program to help combat counterfeit and substandard medicines in the 
developing countries. The program assists 35 countries around the world to ensure the 
quality control of medicines, increase the distribution of the good quality medicines, 
decrease the spread of bad medicines, and provide the technical support for testing the 
quality of pharmaceuticals (United States Pharmacopeia, 2012b). 
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Overall, counterfeit and substandard medicine has become a serious problem that 
needs the attention and collaboration of countries and international organizations to put 
all efforts together to fight against them with the potential to save the lives of million 
people around the world. 
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1.4 FIGURES  
 
 
Figure 1.1: A shop at Adjame market in Abidjan, Ivory Coast to sell medicines freely to 
consumers  
People can buy smuggled drugs for cheaper price, but with a high chance of buying 
counterfeit and substandard medicines (Knox, 2013). 
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Chapter 2 Current testing approaches and technologies 
2.1 TESTING APPROACHES 
Given the pervasive nature of the problem and its substantial impact on health 
systems, there is a dire need for technologies and solutions to address this problem 
comprehensively. The current testing approaches and guidelines from the United States 
Pharmacopeia and World Health Organization are divided into 4 categories in the testing 
order: visual inspection, field, testing, laboratory testing, and dissolution (World Health 
Organization, 1999b). 
2.1.1 Visual Inspection 
According to the International Council of Nurses and the United States of 
Pharmacopeia, the visual inspection of medicines is divided into 2 categories: packaging 
and physical characteristics of the tablet/capsules. For the packaging inspection, the 
container and the closure of the medicine would be inspected first to check if the safety 
seal is still intact. The safety seal is to ensure that the tablet/capsules are protected and 
stored in appropriate conditions to maintain the shelf life. A broken seal can alter the 
shelf life of the APIs due to the exposure to the environmental conditions. Moreover, it 
also means that the content of the API can be switched to other medicine for corrupted 
profit. The second checkpoint is to check if the labels are correct and authentic. These 
include brand name, API name, the manufacture name and address, dosage information, 
the batch number, the manufacture and expiration date, and the storage information. The 
last thing to check for the packaging is the leaflet or package insert to see if the ink’s 
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color and quality is good and the information match with the one on the outside packages. 
For the physical characteristics testing, the tester should check for the uniformity of the 
shape, size, color, and texture. The tablet should not have any cracked, contamination 
spot, inconsistent markings, and peculiar smell (United States Pharmacopeia, 2015).  
2.1.2 Field testing 
The samples that pass the visual inspection would be subjected to the field testing 
for the rough estimation of the chemical analysis. The recommended testing method in 
the field by WHO is Minilab from Global Pharma Health Fund using Thin-Layered 
Chromatography (Affum et al., 2013). The method provides a qualitative answer about 
the chemical content of the medicine samples without the requirement of advanced 
laboratory and trained personnel. It would determine if the samples are counterfeit or not, 
but it cannot distinguish if the samples is substandard or not when the content of the API 
is in the range of 80-95% of API. Further testing is required to detect substandard drugs 
(United States Pharmacopeia, 2015). 
2.1.3 Laboratory testing 
After the field testing, the samples with the API content more than 80% would be 
sent to the advanced laboratory to quantify the actual API contents using High 
Performance Liquid Chromatography (Gandhi, Deshpande, Jagdale, & Godbole, 2010; 
Teddy Ehianeta, 2012). According to standard quality control from WHO, the percentage 
of API has to be in the range 95-105% to be considered as good medicine. HPLC would 
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give an accurate quantification down to 1% with 0.1% of standard deviations. In addition 
to API content, it would determine other impurities in the samples.  
2.1.4 Dissolution 
The last checkpoint for the good quality medicines is the dissolution test. While the 
lab test shows the compositions of the tablet, the dissolution test shows how the tablet 
was manufactured. The dissolution curve of the amount of API release over time is very 
important in the pharmacological perspective since it will ensure the appropriate amount 
of drug release at certain time point to be effective at attacking the pathogens. In the case 
of inappropriate Good Manufacture Practices, the medicines can be pressed into tablet 
incorrectly. This would lead to too fast or too slow release of API inside the body and 
cause ineffective treatment or drug resistance. To perform dissolution, the tablet would be 
dissolve in the solvent for a fixed amount of time (FDA, 1997). The dissolved samples 
would be subjected to HPLC to measure the amount of API released and compared to the 
standard tablet with correct pressing that was dissolved and measure using HPLC. To 
ensure the condition is the same every time the dissolution test is conduct, the dissolution 
set up would be kept at the same location in the laboratory (United States Pharmacopeia, 
2015). 
2.2 CURRENT TECHONOLOGIES 
There are three broad classes or methods used for the detection of substandard 
pharmaceuticals: High performance liquid chromatography (HPLC), hand-held Raman or 
Near-Infrared spectroscopy (RS) instruments, and thin layer chromatography (TLC) 
based systems. 
  11 
2.2.1 High performance liquid chromatography 
HPLC is one of the gold standard methods that have been used for the analysis of 
different pharmaceuticals within the drug tablets (Figure 2.1). There are two phases in the 
HPLC: the stationary phase and the mobile phase. The stationary phase consists of a 
stainless steel with a packed column of microparticles (3-10 µm in diameter), which are 
usually chemically modified silica for the partition process of different chemical 
components in the tablet. For different types of sample, microparticles with different 
chemical structures can be applied. For example, for the separation of ions, column 
packed with resins or polymers with acidic or basic groups are used. The liquid phase is 
the solution of multiple solvents in a specific volume ratio that would determine the 
retention of sample in the column. The solvents in the mobile phase are chosen based on 
their transparency to the detection wavelength and the retention time of sample 
components in the column. For detection, a UV/visible absorption spectrophotometer is 
used to capture the signal at the end of the column during the elution stage of the process. 
The retention time is recorded for each component exiting the column. For other types of 
HPLC, fluorescence spectrophotometer, differential refractometers (RI), electrochemical 
detectors, evaporative light-scattering detectors (ELSD), charged aerosol detectors 
(CAD) can be coupled for the detection of different types of signal’s peak (Nikolin, 
Imamovic, Medanhodzic-Vuk, & M, 2004). Overall, HPLC is a powerful tool for 
quantitative analysis of pharmaceuticals and its impurities. However, the system requires 
a precise pump with a good UV detector and laser source that make a complete system’s 
cost too expensive ($30,000-$100,000) for field testing (Agilent, 2011). Moreover, 
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appropriate maintenance and storage for the advanced devices is required. Also, for 
operation, trained personnel are required. 
2.2.2 Thin layered chromatography - GPHF-MiniLab® 
Thin-Layered Chromatography (TLC) is often used as a pharmaceutical analytical 
method in resource-limited areas (Figure 2.2). In some ways, it is a simplified version of 
an HPLC. A sheet of glass, aluminum, or plastic is coated with absorbent materials like 
cellulose or silica gel and acts as the column in HPLC to separate the different 
components in non-volatile mixtures. For visualization or detection, different dyes are 
spotted on the sheet to identify different chemical compounds in the mixture (Crecelius, 
Clench, & Richards, 2004). One of the most popular applications of TLC is the Minilab 
from Global Pharma Health Fund (GPHF). The Minilab system has been developed to 
work in resource-limited settings. It includes 2 suitcases that weigh about 100 pounds 
each and contain all the equipment and materials for TLC (Affum et al., 2013; World 
Health Organization, 2011b). This is recommended by WHO for the detection of fake 
drugs in the resource-limited regions.  With this method, quick, inexpensive, and 
qualitative results can be obtained in about a couple of hours. However, qualitative 
measurements cannot determine substandard drugs. The entire system is heavy to carry to 
the field. The method is cumbersome and laborious. In addition, user induced errors, due 
to no automation, are also high.  
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2.2.3 Near-infrared spectroscopy 
Near-infrared spectroscopy (NIR) was first introduced as the analytical methods 
for detection of pharmaceuticals in 1997(Figure 2.3). The mechanism of NIR is to scan 
the pure samples with the different wavelengths in the near infrared region between 800 
to 2500 nm and detect the reflectance light from the pure samples to establish a library of 
the unique fingerprints of different chemical (Khan et al., 1997; Martinez, Peinado, 
Liesum, & Betz, 2013; B. A. Olsen, Borer, Perry, & Forbes, 2002). Thus, it would 
provide a non-invasive way to detect the presence of API, impurities, and excipient in the 
tablet and can be a quantitative method, but requires intensive calibration to establish a 
standard curve. However, this method requires significant training. The library 
construction is time-consuming and requires to be done after the device’s repair (B. A. 
Olsen et al., 2002). The NIR highly depends on the formulation of the drug tablets, so an 
intensive batch-batch study and new library construction for different brand of the same 
API has to be conducted to ensure the accuracy of the device. 
2.2.4 Raman spectroscopy 
Raman spectroscopy is another common method used to quantify substandard 
medicine. In Raman, the sample is exposed to laser light. The interaction of the laser light 
with molecules on the surface of the samples shift the laser’s photon energy up and down 
and result in different scattered shifted laser light pattern called unique Raman spectra for 
specific chemical molecules (Figure 2.4). The advantages of RS includes that it provides 
a non-invasive way to identify different pharmaceuticals in the tablet since no sample 
preparation is required. The analysis time is relatively short (10-15 minutes). The 
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operation requires little training. However, there are several field-based challenges. The 
instrument itself is prohibitively expensive ($30,000-$60,000) due to the laser source 
(Markert, Ring, & Campbell, 2011). In addition, the technology only looks at the surface 
of the tablet and not the entire composition. Thus, if the tablet is not uniformly 
distributed, the quantification could be incorrect and the results misleading. Samples may 
decompose/degrade upon the continuous exposure to laser light for more than 10 min. If 
the molecule is auto-fluorescent, the emission spectrum can overlay with the Raman 
spectra as well (Lee, Chang, Wang, & Fu, 2011). 
2.2.5 CD3 
The U.S. Food and Drug Administration’s counterfeit detection device CD3 has been 
developed a decade ago and currently gone under trial in the developing world (Figure 
2.5). The device has a super high resolution camera that can look at the package and the 
surface of the drug tablet with high magnifications, scan the tablets with different 
wavelengths and look at different light absorption and glowing of the tablets’ surface 
(Ranieri, 2013). However, the device cannot quantify the amount of API in the tablets 
since it only looks at the physical properties on the surface of the tablets. It would be 
great for the detection of counterfeit medicine, but not the substandard cases.   
2.3 TECHNOLOGY CHALLENGES AND PROPOSAL 
The current technologies discussed above represent the two ends. These methods 
discussed above reveal a gap where a new platform for the detection of substandard 
medicines can fill in. HPLC provide a precise quantification of API and impurities, but 
not suitable for field testing due to the requirement of trained personnel and advanced lab 
  15 
settings. Raman spectroscopy is modified to be used in the resources-limited settings, but 
the portable version of the system is still unaffordable and can give false negatives since 
it only looked at the surface of the tablet. Similarly, CD3 only looks at the surface of the 
tablet with high-resolution camera.  TLC or Minilab is a field-deployable system, but 
only provides qualitative results and thus cannot detect substandard medicines. Thus, 
relatively low-cost devices that can real-time quantify the concentration of more than 2 
API is urgently needed for the detection of substandard medicine.  
I propose to develop a system that will fill in the gap and focus on two aspects: 
technology and detection reagents (or probe). The development of the system is separated 
into three different aims. In the first aim, there are two goals: to characterize a probe for 
antimalarials and to design a chip that can reliably semi-quantify the API contents of 
antimalarials’ tablets. The second aim is to develop a systematic evolution of ligand 
enrichment system (SELEX) to screen for fluorescent probe for water-soluble drugs. For 
the third aim, to push the technology development further, the goal is to design a chip that 
can real time quantify API concentrations by creating a 3-point standard curve 
simultaneously with the tablet sample on one chip. This would prevent the effect of 
different optical measurements from different users on different days. Overall, the 
platform will shorten the gap between the current technologies for pharmaceutical 
analysis and be suitable for usage in resource-limiting settings. 
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2.4 FIGURES 
 
Figure 2.1: High Performance Liquid Chromatography system 
The set up for high performance liquid chromatography from Agilent Technologies 
(Waters, 2016). 
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Figure 2.2: Thin layered Chromatography 
The Thin layered chromatography - GPHF-MiniLab system that consists of 2 big 
suitcases weighed 200 lbs. each (Global Pharma Health Fund, 2015). 
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Figure 2.3: The handheld near-infrared device  
An example of handheld near-infrared device used in the field (Lanzhou Huaxi Science 
Equipment, 2016). 
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Figure 2.4: Raman spectroscopy 
The handheld device built based on Raman spectroscopy (Wang, Li, Zhang, & An, 2004). 
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Figure 2.5: CD3 
The CD 3 device developed and tested by FDA (Ranieri, 2013). 
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Chapter 3 Development of luminescent assay for quantification of 
Artesunate in Artemisinin Combination Therapy 
3.1 INTRODUCTION 
Historically, the main drugs for malaria treatment were quinine and chloroquine. 
However, there have been multiple cases reported for the drug resistance with quinine 
and chloroquine (Cui et al., 2012; Lacaze et al., 2011). In response, the WHO now 
recommends that patients with malaria should take the artemisinin combination therapy 
(ACT) (Dondorp et al., 2004). Unfortunately, recently, there have been many reports of 
artemisinin resistance in Southeast Asia, where it is likely.  One of the main causes of 
resistance is the use of poor quality drugs (Nayyar, Breman, Newton, & Herrington, 
2012; World Health Organization, 2013b). It has been reported that about 38-52% of 
artesuante (ATS) and 55% of dihydroartemisin (DHA) fail the drug quality control tests 
in the Southeast Asian and African countries (Cockburn, Newton, Agyarko, Akunyili, & 
White, 2005; Nayyar et al., 2012; World Health Organization, 2011b). To respond to the 
counterfeit and substandard ATS, there are currently methods developed to detect ATS in 
the tablets such as: desorption electrospray ionization mass spectroscopy (DESI MS) and 
colorimetric field tests using diazonium salts (Affum et al., 2013; Green, Mount, Wirtz, 
& White, 2000). The DESI MS gives a good quantification of ATS tablets, but only on 
the surface which may cause false measurement if ATS is not uniformly distributed on 
the surface. The colorimetric test is good qualitative measurements. For quantitative 
purpose, extra sample preparation and detection steps are required. As a result, 
quantitative and easy to use assays for the detection of artemisinin (ART) and its 
  22 
derivatives are in urgent need. Thus, as a model system, we chose ART and its 
derivatives to test, validate, and optimize our system. 
3.2 MATERIALS AND METHODS 
3.2.1 Artemisinin Chemistry 
In order to develop and optimize the probe for the technology, we studied the 
mechanism of action of ART and its derivatives. The chemical structures of ART and its 
derivatives all have special peroxide groups. In the presence of ferrous heme irons in 
blood, the O-O bond is cleaved to create reactive oxygen species (ROS) on either the first 
or second oxygen according to the Fenton reaction (Krishna, Uhlemann, & Haynes, 
2004). Then, the ROS overcome the parasite’s antioxidant defense system and kill the 
malarial parasites. The pathway of ART to the products with antimalarial activity is 
briefly summarized in Figure 3.1 (top). This mechanism is applied similarly to other 
derivatives of ART that have the same peroxide groups. With this as an inspiration, an 
assay to detect ROS has been developed using a luminol reaction, an existing reaction 
used to detect blood in forensic science.   In this reaction, luminol reacts with hydrogen 
peroxide under alkaline condition and the catalyst of hematin in blood to convert into a 
chemical compound that emits chemiluminescent signals at 425 nm that can be captured 
by an imaging system (Figure 3.1 - bottom) (University of Bristol, 2002). 
To mimic the mechanism of action of ART and the luminol reaction, the 
hydrogen peroxide solution is replaced with the drug solution. The hematin is used as the 
iron source to catalyze the reaction. The amount of peroxide group in ART and its 
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derivatives correlates to the concentration of ART in the solution. It can be quantified 
using luminol and hematin in the sodium hydroxide solution (Bowles et al., 2012). Before 
the probe can be used to test drug samples, a series of optimization and validation tests 
(the limit of detection/quantification (LOD/LOQ), specificity, repeatability and 
robustness) was performed using the spectrophotometer. To make the platform field-
deployable, a microfluidic chip was designed to carry the mixing of the probe and API 
and their luminescent reaction. 
3.2.2 Optimization of the probe conditions 
3.2.2.1 The ratio of probe to active pharmaceutical ingredients 
To determine the optimal concentration of hematin and luminol in NaOH 0.1 M 
(Sigma, MO), 10 mg each of hematin and luminol were dissolved in 50 ml of NaOH 0.1 
M. The stock solution was serial diluted in PBS (Sigma, MO) to 7 different 
concentrations (8, 6, 4, 2, 1, 0.5, 0.25 mg/50 ml). Different concentrations of hematin and 
luminol were tested with the solution of ART, ATS and DHA (Sigma, MO) 1 mg/ml. 40 
μl of probe at different concentrations of luminol and hematin were mixed with 40 μl of 
ART, ATS or DHA in 96-well plate (Fisher, PA). Measurements were made 
immediately, after mixing in 96-well plate, in the spectrophotometer (Molecular Devices, 
CA) with a kinetic mode of 5 minutes with 1-min intervals at 425 nm emission 
wavelength. The measurements were repeated 4 times for each concentration of luminol 
and hematin. 
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3.2.2.2 The pH of the probe solution 
To find the optimal pH for the maximum luminescent signal, the solution of 
NaOH 1 M was diluted into 4 different concentrations (0.5, 0.1, 0.05, 0.01 M) 
corresponding to 4 different pH values. For the probe preparation, 50 ml solution at each 
concentration was mixed with 2 mg each of hematin and luminol. The concentrations of 
ART, ATS, and DHA for testing were 1 mg/ml. The measurements were made 
immediately, after mixing in 96-well plate, in the spectrophotometer with a kinetic mode 
of 5 minutes with 1-min intervals at 425 nm emission wavelength. The measurements 
were repeated 4 times for each concentration of NaOH. 
3.2.2.3 Limit of detection/quantification 
To determine the LOD and LOQ of the antimalarial probe, the standards from 
ART, ATS, and DHA were dissolved in ethanol (Fisher PA) at concentration 6, 2, 1.6 
mg/ml and diluted into 11 concentrations to determine the limit of detection of each 
pharmaceutical and the linear range of the signal. The measurement was taken by the 
spectrophotometer for 20 minutes with 1 minute intervals. The peak signals were 
correlated to the concentration of API. The measurements were repeated at least twice for 
each concentration of ATS, ART, and DHA. The LOD and LOQ were determined by the 
formula below from the international guideline on the validation of analytical procedures: 
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S
LOD σ∗= 3
S
LOQ σ∗= 10
 
Eq 3-1 
Where σ is the standard deviation of the blank or background signal; S is the slope of the 
calibration curve (International conference on harmonisation of technical requirement for 
registration of pharmaceuticals for human use, 1994).  
The calibration curves for ART, ATS, and DHA were sigmoidal with a linear 
region in the log scale of the x-axis. Thus, the formula was modified to calculate LOD 
and LOQ in the log-scale: 
S
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σ10
 Eq 3-2 
3.2.3 Validation of the assay 
To validate the performance of the detection probe, specificity, repeatability, 
robustness tests were conducted. In all the validation tests, the probe solutions were 
prepared by adding 2 mg each of hematin and luminol into 50 ml of NaOH 0.1 M. All the 
measurements were taken using the spectrophotometer in the kinetic mode of 4 minutes 
with 1-minute intervals. The peak signals were observed at 2 minutes. The list of 
excipients from the Arsuamoon tablets was obtained for the specificity test (World Health 
Organization, 2011a). The detailed protocols of all the validation tests are included in 
annexes section.  
3.2.3.1 Specificity  
A list of excipients from an Arsuamoon tablet was obtained from WHO and US 
Pharmacopeia documents: corn starch, sodium starch glycolate, hydroxypropyl cellulose, 
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sucrose, magnesium stearate, and cellulose (World Health Organization, 2011a). Five 
milligrams of each excipient were dissolved in 1 ml of distilled water. Thirty microliters 
of excipient solutions were mixed with 30 μl of probe. The signals were captured using 
the spectrophotometer for 5 min with 1 min intervals. The measurements were repeated 5 
times for each excipient. 
3.2.3.2 Repeatability 
The stock solution of each pharmaceutical (2 mg/ml for ATS and ART; 1 mg/ml 
for DHA) in ethanol was identified as 100% and diluted into 7 other different 
concentrations at 80%, 60%, 40%, 20%, 10%, 5%, and 0% compared to the stock 
solutions. Five sets of the standards from the same stock solutions were prepared. Thirty 
microliters of API solution and probe were mixed in 96-well plate. The measurements 
were taken immediately using the spectrophotometer and repeated 6 times for each 
concentration of API. 
3.2.3.3 Robustness 
Three 50 ml solutions of the probe were made separately and stored at 3 different 
temperatures 4, 22, 37oC for 3 hours before the first measurements. The ATS samples 
were prepared freshly every day by dissolving 2 mg in 200 µl of ethanol and diluting in 
1.9 ml of water at the temperature according to the probe solution’s temperature. For the 
detection, 40 µl of ATS and 40 µl of the probe were mixed in 96-well plate. The 
measurements were taken for each temperature (n=8) every day until the signal started to 
decrease more than 20% compared to the previous measurement in all temperatures. 
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3.2.4 Chip design and fabrication 
3.2.4.1 Design 
For the luminescent detection, the signal was based on a chemical reaction of the 
probe with API. The signal strength correlated with the volume of the probe and the API. 
To be able to detect the luminescent light, the chip design contained two inlets for probe 
and API that injected the solutions through two long independent channels which were 
used to increase the pressure drop and then combined together into a single channel with 
multiple patterns of herringbone structure for mixing (Figure 3.2). The herringbone 
patterns were the passive mixing methods in microfluidic channel where the Reynold 
number was less than 1 (Lee et al., 2011).  After the mixing region, the solution entered a 
reaction chamber where the API and probe react to emit luminescent light captured by an 
imaging system (Figure 3.2). 
3.2.4.2 Fabrication 
The mold contained three layers of different heights made from SU-8 
(MicroChem, MA) and aluminum (McMaster-Carr, MA) on silicon wafer. The first layer 
was the 200 μm channel made from SU-8 2100 photoresist on a 10-in silicon wafer 
followed the protocol from MicroChem until the post-exposure bake. After that, the 
second layer of SU-8 2025 photoresist was spun on top of the first layer. The mold was 
developed in SU-8 developer. The third layer was made from aluminum with the 
dimension 5x5x3 mm. These blocks were glued to SU-8 channel using super glues. After 
that, the mold was silanized with trichloro(1H,1H,2H,2H-perfluorooctyl)silane (Sigma, 
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MO) for 2 hours under vacuum. The chips were made from PDMS (Fisher, PA) with 10:1 
ratio of base and curing agent for 3 hours at 85oC. The PDMS slabs were bonded to a 
glass slide using oxygen plasma treatment for 1 minute, then 3 hours at 85oC, and at room 
temperature overnight before ready to use. 
3.2.4.3 On-chip testing 
A standard curve of ATS in PBS was developed using photodiode as the sensor in 
optical nest. To prepare the probe solution, 2 mg each of luminol, hematin, and 
fluorescein (Sigma, MO) were dissolved in 50 ml of NaOH 0.1 M. Fluorescein was 
added to alter the emission wavelength of the luminescent signal from 425 nm to 530 nm. 
The luminescent light from the luminol reaction with ATS acts as the transferred energy 
source to excite fluorescein and then the fluorescein emitted the signal at 530 nm 
(Cheeseman, 1999). For the API, 4 mg of API was weighed and dissolved in 200 µl of 
ethanol 200 proof by vortex and diluted in 1.8 ml of phosphate buffered saline (PBS) to 
achieve the 2 mg/ml concentration. The solution was later diluted in 500 µl of PBS to 
bring the concentration down to 1.6 mg/ml. Then, a serial dilution from 1.6 to 1.2, 0.8, 
0.4 mg/ml was made by adding 750, 500, 250 µl of 1.6 mg/ml solution into 250, 500, 750 
µl of PBS in 2ml tubes labelled with concentrations and mixing by vortex. 
The pressure was set to 5 psi. The signals were captured for 5 minutes at 16 Hz. 
The peak signal analysis was used to create a standard curve with 4 different 
concentrations. The measurements were repeated 3 times for each concentration. The 
chips were reused for 3 times. Between measurements, the chips were washed with water 
for 3 minutes and air-dried for 2 minutes. To determine the cleaning protocol, we 
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experimented with different washing (3, 4, and 5 min) and air-dry (1,2,3 min) times 
between the measurements. After washing the chips, we flowed the pure ATS solution in 
the API inlet and water in the probe inlet and captured the signal over 5 minutes. The 
signals were the same as the background signal. Based on the results, we concluded that 
the chip required to be washed for 3 min and dried for 2 min between measurements. 
3.2.4.4 Complete dissolution of the Arsuamoon tablet 
 The probe was prepared as described above. 5 different tablets of Arsuamoon 
(50 mg of ATS/tablet) was weighed and crushed. The amount of powder that was 
equal to the weight of 1 tablet was dissolved in 62.5 ml of PBS to achieve 0.8 
mg/ml concentration of ATS. Three samples were prepared. The mixture was 
stirred for 30 minutes and filtered through 0.22 μm pore. In parallel, a standard at 
0.8 mg/ml of pure ATS was prepared as the control to compare with the tablet 
samples. The measurements were repeated 5 times for the same standard solution 
and one time for each tablet sample. 
To determine the accuracy of the method, we compare our assay’s performance 
with HPLC, the gold standard method for pharmaceutical analysis. The HPLC results 
were conducted at United States Pharmacopeia (USP) facility in Rockville, MD. There 
were three solvents used for the mobile phase: water adjusted the pH to 3 by formic acid, 
acetonitrile, methanol with 8:11:1 ratio. The 4.6-mm x 25-cm column with 5-µm packing 
L1 was used (Zorbax SB-C18). The ATS standard was prepared at the concentration of 4 
mg/ml in acetonitrile. For the tablets, 5 tablets from the same batch were weighed and 
crushed into powder using the paddle. The amount of powder according to the weight of 
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one tablet was measured and dissolved in acetonitrile. The solution was then filtered 
through 0.2 µm filter. For the HPLC operation, the flow rate of the samples was 0.8 
ml/min. The UV detection wavelength was at 216 nm. The injection volume was 20 µl. 
The injection time was 20 minutes (United States Pharmacopeia, 2012a). 
3.3 RESULTS 
This section shows our results in probe optimization, the LOD/LOQ of the probe, 
and the validation of the probe’s performance and the results of our validation scheme on 
the chips using both pure ATS sample and Arsuamoon tablets collected by United States 
Pharmacopeia (USP) from the field. 
3.3.1 Optimization of the probe conditions 
The results of probe optimization are shown in Figure 3.3. It showed the curves of 
luminescent signals of ART, ATS, and DHA. The curve peaked at NaOH 0.1 M for ATS. 
For DHA and ART, the maximum signals were obtained at 0.07 and 0.2 M respectively. 
The standard deviations were relatively small (less than 3%) at their peak values. The 
ratio of hematin and luminol to API curves showed that 2 mg each of hematin and 
luminol in 50 ml of NaOH 0.1 M gave the highest signal for ART and DHA.  For ATS, at 
1 mg of hematin and luminol, the signal was the strongest, but only 10% more than 2 mg 
measurement and the standard deviation was significantly larger than the others (Figure 
3.3). Using equation 2 and graphs in Figure 3.4, the LOD of ART, ATS, and DHA in 
pure form dissolved in ethanol were calculated to be 125, 66, 24 μg/ml using the 
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spectrophotometer. Similarly, the LOQ of ART, ATS, and DHA were 126, 68, and 25 
µg/ml respectively (Table 3.1). 
3.3.2 Validation of the assay 
Specificity. The excipients (corn starch, sodium starch glycolate, hydroxypropyl 
cellulose, sucrose, magnesium stearate, and cellulose) were mixed with the probes and 
the signals were measured over time. From Figure 3.5, the signals were similar to the 
signal of the blank, which was water or ethanol over 5 minutes. 
Repeatability. Figure 3.6 showed that plots of repeatability tests of ART, ATS, 
and DHA for 7 different concentrations. The ranges of the concentrations were picked 
based on the linear range of the signals versus the concentrations. The ranges were 100 -
1600 μg/ml for ART and ATS; and 50-800 μg/ml for DHA. 
Robustness. From Figure 3.7, on the first day, there is no significant difference 
between three detection solutions at different temperatures on the first day, although the 
signal at 22 and 37oC is slightly more than the one at 4oC. After day 1, the signal from 
solution stores at 4oC decrease significantly (more than 20% on the second day). At 22oC, 
the signal decreases slightly on the second day, and more than 20% on the third day, and 
about 50% on the fourth day. For solution store at 37oC, the signal decreases slightly over 
time and reaches ~20% on the fourth day. 
3.3.3 Field sample testing on chip 
After the validation tests, we tested the antimalarial detection probe on chips 
using both pure standard ATS and ATS tablets from the field. During the experimental 
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set up, fluorescein was added to the probe solution to change the emission wavelength 
from 425 nm to 530 nm. Figure 3.8 showed that the peak signal was between 2 and 3 
minutes where the signals of four different concentrations were distinguished from each 
other and then decrease at different rates according to the concentrations. The peak 
signals were captured for each concentration and plotted against the concentration in 
Figure 3.8. The standard deviation was insignificant for all concentrations. There is a 
linear relationship between the luminescent signal and the concentration of ATS ranged 
from 0.4 to 1.6 mg/ml. 
3.3.4 Arsuamoon field sample testing 
For quantification, a standard solution was prepared and 5 readings were taken for 
the same sample. The average signal is 2.38445 with the percentage of RSD of 5.75% 
(Table 3.2-Top). For the three Arsuamoon samples, the average signal is 2.44801 with 
%RSD of 11.4%. Based on the standard, the percentage of recovery is 104% or 52 mg 
compared to 50 mg of ATS stated on the package (Table 3.2-Bottom). The results from 
HPLC showed that the %recovery of ATS from the tablet is 95.4% (47.7 mg) with 0.7% 
RSD. The percentage difference between our assay and HPLC was 8.6%. 
3.4 DISCUSSION 
The optimization tests for the probes showed that the luminescent signal depends 
on two different factors: the concentration of luminol and hematin and the pH of the 
solution determined by the concentration of sodium hydroxide. From Figure 3.3, the 
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optimal condition to produce the highest luminescent signals is 2 mg each of hematin and 
luminol in 50 ml of NaOH 0.1 M. For the LOD/LOQ tests, the summary in  
Table 3.1showed that the methods cover a wide range of concentration of ART, 
ATS and DHA from µg to mg range. This gives the users flexible to choose the volume 
to dissolve the sample in. The upper limit helps to decrease the volume down to 25 ml for 
50 mg ATS tablets.  
In the system validation, the specificity tests demonstrated that the probe was 
highly specific to only ATS (100% for LOQ range) in the tablets and could be used to 
quantitatively estimate the concentration of the ATS in the tablets. The repeatability tests 
showed that the signals for different concentrations were distinguished from each other 
with the standard deviations. Overall, the signals from antimalarial probe were 
reproducible for ATS, ART, and DHA over a range of concentrations 100-1600 μg/ml. 
Finally, in the robustness tests, the reagent storage temperature does not affect the 
luminescent signal significantly on the first day. The signal from the solution stored at 
4oC was lower on the second day because the solution was exposed to ambient light 
occasionally when the fridge was open. From the results, the solution should be prepared 
freshly everyday of testing to ensure the consistent measurement from day to day.  
To quantify the API content of ATS tablets, we developed an ATS standard curve 
on chip using photodiode as the detector. For the analysis, two different approaches, 
peak-picking and integration of signal under the curve methods from the plot of the 
luminescent signal over time, were chosen. By looking at the peak of the curves for 4 
concentrations, we can distinguish and quantify different concentrations of ATS in the 
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solution in the range 400-1600 μg/ml. In the top graph in Figure 3.8, each concentration 
has a unique peak value between 2 and 3 minutes interval. On the other hand, the 
integration of the signal under the curve for 4 min could not distinguish different 
concentrations since the graph of the relative luminescent signal over time (Figure 3.8-
Bottom) showed that the higher the concentration, the more rapid the signal decays, 
especially after 3 min Thus, the peak signal obtained between 2 and 3 minutes of reaction 
time was picked to plot the standard curve of ATS on a chip. The linear range of luminol 
reaction with ATS was in the range 0.4-1.6 mg/ml. Thus, we pick 0.8 mg/ml as the 
control standard to quantify the API content in Arsuamoon tablets.  From table 2B, the % 
recovery is 104%, which is 8.4% higher than HPLC results. Moreover, the %RSD of ours 
assay was significantly higher than HPLC (11.4% versus 0.7%). This may cause by the 
variations from chip to chip since each test was run on a new chip. The alignment of the 
reaction chamber on chip was done manually by hand which can lead to the variation in 
the position of the chamber compared to the photodiode which affects the amount of 
luminescent captured by the photodiode. The system still has many factors that need to be 
controlled and improved to minimize the variations between tests. 
Overall, we demonstrated that our system was able to quantify the ATS tablets as 
well as the conventional 96-wells plate in the spectrophotometer and obtain comparable 
results to the HPLC. Moreover, with our platform, the chips can be cleaned and reused up 
to 3 times before disposal. This reduces the chip manufacture cost per test to about $0.5, 
which is higher than the cost of the wells in the plate ($0.05/well or $4.8/plate). However, 
the cost per chip can be reduced by using plastics as the material for chip’s production 
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(estimated to be less than $0.1/chip). Besides that, our detection platform including the 
pressure system and a photodiode costs less than $3,000 compared to the 
spectrophotometer (>$40,000) or HPLC (up to $100,000) (Agilent, 2011; C. Olsen, 
2010). We have tried to capture signal using cell phone camera, but it is not sensitive 
enough to distinguish different concentrations of ATS.  In addition, our system can 
potentially be miniaturized into a compact suitcase for field testing while the 
spectrophotometer and HPLC have to be set up in advanced laboratory with annual 
maintenance. The drawback of our technology is that the variation from reading to 
reading is significantly higher than that HPLC. This can be reduced by exploring 
different chip fabrication methods such as: injection molding, hot embossing. Our next 
step is to modify the current system into field-deployable platform and test its 
performance with different ATS field samples in both single and fixed dose tablets. 
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3.5 TABLES 
 
Antimalarials LOD (μg/ml) LOQ (μg/ml) 
ATS 66 68 
ART 125 126 
DHA 24 25 
 
Table 3.1: The summary of LOD and LOQ for three different antimalarials (ATS, ART, 
DHA) using the luminol reactions as the quantitative method  
 
From the table, the LOD and LOQ for ATS, ART, and DHA were 66 and 68, 125 and 
126, 24 and 25 respectively. 
  37 
 
Sample 
name 
Info Theoretical 
concentration 
(mg/ml) 
Max 
voltage 
Average 
reading 
%RSD 
Standard Reading 1 0.8 2.5536 2.38448 5.75 
Reading 2 0.8 2.25459 
Reading 3 0.8 2.45197 
Reading 4 0.8 2.23241 
Reading 5 0.8 2.42984 
 
Sample 
name 
Info Theoretical 
concentration 
(mg/ml) 
Max 
voltage 
%Recovery %RSD 
Standard Average 
reading 
0.8 2.38448 100 5.75 
Arsuamoon Sample prep 1 0.8 2.32589 99.1 - 
Sample prep 2 0.8 2.76852 117.95 - 
Sample prep 3 0.8 2.24963 95.85 - 
Average 0.8 2.44801 104.3 11.4 
HPLC 4 - 95.4 0.7 
 
Table 3.2: The summary of the measurements of ATS samples in pure powder and 
Arsuamoon tablets 
 
Top: The summary of the measurements for the ATS standard on microfluidic chip. Five 
readings were conducted. The average signal was 2.38448 V with the RSD of 5.75%. 
Bottom: The summary of the measurements of three different samples of Arsuamoon 
tablets. The average signal was 2.44801 with the %RSD of 11.4%. The average 
percentage of recovery was 104.3%. The % recovery from HPLC was 95.4% with an 
%RSD of 0.7%. 
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3.6 FIGURES 
 
 
Figure 3.1: The action mechanism of ART and the luminol reaction 
 
Top: the cleavage of the peroxide group into oxygen radicals of artemisinin. Bottom: The 
mechanism of the luminol reaction. Luminol in the presence of ferrous iron in haem or 
hematin in blood and basic environment reacts with peroxide group to transform into a 
new compound that emits luminescent signal at 425 nm (Krishna et al., 2004; University 
of Bristol, 2002). 
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Figure 3.2: The CAD draw of chip (Autodesk, Inc., CA)  
 
The picture included the pressure drop channel (200 μm thick and 100 μm wide) (A), the 
mixing channel (200 μm thick and 200 μm wide) with herringbone patterns (40 μm thick 
and 50 μm wide) (B), and the reaction chamber (5 mm by 5 mm and 3 mm thick) (C). 
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Figure 3.3: The optimization of ATS detection probes on NaOH concentration and 
amount of hematin and luminol 
 
Top: the effect of different concentrations of sodium hydroxide on the luminescent signal 
from ART, ATS, and DHA. (n=4)  Bottom: The effect of different ratio of probe to API 
on the luminescent signal of ART, ATS, and DHA. (n=4). The experiments were 
conducted in a 96-well plate system. 
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Figure 3.4: The LOD/LOQ of ART, ATS, and DHA  
 
Each graph represents the relative luminescent units versus the concentration of API 
(n=2). The plots are in natural log scale for the x-axis.  
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Figure 3.5: The graph of the luminescent signal of six different excipients in the 
Arsuamoon tablets that were measured separately with the probe versus time 
 
The concentration of each analytes was 5 mg/ml. The detection wavelength is 425 nm 
and the experimental time is 5 minutes with 1-min intervals. The experiments were 
conducted in a 96-well plate system. (n=5) 
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Figure 3.6: The graphs of the luminescent signal versus concentration for the 
repeatability tests for ART, ATS, and DHA  
 
The experiments were conducted over 7 different concentrations: 1600, 1200, 800, 400, 
200, and100 µg/ml for ART, ATS, and DHA (n=6). The experiments were conducted in a 
96-well plate system.  
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Figure 3.7: The robustness of ATS detection probe at three different 4, 22, and 37oC 
The graph of luminescent signal over time (days) for the probes stored at three different 
4, 22, and 37oC with ATS using the spectrophotometer every day for 4 days including 
error bar (n=8). The experiments were conducted in a 96-well plate system. 
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Figure 3.8: The on chip testing of Arsuamoon tablet using PharmaChk 
 Top: The luminescent signal recorded in voltage over time for each concentration (4 
different concentrations: 1.6, 1.2, 0.8, 0.4 mg/ml). The measurements were taken at 16 
Hz for 5 minutes (n=3). Bottom: The graph of voltage versus the 4 different 
concentrations of ATS on chip. The experiments were conducted in microfluidic chips. 
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Chapter 4 Development of fluorescent assay for quantification of 
Amodiaquine and fixed dose combination testing of Artesunate in the 
present of Amodiaquine 
4.1 INTRODUCTION 
To combat with the increase in number of drug-resistant cases of malaria on 
Southeast Asia and Africa, WHO has recommended the new artemisinin combination 
therapies which are divided in 2 categories: 1) two separate tablets and 2) one fixed-dose 
tablet. One of the most current and common ACT used is artesunate and amodiaquine 
(AS/AQ). Unfortunately, substandard ACT has been found in different countries in 
Africa. For instances, 53.8% of the AS/AQ samples collected from Lagos drug market in 
Nigeria did not have enough API of both ATS and AQ in the packages (Taylor et al., 
2001a). During the pilot study of the quality of antimalarial circulating in 6 sub-Saharan 
countries, WHO found out that 9 out of 38 samples in the category one for AS/AQ 
therapy failed the International Pharmacopeia standard (World Health Organization, 
2011b). For the fixed dose combination therapy, 7 out of 9 samples from Nigeria, 
Cameroon, and Ghana failed the analysis. The cause of the much higher failure rate in 
fixed dose combination therapy is because ATS is not stable under acidic condition 
formed from HCl group in AQ and the effect is more severe in high temperature and 
humidity (Lutgen, 2013). In additions, ATS and AQ can only be quantified 
simultaneously using HPLC (Le Vaillant et al., 2012). This makes the detection of 
substandard antimalarial cumbersome and complicated to execute in the resources-
limited setting. Thus, we have modified our previous assay to detect ATS in the presence 
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of AQ and developed a novel fluorescent assay to detect AQ in the presence of ATS. A 
set of experiment including optimization, selectivity, specificity, repeatability, and 
robustness has been conducted to validate the performance of both assays to detect ATS 
and AQ in the presence of each other using different solvents. 
4.2 MATERIALS AND METHODS 
4.2.1 Amodiaquine Chemistry 
Amodiaquine as an organic compound has ability to quench fluorescent dye like 
eosin Y at certain conditions. It has been documented briefly in a paper in 1970 that eosin 
Y in chloroform would be quenched by organic salt like AQ since eosin Y can be ionized 
to a charged form that make it lose the fluorescent ability (Lelijveld & Kortmann, 1970). 
It has been unknown about the conditions (concentrations, solvent, excitation and 
emission wavelengths) at which the quenching effect can be used to quantify and 
distinguish AQ from other compound. Thus, in section, we developed a novel assay using 
eosin Y to detect AQ with high sensitivity and specificity. 
4.2.2 Optimization of the probe conditions 
4.2.2.1 Excitation and emission wavelengths 
To find the optimal excitation and emission wavelength for the maximum 
fluorescent signal, the solution of Eosin 1 mM was prepared by dissolving 6.5 mg of EY 
in 10 ml of water. The absorbance measurement of EY from 480-560nm with 5 nm 
interval was measured using the spectrophotometer with 100 µl of EY 1mM pipetted in 
the 96 well plate (n=8). As negative controls, a blank of water and AQ at 27 µg/ml were 
  48 
pipetted into the wells with the volume of 100 µl/well (n=8). The wavelength at which 
the maximum absorbance was measured was used as the emission wavelength to scan for 
the emission wavelength of EY. To determine the emission wavelength of EY, 100 µl 
each of EY, water, AQ, mixture of AQ and EY (50:50) was pipetted in the 96-well plate 
with 8 replicates. The measurement was taken in the spectrophotometer with 515 nm 
fixed excitation wavelength and 530-590 nm range of emission wavelengths at 5-nm 
intervals. 
4.2.2.2 Working concentration of probe and solvent 
To determine the optimal concentration of EY (Sigma, MO), a stock solution of 
EY at 1 mM was prepared by dissolving 6.5 mg of EY in 10 ml of water. The stock 
solution was serially diluted into 0.1, 0.01 and 0.001 mM concentrations. A solution of 
AQ at 27 µg/ml was prepared in water as the stock solution (100%) and diluted into 80%, 
60%, 40%, and 20%. One hundred microliter of each concentration of AQ was pipetted 
into wells (Fisher, PA). One hundred microliters of EY at different concentrations was 
pipetted into wells (Fisher, PA) with 2 replicates for each concentration of AQ.  The 
measurement was taken using the spectrophotometer (Molecular Devices, CA) at 515 nm 
excitation and 545 nm emission wavelength. 
4.2.2.3 Limit of detection/quantification 
To determine the LOD and LOQ of EY, the stock solution of AQ were dissolved 
in water (Fisher, PA) at concentration 1000 µg/ml (100%) and diluted into 7 
concentrations (75%, 50%, 25%, 10%, 5%, 1%,0%)  to determine the limit of detection 
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of each pharmaceutical and the linear range of the signal. EY was prepared in 2 different 
solvents (ethanol and water) to see the effect of organic and aqueous solvent on the 
quenching of AQ on EY. A mixture of AQ and EY (100µl:100µl) at different 
concentrations of AQ was pipetted in 96-well plate with 4 replicates. The measurement 
was taken by the spectrophotometer. After that, the working concentrations of AQ was 
narrowed down to 200-20 µg/ml (200, 150, 100, 90, 80, 70, 60, 50, 40, 30, 20, 0 µg/ml) 
to determine the linear range of the standard curve (n=5). The LOD and LOQ were 
determined by Eq 3-1. 
4.2.3 Validation of the assay 
4.2.3.1 Selectivity 
4.2.3.1.1 Chloroquine 
4.2.3.1.1.1 Chloroquine only 
Chloroquine (CL) was chosen to test for selectivity since it had a similar structure 
to AQ and has been known to quench EY. Moreover, it is still the recommended 
antimalarial and manufactured at the same facility with AQ in some countries in Africa 
and Southeast Asia. To determine the selectivity of EY to AQ only, 5 mg of was 
dissolved in water to obtain 1 mg/ml stock solution and diluted by a factor of 10 in water 
to obtain 100% solution of CL. The 100% solution of CL was serially diluted down to 
75%, 50%, 25%, 10%, 5%, 2%, 0% solutions. All the solution was mixed well by vortex. 
One hundred microliter of each concentration of CL was pipetted into wells (Fisher, PA). 
One hundred microliters of EY at different concentrations was pipetted into wells (Fisher, 
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PA) (n=5).  The measurement was taken using the spectrophotometer (Molecular 
Devices, CA) at 515 nm excitation and 545 nm emission wavelength. 
4.2.3.1.1.2 Proportional ratio to amodiaquine 
To determine the selectivity of EY to AQ, CL was spiked in solution of AQ at the 
same concentration. Five milligrams each of AQ and CL was dissolved in 5 ml of water.  
The solution of AQ and CL is diluted by a factor of 10 to obtain the 100% stock solution. 
A serial dilution of the stock solution to 75%, 50%, 25%, 10%, 5%, 2%, and 0% was 
performed. A volume of 100 µl of each concentration was pipetted into 96-well plate and 
later mixed with 100 µl of EY 0.1M before the fluorescent measurement using 
spectrophotometer with 515/545 (excitation/emission). Five replicates were measured for 
each ratio. 
4.2.3.1.1.3 Inversely proportional ratio to amodiaquine 
To determine if the different ratio of AQ and CL will affect the selectivity of EY 
to AQ, the inversely proportional ratio of AQ and CL was prepared. Five milligrams, 
each of AQ and CL were dissolved in 5 ml of water and then diluted by a factor of 10 in 
water. Ten different ratios of AQ:CL was prepared using the prepared solutions prepared 
previously (100%:0%, 95%:5%, 90%:10%, 80%:20%, 60%:40%, 40%:60%, 20%:80%, 
10%:90%, 5%:95%, 0%:100%). A mixture of 100µl of EY 0.1M and each ratio of 
AQ:CL was mixed in the 96-well plate and measured the fluorescent signal using the 
spectrophotometer at 515 nm excitation and 545 nm emission (n=5). 
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4.2.3.1.2 Chloroquine and artesunate 
4.2.3.1.2.1 Proportional ratio to amodiaquine and artesunate 
The experimental set up was similar to the set up in section 4.2.3.1.1.2. The only 
difference was the addition of 1.8 mg of ATS in 500 µl of ethanol to 4.5 ml of water with 
5 mg each of AQ and CL (n=5).  
4.2.3.1.2.2 Inversely proportional ratio to amodiaquine and artesunate 
The experimental set up was similar to the set up in section 4.2.3.1.1.3. The only 
difference was the addition of 1.8 mg of ATS in 500 µl of ethanol to 4.5 ml of water with 
5 mg each of AQ (n=5). 
4.2.3.2 Specificity 
To determine the specificity of EY to AQ, a list of excipient from Winthrop 
tablets was obtained from the WHO documents. There were 6 different excipients: 
Croscarmellose sodium, povidone K30, microcrystalline cellulose, magnesium stearate, 
calcium carbonate and starch, and silica colloidal anhydrous (Sanofi-Aventis, 2010). The 
weight of each excipient was not known and was calculated based on the remaining 
weight of each Winthrop tablet. One Winthrop tablets was about 720 mg with 270 mg of 
AQ and 100 mg of ATS. The weight of 6 excipients was 350 mg. With the assumption 
that the amount of each excipient was the same, the concentration of each excipient in 50 
ml of water after the tablet was dissolved completely would be 300 µg/ml. For each 
excipient, 3mg was dissolved in 10 ml of water and then diluted by a factor of 10 in 
water. The solution of each excipient was filtered through 0.45 µm polypropylene 
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membrane. A mixture of 100 µl of each excipient and 100 µl of EY 1 mM was mixed in 
the 96-well plate and measured the fluorescent signal using the spectrophotometer. Eight 
replicates were prepared for each excipient. 
4.2.3.3 Repeatability  
The repeatability of the standard curve of the detection of AQ was determined by 
making 5 different standard curve of AQ at 5 different concentrations (0%, 25%, 50%, 
75%, 100%=25 µg/ml) in the presence of ATS and CL. A solution of ATS at 0.36 mg/ml 
was prepared by adding 1.8 mg of ATS to 500 µl of ethanol and diluted in 4.5 ml of 
water. After that, 5 mg of AQ was added to the solution of AST. Separately, a solution of 
CL was prepared by dissolving 2 mg of CL in 5 ml of water. A volume of 500 µl of CL 
solution was mixed with the solution of AQ-ATS solution above. The ratio of 
AQ:ATS:CL was the same as the authentic Winthrop tablet with the assumption of  
contamination with 4% of CL, a mixture of ATS, AQ, and CL at fixed concentration of 
AQ, ATS and CL (1, 0.36 and 0.04 mg/ml respectively) was diluted by a factor of 10 to 
achieve 100% stock solution. The stock solution was serially diluted to 75%, 50%, 25%, 
0% with water. A volume of 100 µl of AQ, ATS, CL mixture was mixed with 100 µl of 
EY 0.1mM for each concentration of AQ and measured the fluorescent signal at 515 nm 
excitation and 545 nm emission (n=3 measurements for each standard curve and 5 
replicates of standard curve total). 
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4.2.3.4 Thermal stability 
The thermal stability was tested at 3 different temperatures (4 ºC, 22 ºC, and 37 
ºC). Three tubes of EY at 1 mM were stored at 4 ºC, 22 ºC, and 37 ºC overnight. 
Similarly, solutions of AQ at 25 µg/ml or 100% were prepared and diluted in 75%, 50%, 
25%, 0% solutions of AQ and stored at 4 ºC, 22 ºC, and 37 ºC overnight. The AQ solution 
at different concentrations and temperature was mixed with EY 0.1 mM at the ratio of 
100µl:100µl. The fluorescent signal was measured with spectrophotometer at 515/545 
nm (excitation/emission). 
4.2.3 Winthrop tablet testing 
The EY solution at 1 mM was prepared as described above. Three different tablets 
of Winthrop (270 mg of AQ and 100 mg of ATS/tablet) were tested. Each tablet was 
dissolved in 50 ml of water in a conical tube through sonication for 20 minutes. The 
sampled solution was filtered through 0.45 μm polypropylene membranes. After that, the 
solution was diluted by a factor of 200 with water to bring the concentration of AQ down 
to the measureable concentrations using EY. In parallel, a stock solution of AQ at 25 
µg/ml of pure AQ (Sigma, MO) was prepared as the 100% standard solution. The stock 
solution was diluted to 10, 5, 2, and 0 µg/ml solutions of AQ to compare with the tablet 
samples. The measurements were repeated 3 times for the standard solutions and for each 
tablet with 3 tablets total. 
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4.3 RESULTS 
4.3.1 Optimization of the probe conditions 
To determine the excitation of EY, the absorbance spectrum in the visible 
wavelengths has been conducted. Figure 4.2 showed that EY has the maximum 
absorbance at 515 nm while AQ and blank wells without solution did not show a 
significant increase in signal close to 0 values. Thus, 515 nm was chosen as the excitation 
wavelength for EY. In Figure 4.3, there were three curves of the emission signal from 
EY, AQ and blank. At 545 nm emission wavelength, the signal for EY was relatively 
high (~27,000 RFU) compared to a value of approximately zero for the AQ and blank 
measurement at the same wavelength.  
In the limit of detection and quantification, using Equation 1 and Figure 4.4, the 
calculated LOD of AQ in both water and ethanol using EY was 2-100 µg/ml. The LOQ 
of AQ in both water and ethanol was 3-98 µg/ml. 
For the determination of the working concentrations of AQ in which EY can be 
used to quantify the amount of AQ in the linear fluorescent signal, Figure 4.5 showed that 
the curve of EY fluorescent signal versus the concentration of AQ was a function of an 
exponential decay from 0 to 100 µg/ml. The portion of the curve with the concentration 
of AQ 0-20µg/ml was linear. 
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4.3.2 Validation of the assay 
4.3.2.1 Selectivity  
The quenching effect of EY was caused by many organic compounds that had 
similar structure to AQ. Among those, there was chloroquine (CL) which was an 
antimalarial used in developing countries where certain drug-resistant strains of malaria 
were not present. Thus, in the selectivity test, we tested the chloroquine alone and in 
combination with Artesunate the other API in the combination therapy. In these tests, we 
tested different ratio of CL and AQ in both fashion: proportional ratio with equal amount 
of AQ and CL in the solution and inversely proportional ratio starting with a large 
amount of AQ and a small amount of CL and decreasing the amount of AQ and 
increasing the amount of CL.  
In the first series of tests with CL only, Figure 4.6 showed that at excitation 515 
nm and emission 545 nm, the fluorescent signal of EY did not decrease significantly over 
a wide range of CL concentrations from 2 to 100 µg/ml which were also the working 
concentrations of AQ. The EY signal decreased about ~4% between 0 and 2 µg/ml of CL 
and then became stable over a range of CL concentrations. In the proportional ratio test of 
AQ and CL (Figure 4.7), the fluorescent signal decreased at the same rate over similar 
concentrations of AQ compared to the plot in Figure 4.5 where only AQ was tested. 
Moreover, in Figure 4.8, the graph of the inversely proportional ratio test between AQ 
and CL showed similar curve of fluorescent signal versus the concentrations of AQ with 
the increase in concentration of CL when the concentration of AQ decreased. 
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Similarly, the tests of the ratio between AQ and CL were conducted in the 
presence of ATS at the concentration same as the ratio of ATS and AQ in the Winthrop 
tablets. Under the presence of ATS and CL, the linear curve of EY signal versus the 
concentration of AQ was reserved from 0 to 25% or µg/ml in the top graph of Figure 4.9. 
The bottom graph in Figure 4.9 presented the entire AQ concentration response curve 
with EY and showed similar trend to the curve with only AQ and EY. In the experiment 
of the inversely proportional ratio of AQ and CL with ATS, the curve showed no 
significant difference compared to the one with AQ only. The linear region and the entire 
response curve in the top and bottom graphs in Figure 4.10 were conserved with the 
addition of CL and ATS.  
4.3.2.2 Specificity, repeatability, and thermal stability 
  In the specificity test, the fluorescent signal of EY when interacting with 
AQ was compared with the signal from other soluble excipients in the Winthrop, 
ATS, and EY alone with water. From Figure 4.11, the fluorescent signal from the 
excipient and ATS wells did not decrease compared to the EY alone with water 
while the signal from AQ decreased by 10 folds from the original EY signal. 
  To assess the repeatability of the detection of AQ using EY, 5 different sets 
of 5 AQ concentrations with 5% contamination of CL was tested and calculated for 
averages and standard of deviations. For comparison, one set of AQ concentration 
alone was measured and plotted. The plot in Figure 4.11showed that the curves of 
EY versus AQ concentrations with or without CL were similar. The standard 
deviations for each concentration were less than 3%. The coefficient of 
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determination or R2 value for the linear regression of the AQ curve with CL was 
0.9862.  
  In the last validation test, the thermal stability of the quenching effects was 
conducted. The assay was carried under 3 different temperature 4, 22, 37oC. Figure 
4.13 showed that the AQ curves at different temperatures did not have any 
differences in the signal between different concentrations of AQ. The standard 
deviations were relative small (less than 5%). 
4.3.2.3 Winthrop tablet testing 
A standard curve of AQ was created using 5 different concentrations of AQ in the 
linear range (Figure 4.14). A linear regression equation was fitted through the curve and 
used to back-calculate the concentration of AQ in the Winthrop tablet. The equation was 
below: 
421677.1087 +−= xy   Eq 4-1 
The coefficient of determination was 0.9902. The signal for the Winthrop tablet 
was 41248 RFUs. Plugging the value to the equation above, the concentration of AQ was 
about 84% compared to the signal presence on the package (270 mg). 
4.4 DISCUSSION 
To prove that EY can be used to detect the presence of AQ in both pure powder 
and tablet form under the presence of APIs/excipients/impurities, a series of 
characterization tests was conducted. In the first test, we determined the optimal 
excitation and emission wavelength that would give the maximum signal for EY while 
  58 
there would be no or minimal non-specific signal of fluorescent signal from AQ. The 
excitation was determined by the absorbance test to figure out the wavelength at which 
EY absorbed the best and it was 515 nm. For emission wavelength, at 545 nm, the signal 
was not the highest signal for EY, but it showed that the fluorescent signal for AQ and 
blank was almost zero while the signal of EY was the highest. In the working 
concentration of AQ and the LOD/LOQ test, a wide concentration range of AQ was 
tested since the initial test with the original dose from the pharmaceutical company 
showed that AQ quenched EY at very low concentration of AQ. Figure 4.4and Figure 4.5 
showed that from the original measureable concentration of AQ (5.4 mg/ml) had to be 
diluted by a factor of 200 to reach the linear range of EY for the detection of AQ. The 
linear range was from 2 to 40 µg/ml. However, since the EY signal leveled off around 90 
µg/ml. The LOD/LOQ was 2 times more than the linear range.  
In the validation tests, the chloroquine was chosen to test for the selectivity test 
because it had similar chemical structure to AQ and has been known to be manufactured 
in the same facility with AQ as antimalarial. From Figure 4.6, we can see that the 
working concentration of CL was much higher than AQ. In the concentration range of 
AQ, CL did not quench the fluorescent signal of EY. To confirm the effect of CL on EY, 
we ran tests at different ratio of CL and AQ in the same amount or reverse amount of AQ 
to CL. In both tests, CL did not affect the reaction between AQ and EY and the linear 
range of AQ was reserved (Figure 4.7and Figure 4.8). To imitate the scenario in the 
tablet, we added ATS in the mixture of CL and AQ and ran the tests again. Similarly, the 
EY signal was quenched in the presence of different concentration of AQ at the same 
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decay curve like the one without ATS and CL. 
In the specificity test, the excipients in the Winthrop tablets and artesunate were 
tested. This test was to show that other chemical in the tablet cannot cause any non-
specific quenching of the fluorescent signal of EY. In Figure 4.11, there were one 
negative control (EY only) and one positive control (EY and AQ) to validate that the 
assay was working on the date of testing. From the bar plot, EY did not interact with any 
of the excipients or API like ATS.  
The repeatability test was run on 5 different sets of AQ prepared separately. This 
test was to account the human and machine errors during the weighing, pipetting, and 
fluorescent readings. The small standard deviation in Figure 4.12 showed that the assay 
was repeatable under different measurement and preparation conditions. In the last 
validation test, we wanted to determine whether the fluorescent signal would change with 
temperature since the assay may be conducted at different temperature from advanced 
laboratory to hospitals in developing countries. The curves from Figure 4.13 showed that 
the temperatures from 4 to 37 ºC did not affect the fluorescent signal of EY.  
After the validation experiment, the assay was run on the real Winthrop tablets 
collected from Ghana before the expiration date. The result showed that the tablet has 
only 84% of AQ for 3 different tablets from the same batch. This showed the high 
precision of the assay to test the tablet. To assess the accuracy of the assay, the results 
need to be confirmed with UV-HPLC in the future step.  
Overall, we have developed a novel fluorescent assay to detect AQ using the 
quenching effect of AQ on EY. Through a series of tests, we figured out the optimal 
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testing condition for EY and validated the sensitivity, selectivity, specificity, 
repeatability, and thermal stability of EY with AQ under the presence of other excipients 
and API in the tablets. This assay can be potential new approach to detect AQ with high 
precision and accuracy in the fixed-dose combination therapy for antimalarial without the 
need to extract AQ and ATS separately from the tablets. 
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4.5 FIGURES 
 
 
Figure 4.1: The chemical structure of eosin Y and its excitation/emission wavelengths 
Left: The chemical structure of eosin Y. Right: the excitation and emission spectrum of 
eosin Y. 
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Figure 4.2: The absorbance scanning of a blank, detection probe (EY) at 0.1 mM, and AQ 
at 27 µg/ml 
The plot showed that EY has maximum absorption at 515 nm. (n=8) 
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Figure 4.3: The emission scans from 530 to 590 with 5-nm intervals and 515 nm 
excitation wavelength for EY  
The experiment was run with a blank of water, AQ, and mixture of AQ and EY as the 
negative controls. (n=8) 
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Figure 4.4: The LOD/LOQ of AQ in water and ethanol 
 
Top: The LOD/LOQ of AQ using EY in ethanol (n=4). Bottom: The LOD/LOQ of AQ 
using EY in ethanol. (n=4) 
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Figure 4.5: Determination of linear range of AQ detection curve  
The plot of fluorescent signal of EY in the presence of AQ at 12 concentrations (200, 
150, 100, 90, 80, 70, 60, 50, 40, 30, 20, 0 µg/ml) will determine the range of AQ 
concentrations that produced a linear curve of EY fluorescent signal of EY when mixing 
with EY. 
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Figure 4.6: Selectivity test of chloroquine with eosin Y 
The fluorescent signal of eosin Y when reacting with CL at 8 different concentrations (0, 
2, 5, 10, 25, 50, 75, 100%) was plotted. 100% equaled to 100 µg/ml of CL.The excitation 
and emission wavelengths were 515 nm and 545 nm. (n=5) 
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Figure 4.7: The detection curve of AQ in the presence of CL in the proportional order 
 
The fluorescent signal of eosin Y when reacting with both AQ and CL at the same 
concentrations ranged from (0, 2, 5, 10, 25, 50, 75, and 100%) was plotted. 100% equaled 
to 100 µg/ml for both AQ and CL at excitation 515 nm and emission 545 nm. (n=5) 
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Figure 4.8: The detection curve of AQ in the presence of CL in inversely proportional 
order  
The fluorescent signal of eosin Y when reacting with both AQ and CL at the inversely 
proportional concentrations ranged from (0, 5, 10, 20, 40, 60, 80, 90, 95 and 100%) was 
plotted. The solution of 100% equaled to 100 µg/ml for AQ and 0% to 100 µg/ml of CL. 
As the concentration of AQ decreased, the concentration of CL increased. The total 
concentration of AQ and CL for each point was 100% or 100 µg/ml. The red point was 
the signal from eosin Y only at 515/545 nm (excitation/emission). (n=5) 
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Figure 4.9: The detection curve of AQ in the presence of CL and ATS in proportional 
order  
The fluorescent signal of eosin Y when reacting with both AQ and CL in the presence of 
ATS at the same concentrations ranged from (0, 2, 5, 10, 25, 50, 75, and 100%) was 
plotted. The solution of 100% equaled to 100 µg/ml for both AQ and CL; and 36 µg/ml 
for ATS. The red point is the signal from eosin Y only. Top: The zoom-in portion of the 
linear region of the entire curve ranged from 0 to 25%. Bottom: The entire curve of 
fluorescent signal of eosin was an exponential decay in fluorescent signal. The excitation 
wavelength was 515 nm and the emission wavelength was 545 nm. (n=5) 
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Figure 4.10: The detection curve of AQ in the presence of ATS in proportional order and 
CL in inversely proportional order  
The fluorescent signal of eosin Y when reacting with both AQ and CL at the inversely 
proportional concentrations ranged from (0, 5, 10, 20, 40, 60, 80, 90, 95 and 100%) was 
plotted. 100% equals to 100 µg/ml for AQ and 36 µg/ml for ATS and 0% equals to 100 
µg/ml of CL. As the concentration of AQ decreased, the concentration of CL increased. 
The total concentration of AQ and CL for each point was 100% or 100 µg/ml. The red 
point was the signal from eosin Y only. A: The zoom-in portion of the linear region of the 
entire curve ranged from 0 to 25%. B: The entire curve of fluorescent signal of eosin was 
an exponential decay in fluorescent signal. The excitation wavelength was 525 nm and 
the emission wavelength was 545 nm. (n=5) 
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Figure 4.11: The Specificity of eosin Y to Winthrop’s excipients 
 
The fluorescent signal of eosin Y when reacting with 5 different excipients from 
Winthrop tablet at the concentration of 23 µg/ml for all excipients was plotted. The last 
three columns were the fluorescent signal of eosin Y only, AQ at 100 µg/ml and eosin Y 
with AQ at 100 µg/ml. The excitation wavelength was 515 nm and the emission 
wavelength was 545 nm. (n=5) 
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Figure 4.12: The standard curve of AQ with 5% CL contamination 
The standard dilution curve of AQ at 5 different concentrations (6.25, 12.5, 18.75, and 25 
µg/ml or 25%, 50%, 75%, and 100%) at 515/545 nm (excitation/emission) was presented. 
There are two curves: one with 4% contamination of CL (n= 3 measurements with 5 
samples) and one without CL (n=1 sample with 3 measurements/sample). The error bar is 
very small (less than 5%). 
  73 
 
Figure 4.13: The standard curves of AQ at 4 ºC, 22 ºC, and 37 ºC 
The standard curve of AQ at 0, 25, 50, 75, 100% concentrations (100%=25 µg/ml) was 
created ad measured at 3 different temperatures (4 ºC, 22 ºC, and 37 ºC). 3 replicates 
were measured for each of the concentration of AQ at each temperature. The standard 
curves at 4 ºC, 22 ºC, and 37 ºC were overlapped with each other. The errors bars are less 
than 1%. 
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Figure 4.14: The plot of AQ standard curve at 5 different concentrations (0, 2, 5, 10, 25 
µg/ml) 
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Chapter 5 Systematic Evolution of Ligands Enrichment for Trimethoprim 
5.1 INTRODUCTION 
The assay developments using luminol and eosin Y in chapter 3 and 4 was only 
suitable specific to small chemicals which have the special peroxide groups like ATS or 
the quenching ability through ionization. A more general system/protocol to generate 
different detection probes is required. There are two approaches for probe development 
by looking at: chemical and physical properties. Most of current detection systems focus 
on the physical properties. For development of probes, the chemical properties are 
chosen. Specifically, the detection based on the binding of short nucleic acid sequences 
called aptamers is investigated in this chapter.  
To validate the performance of the aptamer system, antibacterials are chosen as 
the model. Like antimalarials, antibacterial agents have been determined to be among the 
most popular substandard drugs, especially the well-developed and studied antibiotics 
like trimethoprim (TMP) and sulfamethoxazole (SMZ) (Kelesidis, Kelesidis, Rafailidis, 
& Falagas, 2007) . Most of cases were found in Africa and Southeast Asia where 
bacterial infections were easily widespread. In the case study in Nigeria, about 48% of 
antibacterials were substandard with the API content outside the acceptable range (Taylor 
et al., 2001b). Also, in the study of WHO in Vietnam and Myanmar, about 20% of the co-
trimoxazole were found to be substandard (Wondemagegnehu, 1999). Like antimalarials, 
substandard antibacterial can lead to the increase in mortality rate and drug-resistant 
cases. The gold standard methods for substandard drugs detection is HPLC due to its 
versatility in quantifying multiple components simultaneously, but not many lab in the 
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developing can afford and have trained personnel to use it (Shamsa & Amani, 2006). As 
the results, an assay that can quantify both TMP and SMZ in the same tablet in the 
resource-limited setting would be ideal. Since TMP in the salt form with lactate group are 
slightly soluble in water, aptamer-based probes would be suitable for detection. 
Moreover, the probes can be attached with different fluorescent dyes to allow the specific 
detection of TMP. Here, we are going to explore different protocols and microbiology 
techniques to optimize the systematic evolution of ligands by exponential enrichment 
process (SELEX) to develop an aptamer specific to the small molecule drug target. 
Aptamers are relatively short sequences of nucleic acids or peptides that change 
their secondary structure upon their binding to another chemical. This binding can lead to 
the increase in decrease in the fluorescent signal that is correlated with concentration of 
the chemical in the solution (Blind & Blank, 2015). Due its sensitive and specific binding 
to different targets and the ability to attach different fluorescent dyes to its structure, 
aptamers has been developed as detection probes in therapeutic applications like drug 
delivery. The advantages of aptamer-probe are that it can be easily modified to suit the 
need of imaging system and can be attached with different fluorescent dyes for 
multiplexed detection of different targets (Stoltenburg, Reinemann, & Strehlitz, 2007). 
Moreover, due to their chemical structures, aptamers has the ability to form secondary 
structures based on the arrangement of nucleotides within the sequence. This property 
allows aptamers to bind specifically to the targets.  
In pharmaceutical analysis, there are very few aptamers that have been developed 
to detect different API components in the tablets. Thus, I proposed to use a systematic 
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evolution of ligands by exponential enrichment (SELEX) that has been developed for 
many decades to screen for specific aptamers that bind to pharmaceutical targets.  
SELEX begins with a library of 1014-1015 random sequences of nucleic acids with 
the length 30-100 nucleotides (nt), which depend on the sizes of the target. The aptamers 
have two fixed short sequences (10-40 nt) at the two ends that serve as primers during the 
amplification step. For RNA aptamers, one of the primers contains T7 promoter for RNA 
polymerase to bind. The targets for selection can be ranged from small organic 
molecules, nucleic acids, peptides, proteins, cell surface’s markers, viruses, antibiotics,… 
SELEX starts with the generation of random library of DNA, RNA, or peptides 
(Ellington & Szostak, 1992; Hermann & Patel, 2000; Srisawat, Goldstein, & Engelke, 
2001; Ulrich, Magdesian, Alves, & Colli, 2002). The nucleic acid library goes through a 
selection and enrichment process that includes 10-20 cycles of the same steps to screen 
for the aptamers that are highly specific to the target. After the cycles, the sequences 
remaining in the library are cloned and/or sequenced to determine the secondary 
structure. Finally, the aptamers are post-modified to attach different fluorescent dye on 
one end and enhance the stability of aptamers in the testing environments. The SELEX 
process can be divided into 5 different main steps: the selection of the target-bound 
aptamers from the unbound, the amplification of the aptamers, the conditioning, the 
cloning and sequencing, and the characterization/modifications of the final aptamer  
(Stoltenburg et al., 2007) (Figure 5.1) As a proof of concept, trimethoprim was used as 
the target. The chemical structure was described in Figure 5.3. 
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5.1.1 Selection of bound and unbound aptamers 
This process starts with a library of 1013-1015 molecules or 2 nmol of random 
aptamers. The library can be amplified for 20-30 cycles using Polymerase Chain 
Reaction (PCR) and isolated the aptamers from the rest of the reaction to begin the first 
cycle of SELEX. The targets are incubated with the aptamer library for a period of time 
to allow the binding to the targets at the concentration of target from 10 to 1000 µM. The 
next step is the partitioning step that separates the unbound aptamers from the unbound 
ones. This step is crucial to achieve high specificity and sensitivity of aptamers to the 
target.  
There are multiple methods used for the separation depending on the size and 
chemical properties of the targets. For targets that are relatively large (about 30000 
Daltons) and have special chemical groups in the structure like amines, carboxylate, etc., 
the targets can be immobilized on a chromatography column based on sizes, charges or 
covalent bonds to modified beads in the column (Mann, Reinemann, Stoltenburg, & 
Strehlitz, 2005). After that, the aptamers would be injected to the column. Only the bound 
aptamers remain in the column and can be release from the column by changing injection 
buffers. On the other hands, when the targets are relatively small like small organic 
molecules and peptides, the aptamers can be first immobilized like Capture SELEX 
(Figure 5.2) on magnetic beads through biotin-streptavidin binding described in the 
schematic in Figure 5.4 (Spiga, Maietta, & Guiducci, 2015; Stoltenburg, Nikolaus, & 
Strehlitz, 2012). Then, the beads are incubated in the target solution. The beads are 
washed with buffers to remove all the unbound aptamers and then incubate with the 
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target. The aptamers bound to the targets will release from the beads into the solution. 
The solution would be separated from the beads, collected, and used in the next step. 
Another approach for small targets is using graphene oxide to separate the bound from 
the unbound ones. The aptamers are incubated with the targets and then the graphene 
oxide. The bound aptamers would not bind to graphene oxide since they cannot form π-
stacking interaction with graphene oxide, thus remains in the solution (Park, Tatavarty, 
Kim, Jung, & Gu, 2012).  Third, if the target-aptamer complex is significantly larger than 
the individual like virus or complex proteins, filter membrane with specific molecular 
weight cutoffs can be used to separate the complex from the unbound aptamers (Kirby et 
al., 2004). Another method is capillary electrophoresis that uses electric field to separate 
the bound and unbound aptamer by size or charge similarly to column chromatography 
but in smaller scale. If the targets are cell surface markers, the flow cytometry are used to 
separate cells with bound aptamers from the solution (Ulrich et al., 2002). Alternatively, 
surface enhanced resonance and electrophoretic mobility shift assay can be used for 
selection of the bound aptamers from the unbound one (Stoltenburg et al., 2007). 
After the partitioning, the bound aptamers are eluted from targets by heat or the 
addition of urea, sodium dodecyl sulfate or ethylenediaminetetraacetic acid (EDTA) 
when the target are immobilized. These factors weaken the affinity between the aptamers 
and targets and release them into the elution buffer (Bianchini et al., 2001). In the case of 
immobilization of aptamer, the bound aptamers can be separated using a magnet from 
magnetic beads or centrifugation.  
In the case of small organic molecules, before the bound aptamers are ready for 
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amplification, they should be separated from the targets using alcohol precipitation for 
alcohol-soluble organic compounds or phenyl chloroform separation for small peptides. 
5.1.2 Amplification 
In the amplification step, depending on the types of aptamers, there are two 
common ways to amplify the aptamers pool. For RNA aptamers, the sequences are 
reverse-transcribed into complimentary DNA (cDNA), which is amplified during 
subsequent Polymerase Chain Reaction. For DNA aptamers, the sequences are directly 
amplified using PCR. During the amplification, the amount of aptamers can be quantified 
using Taqman probe PCR described in Figure 5.5 or Sybr Green PCR in Figure 5.7. For 
Taqman probe, it only works for Capture-SELEX protocol where there is a fixed/docking 
sequence separating the random regions into 2 different sequences. The Taqman probe is 
a sequence about 10-20 nucleotides in length with a fluorescent dye and quencher 
attached at both ends. Due to Forster Resonance Energy Transfer (FRET), it does not 
emit fluorescence under the presence of quencher in the short distance (less than 10 nm) 
(Nagy et al., 2016). With this ability, Taqman probe can be designed to be complimentary 
to the docking sequence so that during PCR Taqman probe can bind to the DNA 
aptamers. When Taq DNA polymerase incorporated nucleotide to the Taqman probe 
sites, it would chop off the Taqman probe and the fluorescent dyes would cleave from the 
quenchers and emit the signal. In the case of Sybr Green PCR, Sybr Green is a special 
fluorescent molecule that only binds and emitting fluorescence only to double stranded 
DNA. Using this ability of Sybr Green, we can use this assay to determine how much of 
single-stranded DNA aptamers present in the solution after the incubation step (Dinoop, 
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Parija, Mandal, Swaminathan, & Narayanan, 2016). In both cases, a standard curve of 
different concentrations of random aptamers would need to be created in the log scale to 
be used to calculate the amount of DNA aptamer in the unknown samples from the 
SELEX cycles. 
Alternatively, the aptamers can be modified to incorporate fluorescent molecules 
to the 5’-end of the forward primer in the first cycles, so the aptamers eluted from second 
cycle can be measured using fluorescent reading mode in the spectrophotometer 
(Stoltenburg et al., 2012). Moreover, in the preparation for the conditioning step, a 
reverse primer with phosphorylated 5’-end would be used to during PCR so that the 
complimentary strain of DNA aptamers can be digested in the next step. 
5.1.3 Conditioning 
Since the products in the amplification step have two strands, a conditioning step 
is required to separate the aptamer strands from its complimentary strands. For RNA 
aptamer, during the amplification step, its primer attached to the cDNA aptamer strands 
has the T7 promoter, which is the binding site for RNA polymerase to start the 
transcription of cDNA back to RNA aptamers. The complimentary DNA strands are 
digested using DNAse enzyme at 37oC for at least 4 hours. For DNA aptamers, there are 
multiple ways to recollect only DNA aptamer, but not the complimentary strands. Firstly, 
during the amplification step, the unwanted DNA strands are modified by adding HEGL-
spacer with poly-A tail (15-20 nucleotides) to the 5’ end of the primer or a ribose residue 
(ribo-U) to the 3’ terminal. These modifications help to either lengthen (for the spacer 
with the polyA tail adding to the end of the complimentary strands) or shorten (for ribo-U 
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with the deletion of the reverse primers from the complimentary ones) the length of the 
unwanted sequences, so there would be two strands of DNA at different lengths after the 
amplification step. After that, the desired DNA sequences are extracted using urea 
denaturing Polyacrylamide Gel Electrophoresis (PAGE) (Stoltenburg et al., 2012; 
Summer, Grämer, & Dröge, 2009). Another way is to attach biotin molecules to the end 
of the unwanted sequences so that they can be separated from the aptamers using urea 
denaturing PAGE or attaching to surface with streptavidin. In addition, an enzymatic 
digestion of Lambda exonuclease can be used to cleavage the unwanted sequences with 
5’ phosphorylated ends. 
5.1.4 Sanger Sequencing and Next generation sequencing 
After 6-20 cycles of SELEX, the remaining aptamers are cloned into E. coli 
bacterial vectors and get transformed into the E. coli bacteria. The bacteria would be 
grown in Luria-Bertani (LB) agar plate with X-gal/IPTG to distinguish a good insertion 
(white) from no insertion colony (blue) based on the color of the colonies. Each 
individual white colony is cultured in LB media with ampicillin, extracted, and 
sequenced using Sanger sequencing. However, when Next Generation Sequencing (NGS) 
becomes more affordable, the aptamers after the cycles can go directly to library 
preparation and then sequencing. This can yield about 15 million reads per run and 
aptamers from different cycles can be barcoded to be sequenced simultaneously. After 
the sequencing step, the sequences can be aligned using BLAST from NIH website if 
Sanger sequencing was used. In the case of NGS, the data has to be indexed and counted 
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using a program Tallymer in the Genome Tools packages developed at University of 
Hamburg, Germany 
5.1.5 Characterization and post-modifications 
When the sequences from the cycles are obtained, a binding study in conducted to 
determine which sequences had the highest affinity to the target. Then, the aptamer with 
highest affinity would go under dose response study to calculate the disassociation 
constant (KD) between the aptamer and targets. The next test is the test about the 
specificity of the aptamers with other molecules with similar structure the target and 
other chemicals that may be dissolved in the solution with the targets. Finally, the 
aptamers with highest specificity and affinity go under post-modifications process to 
increase the stability. For RNA aptamers, the 2’-OH groups are replaced with with 2’-F 
or 2’-NH2 group or 2’-OCH3 to prevent RNA degradation from RNAse. Moreover, RNA 
nucleotides can be replaced by locked nucleic acids where the 2’-oxygen and the 4’-
carbon in the sugar ring are covalently bonded to methylene. DNA aptamers can be 
capped with streptavidin-biotin or inverted thymidine in the 3’-end or 
amine/phosphate/PEG/cholesterol/fatty acids/protein in the 5’-end. Finally, the modified 
aptamer may go under the SELEX again to ensure the comparable affinity to the target 
(Stoltenburg et al., 2007). 
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5.2 MATERIALS AND METHODS 
5.2.1 CAPTURE - SELEX  
To develop an aptamer for TMP, the Capture-SELEX protocol was modified 
some step to increase the probability of finding the aptamer. Specifically, Capture-
SELEX was designed for small organic molecules, which can be fixed on any surfaces, 
so the aptamers would be fixed on magnetic beads in this protocol. The schematic that 
summarized the Capture-SELEX step was in Figure 5.2. 
5.2.1.1 Buffer and target preparation 
All the reagents were bought from Sigma Aldrich. For the target, trimethoprim 
(TMP), an antibacterial, was used in combination with sulfamethoxazole to treat bacterial 
infection. The molecular weight of the salt form of TMP (trimethoprim lactate) is ~380 
g/ml. to make 10 ml of 1mM concentration of TMP, 3.8 g of TMP lactate was dissolved 
in 1000 µl of ethanol, and then 9 ml of selection buffer. The target solution was aliquoted 
into 500 µl tube and stored in the -20 ºC freezer until it was ready to incubate with 
aptamers. The 10 ml solution of the selection buffer (SE) was made from 1 ml of sodium 
chloride (NaCl) 1M, 200 µl of magnesium chloride (MgCl2) 100mM, 500 µl of 
potassium chloride (KCl) 100mM, 100 µl of calcium chloride (CaCl2) 100mM, and 8.2 
mL of nuclease free water. The binding and washing buffer (BW) with 2 times 
concentration used to condition the magnetic beads was made of 100 µl of 100x Tris-
EDTA, 4 ml of NaCl 5 M, and 5.9 ml nuclease free water. The elution buffer (EB) was 
prepared using 200 µl of EDTA 0.1 M, 1ml of sodium acetate (NaCH3COO) 3 M, and 
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8.8 ml of nuclease free water. The TBE 10x buffer was consisted of 108 g of Tris base 
and 55 g of boric acid dissolved in 800 ml of distilled water and 4 ml of EDTA 0.5 M and 
then diluted to 1 l using distilled water. The TBE solution was stirred on the stir plate 
until the solution becomes completely clear. The solution of ammonium persulfate 30% 
(APS) was made with 150 mg of APS dissolved in 500 µl of water. 
The library in this SELEX protocol is 88 nucleotide sequences with two fixed 
primer at 2 ends and 25 random nucleotides that is plunked by a fixed complementary 
docking sequences like below: 
5’ – CCTGCCACGCTCCGCAAGCTT – N8 – CTGCAGCGATTCTTGATCG – N17 
– ATAGCTTGGCACCCGCATCGT – 3’ 
The bolded sequences are the binding sites for primers during PCR. The 
underlined sequence is the complimentary region to the biotinylated docking sequence 
bound to the magnetics beads (Stoltenburg et al., 2012). For the DNA library, the 
biotinylated docking sequence and primers, they were ordered from Integrated DNA 
Technology and dissolve in nuclease free water to achieve concentration of 100 µM. 
5.2.1.2 Aptamer binding to the magnetic beads 
Firstly, there were two optimization steps to be done to determine the binding 
capacity of the magnetic beads to biotinylated docking sequences and the binding of the 
docking sequence and aptamer complexes to the beads. For the biotin-streptavidin 
binding capacity, different amount of biotinylated docking sequences (1, 1.5, 2 nmoles or 
10, 15, 20 µl of docking sequence at 100 µM was incubated with 100 µl of magnetic 
beads. The amount of docking sequences remaining in the supernatant before and after 
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the incubation was measured using the Nanodrop. The theoretical biotin-binding capacity 
of magnetic beads was about 250 pmoles, which was 4, 6, and 8 times less than the 
amount of biotinylated sequences was used.  
In the binding of the docking sequence and aptamer complexes to the beads 
through the biotin-streptavidin bonds, the docking sequences were incubated with the 
aptamers at ratio of 1:1 and 1:2. The Nanodrop measurements were taken for the docking 
sequences, aptamers, and the complexes before annealing, after annealing, and after 
incubation. The percentage of bond complexes was calculated by comparing to the 
measurement after annealing. The detailed annealing and incubation steps were described 
below. 
In the first round of SELEX, 50 µl of docking sequences at the concentration of 
100 µM was diluted in 1450 µl of BW buffer. Similarly, 50 µl of aptamer at 100 µM was 
mixed with 1450 µl of BW buffer. All the solutions were mixed by vortex. After that, a 
solution of 1500 µl of docking sequencing was mixed with 1500 µl of aptamer solution in 
15 ml conical tube. The mixture was aliquoted into 96-well PCR plate. The plate was 
incubated in the thermal cycler at 95 ºC for 10 minutes; cool down and hold at 60 ºC for 5 
minutes and slowly cool down to 4 ºC over 18 minutes. The solutions from the well were 
pooled together into microcentrifuge tube for the next step.  
Simultaneously, the Dynabeads® streptavidin-coated magnetic beads in the vial 
(Thermo Scientific, CA) were re-suspended by vortex for 30 seconds continuously. A 
volume of125 µl of Dynabeads® magnetic beads was transferred to 2 tubes (125 µl per 
tube). One milliliter of BW was added to the beads in the microcentrifuge tubes. To wash 
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the beads, the tubes were placed on a magnet for 1 min and the supernatant were 
carefully discarded to the waste container. 
The tubes were removed from the magnet and the washed magnetic beads were 
re-suspended in 1 ml of BW. The washing steps were repeated two more times. In the 
final the beads were re-suspended in 1ml BW buffer and pooled together into 2 ml tube in 
the first round. The solution of washed beads was divided into 5 tubes with 400 µl of 
beads per tube. The supernatant in each tube was removed from the beads using the 
magnet and the beads were re-suspended in 600 µl of the docking sequence and aptamer 
mixture and 600 µl of BW. The tubes were incubated at 4 ºC overnight on a gentle shaker 
for 20-22 hours.  
5.2.1.3 Binding to the targets  
On the next day, the magnetic beads were washed with 500 µl of selection buffer 
for 3 times to remove the aptamers that were not bound to the beads through the biotin-
streptavidin bonds. After that, they are incubated in 500 µl of selection buffer at room 
temperature for 15 minutes with mild shaking to remove unbound/weakened-bound 
aptamers. Again, the beads were washed with 500 µl of selection buffer for 3 times. The 
beads in 5 tubes were re-suspended in 500 µl of selection buffer per tube. All the solution 
was pooled together into 15 ml tube and divided into 5 microcentrifuge tubes (500 µl per 
tube). One tube was for the negative control and four tubes for the incubation with the 
target. The control tubes was re-suspended in 400 µl of selection buffer while the target 
tubes were re-suspended in 400 µl of TMP 100 µM diluted by a factor of 10 from the 
stock solution prepared and stored in the freezer. All the tubes were incubated on a shaker 
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for 45 minutes. After the incubation, all the solutions with TMP was pooled together in 2 
ml tubes and mixed well to be ready for the amplification step. 
5.2.1.4 Amplification – Taqman Probe 
The solution of 1600 µl of aptamer with TMP is mixed with PCR mastermix at 
the ratio 75 µl:25 µl of aptamers. The forward primer was 5’ – CCTGCCACGCTCCGC 
– 3’ while the reverse primer was 5’-phospho-ACGATGCGGGTGCCAAGCTAT–3’ 
with the 5’ end phosphorylated for Lambda reaction or 5’–AAAAAAAAAAAAAAA – 
spacer 18 – ACGATGCGGGTGCCAAGCTAT – 3’ with an 18-atom hexa-
ethyleneglycol spacer in between the polyA tail and the reverse primer (Stoltenburg et al., 
2012). The Taqman probe was 5’-FAM-CAAGAATCGCTGCAG-Quencher-3’ with the 
5’ end attached to the fluorescein molecule and 3’ end to a Iowa black quencher. The 
PCR mastermix was prepared by adding all the components presented in Table 5.3 
together except for the DNA aptamers in a tube. All the mixing was done by vortex, 
except for the DNA Polymerase which was mixed by putting the tube upside down 
multiple times. A set of standards of DNA aptamers at 5 different concentrations (109, 
1010, 1011, 1012, and 1013 copies/ml) was prepared and run under PCR with the aptamer 
samples with and without TMP for quantification of aptamers. After the PCR reagents 
and DNA samples were mixed and pipetted in the 96-well PCR plate, the plate was 
centrifuged at 2500 rpm for 1 minute to drag down all the drops on the edge of the wells. 
The PCR was carried in the Applied Biosystems 7300 Real-Time PCR system to quantify 
the aptamer samples using the Taqman probe. The program was set up according to Table 
5.4.   
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5.2.1.5 DNA purification  
5.2.1.5.1 Polyacrylamide precipitation 
The PCR solution was precipitated in 75% ethanol using Linear Polyacrylamide 
(LPA). For each precipitation tube, 500 µL of the DNA aptamer were added in a 2 ml 
microcentrifuge tube with 50 µl of 3 M sodium acetate buffer at pH 5.2, 2 µL of 
GenElute LPA (25 ug/uL) from Sigma Aldrich and 1250 µl of 100% ethanol. The 
mixtures were vortexed for 15 seconds. They were centrifuged for 5 minutes in a 
microcentrifuge at maximum speed (14,000 rpm). At the bottom of each tube, a white 
pellet would be formed. The supernatant were carefully discarded to the waste container. 
The pellets were re-suspended in 200 µL of 70% ethanol. The solutions were centrifuged 
for 5 minutes at 14000 rpm and the supernatants were removed. The pellets were allowed 
to air dry in the open tubes for 10 minutes. The DNA/LPA pellets were dissolved in 100 
µl of 1x TE buffer at pH 8. The precipitation process was repeated again to decrease the 
PCR solution 100 µl to be ready for the separation step using gel electrophoresis. 
5.2.1.5.2 ChargeSwitch® PCR cleanup 
The DNA aptamers purification step was performed using the ChargeSwitch® 
PCR cleanup kit from Thermo Scientific. In the preparation step, the tube containing the 
ChargeSwitch® magnetic beads was vortexed for 15 seconds to fully re-suspend and 
evenly distribute the beads in the storage buffer. After that, 400 µl of PCR solution from 
the amplification step were transferred to a PCR graded 2mL microcentrifuge tube. In the 
first round, there were 16 tubes total from 6300 ul of PCR products). A volume of 300 µl 
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of Purification Buffer (N5) was added to the tubes. After 40 µL ChargeSwitch® 
Magnetic Beads was added to the tubes, they are mixed together by pipetting up and 
down gently without forming bubbles. The mixture was incubated at room temperature 
for 3 minutes. The tubes were placed on magnet rack for 1 minute to form tight pellets on 
the wall of the tubes. The supernatants were carefully removed from the tubes without 
disturbing the pellets and discarded to the waste container. 
In the next step, the DNA aptamers were washed with 800 μL Wash Buffer (W12) 
per tube. The solutions were mixed by pipetting up and down gently. The tubes were 
placed on the magnetic rack to take out the supernatant to the waste container. The 
washing step was repeated one more time. 
In the elution step, the magnetic beads were re-suspended in 100 µl Elution 
Buffer (E5; 10 mM Tris-HCl, pH 8.5) by flicking the tube. The mixtures were incubated 
at room temperature for 5 minutes. After that, the supernatants were separated from the 
beads and transferred to new tubes (16 tubes total) for separation step using Lambda 
digestion. 
5.2.1.6 Separation 
5.2.1.6.1 Gel electrophoresis and elution 
To run denaturing PAGE for all aptamer solution from PCR, two 10.1 x 8.2 cm x 
1 mm gels were prepared. The gel set up was purchase from Bio-Rad. For each gel, 10 ml 
gel solution of 10% acrylamide was prepared according to Table 5.5. Ultrapure urea was 
weighed and dissolved in a desire amount of the acrylamide 40% solution. One milliliter 
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of TBE 10x was added to the solution. The mixture was warmed up in 37 ºC incubator for 
5 min and vortex and warm up again at 37 ºC if all the urea does not dissolve. After that, 
33 µl of ammonium persulfate 30% was added and mixed gently by inverting the tube up 
and down 10 times. In the final step, TEMED was added to the mixture and mixed well. 
The gel solution was poured immediately into the gel plates using serological pipette. A 
comb of 10 bars with 1 mm thickness was inserted between the plates. The gels were 
polymerizing for 15 minutes. To see if the gel was polymerized, the gel remaining is 
checked if it is solidified. 
When the gel was ready, the gel apparatus was set up. The comb was removed 
and the gel was washed with distilled water and assembly to the gel apparatus according 
to the instruction from Bio-rad. One liter of TBE1x was prepared and filled in the lower 
chamber to make sure the glass plates with gel were submerged until the mark for 2 gels 
on the gel box. After that, the upper chamber was filled up to the top of the gel with TBE 
1x buffer. 
The gel was pre-run using the high voltage power supply box to heat up to 55 ºC 
so that the temperature after while the real run was between 45-55 ºC. The lid of the gel 
box was closed and connected to the power supply. The power was turned on for 40 
minutes at 40 Watts, 590 Volts, 80 milli Ampere, and 55 ºC). 
While the gel was heated, the aptamer samples were prepared by adding 100 µl of 
samples to 200 µl of RNA 2x loading blue dye from New England Biolabs. On the side, a 
DNA ladder solution was made by adding 5 µl of DNA ladder from Thermo Scientific to 
10 µl of dye. Before the samples and ladder could be loaded on the gel, they must be 
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heated to 95 ºC for 10 minutes and cooled down immediately into ice bucket to prevent 
the annealing of the single stranded DNA. The samples and ladder were loading to the gel 
immediately after this step.  
When the pre-run was finished, the well was washed with TBE 1x buffer to 
remove any excessive urea from the well that would prevent the sample to run. Eight 
microliters of ladder and 15 µl of aptamers were loaded separately into each well like the 
table below.  
Ladder 
8 µl 
Sample 
15 µl 
Sample 
15 µl 
Sample 
15 µl 
Sample 
15 µl 
Sample 
15 µl 
Sample 
15 µl 
Sample 
15 µl 
Sample 
15 µl 
Sample 
15 µl 
 
The gels were run at constant power (40 W, 500 V, 80mA, and 50 ºC) to maintain 
a gel temperature of 45-50 ºC. The run time was about 30 minutes or until the front 
marker exited the gel and the second marker about 1 cm above the end of the gels. 
When the run was done, the gel was removed from the gel box, washed with 
distilled water and disassembly from the glass plates into empty plastic box. For each gel, 
5 µl of Sybr Gold dye from Thermo Scientific and 50 ml of TBE running buffer were 
added to the box and put on the gentle shaker for 30 minutes. After that, the gel was 
exposed to UV lamp in the dark room to visualize the DNA aptamer bands and its 
complimentary strands. The aptamer bands were cut from the gel and transferred to a new 
PCR tube for DNA elution. 
From the PAGE, there were 18 pieces of gel total. The gel pieces were crushed in 
a 500 µl tube with a 1mm-diameter hole at the bottom by centrifuging at 14000 rpm for 
10 min into a 1.5 ml tube. Two pieces of gel was crushed into one tube. The gel powders 
were eluted in 400 ul of elution buffer at 2mM EDTA and 300 mM sodium acetate at pH 
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7.8 at 80 ºC for 150 minutes. The tubes were vortexed for 5 seconds every 30 minutes. 
The eluted supernatants were separated from the gel using Millipore filter tube and 
centrifuging at 14000 rpm for 5 minutes. The solution was precipitated again using LPA 
to decrease the volume to 450 µl of aptamer in selection buffer and stored in the freezer 
for the next cycle. 
5.2.1.6.2 Digestion of aptamer’s complimentary strands 
During the amplification step, the reverse primers with phosphorylated were 
attached to the complimentary sequences of the aptamers. Thus, in the digestion step, 
lambda exonuclease digestion kit from Thermo Scientific was used to digest the 
phosphorylated complimentary sequences.  The mastermix of the enzymatic reaction was 
prepared as described in Table 5.6. After the PCR cleanup step in the previous section, 
there were 1000 µl of PCR products left and aliquoted to 10 different tubes. For each 
100µl of PCR product, 100 µl of mastermix was added to the tube. The reactions were 
carried at 37 ºC for 2 hours. At the end of the incubation, the enzymes were inactivated 
by adding 10 µl of EDTA 0.5 M to the reactions. The digested solution went under PCR 
cleanup again to reduce the volume to 700. 
From the cycle 2 and up, in the binding of the docking sequences and aptamer 
complex to the beads, 50 µl of docking sequences 10 µM was mixed with 700 µl of 
aptamer from the previous cycle in 2 ml DNA low bind tube and 750 µl of BW 2X and 
incubated overnight. After the washing step on the next day, the beads were re-suspended 
in 800 µl of selection buffer and divided into 2 tubes for samples with and without TMP. 
The number of PCR reactions was adjusted to the aptamer volume after the incubation 
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with TMP. All the other steps were kept the same. The graph of the amount of aptamer 
eluted in both samples with and without TMP after each cycle was plotted to determine at 
which the ratio of samples with TMP to without TMP start to plateau or decrease. 
5.2.1.7 Bacterial cloning and DNA extraction 
After 10-15 cycles, the SELEX cycles was stopped. The aptamers collected at the 
end of the cycles were gone under another PCR with primers without any modification to 
be ready for bacterial cloning.  
The TOPO PCR cloning kit from Life Technologies for Taq DNA polymerase 
amplification was used. The first step was to ligate the PCR product to the bacterial 
TOPO vector (Figure 5.6). Four reactions were prepared by mixing all the components 
provided in Table 5.7 and flicking the tubes.  They are incubated at room temperature for 
30 minutes and put on ice or stored in the freezer until the bacterial transformation step.  
The agar plate with 100 µg/ml ampicillin and 40 mg/ml X-gal in dimethylformamide was 
prepared by mixing a pre-mix package of agar powder from Life Technologies with 200 
ml of autoclaved water. The mixture was heated in the microwave for 3 minutes at 100% 
power until it became clear. The homogenous solution was poured into 10 cm 
polystyrene petri dish at 20 ml/ml dish and solidified for at least 1 hour before use. The 
LB broth was prepared at the same fashion using the pre-mix package from Life 
Technologies and store in 500 ml glass bottle in the refrigerator at 4 ºC.  
Before the transformation, the agar plate was warmed up in the 37 ºC incubator 
for at least 1 hour. The bacteria provided from the kit were thawed on ice, one vial of 
bacteria for one reaction. The SOC medium and the TOPO reactions were warmed up to 
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room temperature. After that, 2 µl of TOPO reaction was added to the bacteria vial and 
the vial was flicked to mix. The vials were incubated on ice for 30 minutes. The bacteria 
were heat-shocked at 42 ºC for 45 s to allow the transformation of the vectors to the 
bacteria. The vial was transferred to ice bucket immediately and 250 µl of SOC media 
was added to the vial at room temperature. Then, they were shaken horizontally at 200 
rpm for 45 minutes at 37 ºC. A volume of 45 µl of the bacteria solution was applied 
evenly on the pre-warmed agar plate using bacteria spreading applicator. The plates were 
incubated over night at 37 ºC. 
On the next day, each single big colony having white or light blue color was 
picked by pipette tips and transferred to 5 ml tube with loose cap. About 50 colonies were 
picked and 3 ml of LB broth was added into each tube. The bacterial cultures were 
incubated at 37 ºC in shaker at 900 rpm for 18 hours. The tube with cloudy haze after 18 
hours incubation indicated successful growth of the bacteria. A volume of 500 µl of the 
culture was stored in 20% glycerol solution by mixing with 500 µl of glycerol 40% in the 
-80 ºC. The remaining volume for each culture was for DNA extraction. 
The bacteria from the culture were harvested by centrifuging the liquid at 9000 
rpm for 5 minutes at room temperature. The supernatants were discarded and there were 
big white pellet at the bottom of the tube. The DNA extraction kit from Qiagen was used 
for bacterial DNA extraction. For buffer preparations, the RNase A solution was added to 
the buffer P1 and ethanol 100% was added to the buffer PE according to the instructions 
on the kit. Buffers P2 and N3 were warmed up to 37 ºC to prevent any salt precipitation. 
When all the buffers were ready, the bacteria pellets were re-suspended in 250 µl of 
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buffer P1 and transferred to 2 ml microcentrifuge tubes. A volume of 250 µl of buffer P2 
was added and mixed gently by inverting the tubes for 10 times. Then, 350 µl of buffer 
N3 was added and mixed similarly. The mixtures were centrifuged for 10 minutes at 
14000 rpm. The supernatants were applied to the QIAprep spin column by pipetting and 
centrifuging at 14000 rpm for 1 minute. The flow-through in the collection tubes was 
discarded. The columns were washed with 0.5 ml of buffer PB and centrifuged for 1 
minute. The final wash was with 0.75 ml of buffer PE for 1 minute of centrifugation. The 
column was centrifuged again for 1 minute to remove any residual wash buffer. The 
columns were placed in 1.5 ml PCR tubes. The bacterial DNA was eluted from the 
column with 100 µl of buffer EB (10 mM Tris-Cl, pH 8.5). The columns was incubated 
with the buffer EB for 1 minute and centrifuged for 1 minute. 
To check if the PCR products were inserted to the bacterial vector correctly, a 
restriction enzyme digestion test was performed. The restriction enzyme would cut the 
plasmid to produce 2 different products: the PCR products or insertion product and the 
remaining sequences of plasmid. The digestion reactions were prepared for each colony 
according to Table 5.8. The EcoRI restriction enzymes at concentration of 20000 units/ml 
were purchased from New England Biolabs. Each 1 µl of EcoRI can digest 5 µg of DNA 
plasmid.  The reactions were incubated at 37 ºC for 3 hours. 
The results from the digestion were confirmed with non-denaturing PAGE 10% 
gel. The preparation and running set up were the same as the denaturing PAGE, except 
there would be no urea added. The dye was DNA loading 6x blue dye from New England 
Biolabs. The gel was run at 75 V, 10 mA, and 1 W for 2.5 hours. 
  97 
5.2.1.8 Sequencing 
 5.2.1.8.1 Sanger sequencing 
The extracted DNA plasmids from the purification step were quantified using 
Nanodrop to make the amount of DNA was more than 50 ng/µl. Ten microliters of the 
plasmid were mixed with 5 µl of the plasmid primer M13F (18 nucleotides),5’-
TGTAAAACGACGGCCAGT-3’. The solution was sent for Sanger Sequencing service 
at Genewiz in Cambridge, MA. Fifty samples were sequenced. The aptamer primer 
sequences were identified in the results and the aptamers were cut from the rest of the 
sequences. The aptamer sequences were saved as fasta format and imported into NIH 
BLAST program to align the sequences and group them into different groups with similar 
conservative regions.  
5.2.1.8.2 Next generation sequencing 
After 10-20 cycles of SELEX, the DNA aptamers were amplified and purified 
using PCR with unmodified primers and PCR cleanup kit. The sample was sent to next 
generation sequencing at Tuft Core Facility Genomics. The size and quantity of DNA 
aptamers was analyzed using Bioanalyzer. A size selection step was performed to isolate 
only the sequences from 50 to 500 base pairs. The sequences were ligated to TruSeq 
adapter 15 (5’GATCGGAAGAGCACACGTCTGAACTCCAGTCACATGTCAGAAT 
CTCGTATGCCGTCTTCTGCTTG-3’) using TruSeq Nano DNA from Illumina. After 
the ligation step, the aptamers were sequenced using MiSeq Standard V2 SE250. The 
sequencing yielded 4 million reads total. For data analysis, the sequences were trimmed 
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with Sequences Alignment/Map (SAM tools) to 70 base pairs and aligned with the 
primers from the original sequences using Bowtie software from Gene Pattern from 
Broad Institute. The aligned sequences were counted for the number of replicates for each 
unique sequence using the Tallymer on the Genome Tools packages developed by 
University of Hamburg. Only sequences that had more 1000 reads would be tested for the 
affinity with TMP at 200 µM. 
5.2.2 GRAPHENE OXIDE – SELEX 
The graphene oxide SELEX used graphene oxide as the material to bind the 
aptamers in the single stranded state through the π-stacking interaction with graphene 
oxide (GO). Upon the binding with trimethoprim, these interactions would be weakened 
and released the aptamers from the GO. To test the affinity of the aptamer, the GO-
SELEX protocol was used (Nguyen, Kwon, Kim, & Gu, 2014; Park et al., 2012). 
5.2.2.1 Graphene oxide binding capacity 
In the GO-SELEX, the binding buffer (BB) was used in the binding of GO to 
aptamers. The solution of 10 ml BB 2x concentrations was made from 0.4 ml of Tris-HCl 
1 M, 2 ml of NaCl 1M, 0.4 ml of MgCl2 100 mM, 1 ml of KCl 100 mM, 0.2 ml of CaCl 
100 mM, and 6 ml of nuclease free water (NFW). The aptamers solution was prepared by 
adding 96 µl of single stranded random DNA aptamers to 300 µl of BB 2x and 204 µl of 
NFW. The aptamers was heated to 95 ºC for 15 minutes and cooled down in ice bucket 
for 5 minutes and let equilibrate to room temperature for 5 minutes. After that, the 
solution was divided in to 4 tubes of 150 µl per tube and 150 µl of BB buffer was added 
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to each tube. The tubes were placed on the shaker for 30 minutes at room temperature. 
Then, different amounts of GO (150, 100, 75, and 15 µl) were added to each tube with 
350 µl of BB2x and 200 µl of NFW. These tubes were incubated at room temperature for 
2 hours on the shaker. They were centrifuged at 14000 rpm for 5 minutes. Eight hundred 
microliters of supernatants from each tube were transferred to new tubes. The 
centrifugation step was repeated for 2 more times. Each time, 750 and 700 µl of the 
supernatant was transferred to new tubes respectively. The amounts of aptamers eluted 
from GO at different concentrations and before the incubation with GO were measured 
using Nanodrop. The binding constant of graphene oxide was calculated from the graph 
of the percentage of aptamers bound versus the amount of graphene oxide. 
In the affinity test with the aptamers, all the steps were prepared the same as the 
binding capacity test of graphene oxide above. However, during the 30 minutes 
incubation, one negative control with 150 µl of BB 1x and one samples with 150 µl of 
TMP 200 µM were added to the aptamers. For the incubation with graphene oxide, 150 
µl of GO were used. The amounts of aptamers eluted from the affinity test were 
measured by Sybr Green quantitative PCR. 
5.2.2.2 Aptamer amplification and quantification – Sybr Green 
The solution of aptamer from the binding step was precipitated using alcohol and 
re-diluted in TE buffer from Thermo Scientific. For every 675 µl of the aptamer solution, 
75 µl of sodium acetate 3M, 3 µl of glycogen from Fisher, and 750 µl of isopropanol 
were added and mixed well by vortex. The mixtures were centrifuged at 14000 rpm for 
10 minutes to form white pellets at the bottom of the tubes and the supernatants were 
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discarded. Five hundred microliters of 75% ethanol solution was added to the tube and 
centrifuged at 14000 rpm for 5 minutes. The supernatants were removed and the pellets 
were air dried for 10 minutes. The pellets were re-suspended in 70 µl of TE over night at 
room temperature. 
The samples were quantified using Sybr Green qPCR.  For each 20 µl of PCR 
reaction, 10 µl of mastermix 10x from Thermo Scientific, 1 µl of forward primers 10 µM, 
1 µl of reverse primers 10 µM, 3 µl of NFW, and 5 µl of aptamers was mixed together. 
The PCR program was the same as Table 5.4. 
5.2.2.3 Characterization 
After the analysis of the sequencing data, the aptamers with more than 1000 reads 
were isolated for affinity test. Each unique aptamer was tested with 3 different 
solutions/conditions using graphene oxide: the negative control of BB 1x as background, 
the sulfamethoxazole 200 µM solution as the specificity, and TMP 200 µM solution. The 
aptamers showing the highest affinity to TMP was tested with the repeatability. The same 
experiment was rerun for 10 times with TMP 200 µM, 5 times with SMZ 200 µM and 
BB 1x.  
5.3 RESULTS AND DISCUSSIONS 
From literature research, the aptamers for small molecules with molecular weight 
less than 1000 Daltons was less than 10. One of the challenges was the partitioning step 
for the target-bound to the unbound aptamers. From small molecules, the target was too 
small to be immobilized. Thus, we explored different methods to immobilize the 
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aptamers. From the paper on Capture-SELEX published by Stoltenburgh in 2012, the 
similar immobilization process was used, but the aptamers annealed to the biotinylated 
docking sequences first and then to the streptavidin magnetic beads through biotin-
streptavidin bonds. A set of optimization steps was performed to determine the ratio of 
the aptamers to docking sequences and then the binding capacity of the magnetic beads. 
In the instructions from Life Technologies, the binding capacity of biotinylated sequences 
to the magnetic beads was about ~250 pmoles depending on the length of the docking 
sequences. Based on Table 5.1, the binding capacity of the beads was about 500 pmoles 
for the docking sequences only using the Nanodrop measurements. The efficiency of the 
annealing step of the docking sequences to the aptamers was confirmed in the PAGE gel 
in Figure 5.8. The aptamer and docking sequences by themselves showed up around 80 
and 20 base pairs (bp) compared to the ladder while the annealed samples showed only 
one band at 100 bp. This proved that most of aptamers and docking sequences annealed 
together to a complex moved at the same speed with 100 bp sequences in the gel. 
Furthermore, in Table 5.2, the results showed that about 250 pmoles of docking sequence 
and aptamer complex were immobilized on the magnetic beads due to the bulky 
confirmation of the complex (100 bp) compared to the docking sequences (20 bp). Using 
the Avogadro constant to calculate the number of aptamers, we successfully immobilized 
1014 molecules on 100 µl of magnetic beads.  
For quantification of aptamers in the solution, Taqman probe PCR was chosen. 
On Figure 5.9, we showed that we can detect aptamer concentrations in the range of 1010-
1013 aptamers/ml. the range fell within the amount of aptamers eluted during the 
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incubation step with the targets. In the DNA purification/conditioning step, the urea 
denaturing PAGE gel was run to confirm the lengths of the aptamers and complimentary 
sequences. Figure 5.10 showed that there were 2 bands at 110 and 90 bp for 
complimentary strands and aptamers in the PCR samples while the aptamers alone was 
around the 90 bp band. This implied that using PCR and modified reverse primers, we 
were able to purify and separate the complimentary strands from the aptamers. After that, 
the DNA was eluted from the gel at 80oC for 2.5 hours. However, the elution efficiency 
was about 10-20%. 
The other method to aptamer purification was to use the ChargeSwitch PCR clean 
up kit from Life Technologies and then Lambda digestion reaction to cleave the 
complimentary sequences. From Figure 5.11, the samples without Lambda enzyme 
remained double stranded and showed up at approximately 180 bp while the bands for 
samples with Lambda was between 80 and 90 bp. In addition, the brightness of the 
samples without Lambda was much brighter than the one with Lambda since the amount 
of DNA decreases by one half after the digestion and clean up step. The efficiency of 
PCR clean up kit was about 90%. By comparing the efficiency between 2 methods, we 
chose the PCR clean up and Lambda digestion for SELEX cycles. 
After each step in the SELEX cycles, we ran the SELEX cycles for 15 cycles with 
TMP at 200 µM. In each cycle, the amount of DNA aptamers eluted in the samples with 
and without TMP was quantified and the enrichment factor was calculated by taking the 
ratio of the samples with TMP to the samples without TMP. The enrichment factor for 15 
cycles was plotted in Figure 5.12. The SELEX process stopped at cycle 15 when the 
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enrichment factor was more than 2. In the first time running SELEX, the aptamers was 
cloned into bacterial vector using TOPO PCR cloning kit. The bacteria were extracted to 
collect the DNA plasmids. The restriction enzyme reactions performed on each clones to 
see if the PCR products of the aptamers were successfully incorporated into the bacterial 
vector. The gel in Figure 5.13 showed that the aptamers was in the plasmids. The plasmid 
was sent out for Sanger sequencing. The sequences obtain from the sequencing results 
were tested for affinity with TMP by running the SELEX cycle again on each unique 
sequence. However, no sequences were binding to TMP at high affinity. Thus, the 
SELEX cycles were repeated again.  
In the second run of SELEX, all the steps were kept the same and the Lambda 
digestion was used to separate the aptamers from the complimentary sequences. After 15 
cycles, the aptamers was sent for next generation sequencing to obtain about 8 million 
reads in the pool. Using bioinformatics software, 5 unique sequences were identified in 
Table 5.9.  From results, most of the sequences didn’t have the docking sequences in the 
middle, so we used graphene oxide to test the aptamers’ affinity to TMP. Graphene 
oxides were used to immobilize the aptamer. Under the presence of TMP, the aptamers 
bound to TMP should be eluted from the graphene oxide due to change in secondary 
confirmation. The binding capacity of graphene oxide was tested and showed in Figure 
5.14. For each sequence, the aptamer was tested with binding buffer only, TMP at 200 
µM, and other API SMZ at 200 µM. Apart from TMP aptamer, a random DNA 
sequences at 90 bp was tested at the same conditions as negative control to show that 
TMP did not bind to random DNA sequences. The samples were quantified using Sybr 
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Green PCR. A 4-point standard curve of Sybr Green PCR in the range 109-1012 copies/ml 
was created. The results were showed in Figure 5.16. The aptamer labeled AP4 was the 
one with the highest affinity to TMP with enrichment factor of 4 while the ones with 
buffer and SMZ were about 1-1.5. The affinity test for aptamer AP4 was repeated 10 
times for TMP and 5 times for binding buffer and SMZ by 2 different people. Figure 5.17 
showed that the binding affinity of AP4 to TMP was repeatable even though the error 
bars was big (about 50% of the signal). This result confirmed that we found an aptamer 
that specifically bound to TMP. With further future testing to see whether the aptamers is 
sensitive to different concentrations of TMP, we can potentially modify this aptamer to 
detect TMP in certain solvents. Overall, we successfully optimized different steps of 
SELEX cycles and used the optimize protocols to find an aptamer bound specifically to 
TMP. 
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5.4 TABLES 
 
The ratio of biotin to 
binding sites on 
magnetic beads and the 
theoretical amount of 
biotinylated docking 
sequences (nmoles) 
The amount 
biotinylated 
docking 
seqeunces bound 
to beads (ng/µl) 
The number of 
moles of bound 
biotinylated 
sequence 
(nmoles) 
% bound to 
binding sites 
4x 1 nmole 6 0.602603 53% 
6x 1.5 nmoles 6.175 0.620179 38% 
8x 2 nmoles 6.55 0.657842 30% 
 
Table 5.1: The summary of aptamers to the magnetic beads  
 
The binding of biotinylated docking sequences was bound to the streptavidin-coated 
magnetic beads at different ratio of the biotinylated sequences to the binding sites on the 
beads based on the values provided by the manufacturers (250 pmoles per 100 µl of 
beads or ~108 beads) 
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 Measurement (ng/ul)   
 1 2 3 Average STDEV 
Docking sequences (1 nmole) 36.7 35.4 34.3 35.46667 1.201388 
Aptamer (1 nmole) 82 84.3 87.7 84.66667 2.867635 
Aptamer (2 nmole) 179.4 176.5 180.3 178.7333 1.985783 
Mix 1:1 before annealing 49.4 50.5 51.6 50.5 1.1 
Mix 1:2 before annealing 92.8 94.5 94.5 93.93333 0.981495 
After annealing 1:1 44.9 48.8 47.6 47.1 1.997498 
After annealing 1:2 93.1 94 95.8 94.3 1.374773 
After incubation 1:1 36.2 34.7 36 35.63333 0.814453 
After incubation 1:2 82.5 83 82 82.5 0.5 
 
 ratio 1:1 (ng/µl) ratio 1:2 (ng/µl) 
Before incubation 47.1 94.3 
After incubation 35.63333 82.5 
%binding 24.3% 1.85% 
 
Table 5.2: The summary of the binding of annealed docking sequences and DNA 
aptamers complex to the magnetic beads at 2 different ratios of biotinylated sequences to 
aptamers (1:2, 1:1) 
 
Top: the NanoDrop measurement of the solution of docking sequences, aptamers before 
annealing, after annealing, and after incubation with beads. Bottom: the calculation of the 
amount of docking sequence and aptamer complexes bound to the beads at 2 different 
ratios of the biotinylated docking sequences to aptamers. 
  107 
 
Ingredient Final concentration Amount (µl) 
Water - 36 
Fwd primer with 
fluorescein 10uM 
1 µM 5 
Rev primer 10 µM with 
spacer-polyA tail 
1 µM 5 
Taqman prob 10uM 1 uM 5 
Reaction buffer 10x 1x 10 
dNTP 20 mM 0.8 mM 4 
Reference dye 10 uM  3 
MgCl2 50 mM 3mM 6 
DNA polymerase 5 U 1 
DNA sample - 25 
 
Table 5.3: The components of the PCR used to amplify the aptamer in each SELEX 
cycles 
 
They were water, forward primer, reverse primer, Taqman probe, PCR reaction buffer 
10x, deoxynucleotides (dNTP), reference dye (ROX), MgCl2, DNA Polymerase, and 
DNA aptamers.  The table included the concentration (if applicable) and the volume of 
each component for one 100 µl PCR reaction well. 
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  PCR Programme  
Step 1 95 ºC, 10 min 
Step 2 95 ºC, 1 min 
Step 3 55 ºC, 1 min 
Step 4 72 ºC, 1min 
Step 5 Repeat steps 2-4 30 more times 
Step 6 72 ºC, 15min 
Step 7 4 ºC, forever 
 
Table 5.4: The PCR program that was used to amplify and quantify the amount of DNA 
aptamers in the samples by compared to the standard curve 
 
The wells were heated up for 10 min at 95 ºC. Then, they entered 30 cycles of 3 steps (1 
min at 95 ºC, 1 min at 55 ºC, and 1 min at 72 ºC. Finally, they were held at 72 ºC for 15 
min and the temperature was ramped down to 4 ºC and held there until ready for the next 
step or stored in the freezer. 
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Volume 10 ml 
Acrylamide 
concentration 
10% 12.5% 15% 
Urea (g) 4.8 4.8 4.8 
40% Acrylamide 
(ml) 
2.5 3.125 3.75 
30% APS (µl) 33 33 33 
TEMED (µl) 15 15 15 
10x TBE (ml) 1 1 1 
Distilled water (ml) Adding until 10 ml Adding until 10 ml Adding until 10 ml 
 
Table 5.5: The components of the urea denaturing gel at 10, 12.5, and 15% acrylamide 
 
It included the volumes or weights of all the ingredients (urea, acrylamide, ammonium 
persulfate, TEMED, TBE, and water) 
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Sample ID Volume (ul) per reaction 10 reactions/tube (ul) 
Lambda  1 10 
PCR products 50 - 
10x Lambda Reaction buffer 10 100 
Water 39 390 
 
Table 5.6: The components of Lambda exonuclease reaction 
 
It included the volumes of all components (Lambda enzyme, PCR product, 10x Lambda 
reaction buffer, and water). 
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Reagents  Volume (µl) 
PCR products  4 
Salt solution 1 
TOPO vector 1 
Total reaction volume 6 
 
Table 5.7: The components of the ligation reactions of the PCR products to the bacterial 
vector 
 
It included PCR products, salt solution, and TOPO vector. The total volume was 6 µl. 
Water can be added if the total volume was under 6 µl. 
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Reagents  Volume (µl) 
10x EcoRI buffer 2 
EcoRI 1 
DNA plasmid 15 
Water 2 
Total reaction volume 20 
 
Table 5.8: The component of the EcoRI restriction enzyme digestion 
 
It included 10x EcoRI buffer, EcoRI enzyme, DNA plasmid, and water. The total 
reaction volume was 20 µl. 
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Aptamer 
ID 
DNA aptamer structure 
AP1 CCTGCCACGCTCCGCACCCTGCAGCGATCGTCCTGTGTGCTAGGT
CCATAGCTTGGCACCCGCATCGT 
AP2 CCTGCCACGCTCCGCACGACAACCCGAACACGTGTCCTGCGCCAT
AGCTTGGCACCCGCATCGT 
AP3 CCTGCCACGCTCCGCAAGGGGCACCTGTAGGGGCACTCACCCGA
CAGCATAGCTTGGCACCCGCATCGT 
AP4 CCTGCCACGCTCCGCACCACTGCTGATCGCACCGTTCGTAGCATG
TATAGCTTGGCACCCGCATCGT 
AP5 CCTGCCACGCTCCGCAAGGCGATTCTTGGTGGAACAAGGTGGGA
CAGGTATAGCTTGGCACCCGCATCGT 
 
Table 5.9: The list of all the aptamers that has more than 1000 reads in the next 
generation sequencing data 
 
The table included the aptamer ID and the structures of the DNA aptamers. The 
sequences that were highlighted in yellow are the forward and reverse sequences for 
PCR. 
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 5.5 FIGURES 
 
Figure 5.1: The schematic of SELEX process 
 
It started with a library of nucleic acids or peptides. The library was incubated with 
target. The target-bound aptamers were partitioned from the unbound and gone under 
amplification step and conditioning step to recover the target-bound aptamers to be ready 
for the next cycle. After 6-20 cycles, the aptamers was cloned into E. Coli bacterial 
vector and then sent out for Sanger sequencing or Next Generation Sequencing 
(University of Southern of Denmark, 2016). 
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Figure 5.2: The schematic of Capture – SELEX  
 
It included all the steps in the cycles (immobilization, target binding, amplification, and 
purification) to the after cycle steps (cloning, sequencing, data analysis, binding studies, 
and modifications) (Stoltenburg et al., 2012). 
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Figure 5.3: The chemical structure of trimethoprim lactate (Sigma Aldrich, 2016) 
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Figure 5.4: The schematic of how the aptamers binds to the docking sequence and how 
the docking-aptamer complex binds to the streptavidin coated magnetic beads through the 
biotin attached in the docking sequence 
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Figure 5.5: The schematic of qPCR using Taqman probe 
It showed how the Taqman probe with quenchers and reporters binds to DNA target and 
gets cleaved by the DNA polymerase to the release the fluorescent molecules for 
quantification of DNA targets (Bio-rad, 2016).  
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Figure 5.6: The schematic of the TOPO vector that was used to ligate to the aptamer PCR 
products and transformed to the E. coli bacteria 
It showed where the M13 primers were for Sanger sequencing (ThermoFisher Scientific, 
2016).
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Figure 5.7: The schematic of qPCR using Sybr Green 
It showed the mechanism of how Sybr Green PCR can be used to quantify the amount of 
single stranded DNA aptamer in the solution (Kuzdralinski, 2011). 
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Figure 5.8: The image of the PAGE gel of samples during the incubation step in Capture 
SELEX  
From right to left, the lanes were the DNA ladder, the biotinylated docking sequences, 
the aptamers, the aptamer and docking sequence complex after annealing together, and 
the complex after incubation with streptavidin-coated magnetic beads.  
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Figure 5.9: The PCR standard curve with Taqman probe as the quantification method 
The concentrations of DNA aptamers were 1010, 1011, 1012, 1013 copies/ml. The x-axis 
(aptamer concentration) of the plot was in log scale while the y-axis (the Ct value) was in 
normal scale. 
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Figure 5.10: The image of the gel to show that after running PCR with elongated reverse 
primers 
The complimentary sequences to the aptamers were 15 nucleotides longer than the 
aptamers and thus migrating slower than the aptamers. The gel included the aptamers in 
double and single stranded DNA aptamers. 
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Figure 5.11: The image of the gel to show that the aptamer after the Lambda digestion 
All became single stranded and migrated faster in the gel compared to the negative 
control where no Lambda was added. The mixture of the samples with and without 
Lambda showed there were 2 bands of single stranded and double stranded DNA 
aptamers. 
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Figure 5.12: The graph of the enrichment factor calculated by the ratio of DNA eluted in 
TMP solution to the one in buffer only from cycle 3 to cycle 14 
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Figure 5.13: The image of the gel to show the product after restriction enzyme digestion 
of the TOPO vector after ligation with the PCR products 
The gel showed that the TOPO vector stayed that top of the well due to its size more than 
1000 base pairs while the PCR products around 88 base pairs showed up between the 90 
and 80 bp bands on the gel. 
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Figure 5.14: The binding capacity of graphene oxide to DNA aptamers 
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Figure 5.15: The standard curve of Sybr green PCR  
The concentrations of aptamers quantified were 109, 1010, 1011, and 1012 copies/ml. 
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Figure 5.16: The graph of affinity test of all the 5 aptamers isolated from the NGS data  
Each aptamer was tested in 3 conditions: with BB buffer, with SMZ at 200 µM, and with 
TMP at 200 µM. All the signals were normalized to the negative control with BB buffer 
only. 
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Figure 5.17: The graph of enrichment factor of aptamer with the highest affinity to the 
TMP for 3 conditions (BB only, SMZ 200 µM, and TMP 200 µM 
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Chapter 6 Field Trial Testing of PharmaChk platform on Artesunate 
Samples in Accra, Ghana 
6.1 INTRODUCTION 
Previously, in chapter 4, we have presented a new and quantitative method for 
testing medicines and identifying counterfeit and substandard medication. The 
PharmaChk platform utilizes microfluidics to provide a method for specifically targeting 
a known active pharmaceutical ingredient (API) and analyzing its content within a dosage 
form (Figure 6.1-Top).  
To validate the performance of PharmaChk in low-resource settings, we chose to 
use antimalarial, artesunate (ATS) specifically, samples as a model system. About 3.3 
billion of the world’s population is at risk of malaria (Center for Disease Control and 
Prevention, 2014; World Health Organization, 2013a). In 2010, malaria caused the death 
of 660,000 among more than 200 million reported infections (World Health 
Organization, 2013a). Unfortunately, antimalarials are a common target for counterfeit 
and substandard medicine (Karunamoorthi, 2014; World Health Organization, 2013c). To 
confront this underappreciated but significant public health problem, a quantitative 
platform that is mobile, robust and scalable for the detection of artesunate quality in both 
mono- and combination therapy is urgently needed.   
In our present work, we built a microfluidic chip to analyze API content of only 
artesunate in both pure and tablet form. This design uses a simple staggered-herringbone 
(SHB) mixer to combine an artesunate sample with a reporter solution to produce a 
luminescence signal (Figure 6.1-Bottom) (Ho, Desai, & Zaman, 2015). We conducted 
initial tests in Boston, MA and at U.S. Pharmacopeial Convention (USP) facilities in 
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Rockville, MD and subsequent field tests of the PharmaChk system using this chip design 
to test three antimalarial field samples in Ghana (discussed below) and trained local staff 
to assess the user-friendliness of the technology as well. The three medicines tested in 
Ghana were “Lever®” from Geneith Pharmaceuticals Limited (tablets), “Camosunate®” 
from Danadams Pharmaceuticals Industry Limited (tablets), and “Glunate®” from Guilin 
Pharmaceuticals Co (powder for injection). The injectable form of ATS has been widely 
used in a variety of scenarios, especially for infants and children, but the GPHF 
MinilabTM (the current field standard recommended by WHO) does not have protocol to 
test ATS in injectable form, and has limited quantitative ability for tablet testing (United 
States Pharmacopeia, 2012a).  The tests were conducted at the USP Center for 
Pharmaceutical Advancement and Training (CePAT) in Accra, Ghana. CePAT is 
operated by the United States Pharmacopeial Convention. The samples were acquired 
locally, by Ghanaian staff members at CePAT from the local pharmacies in and around 
Accra and the test results were compared against the GPHF MinilabTM (for tablet testing) 
and HPLC-UV (one of the gold standard for pharmaceutical analysis for both tablet and 
injectable formulations). 
The PharmaChk prototype (Figure 6.1-Top) was developed by joint efforts from the 
PharmaChk team at Boston University with input from partners (for full list of supporting 
organizations, see acknowledgements). The prototype, shown in Figure 6.1, was 
transported to Accra by air. The fundamental goal of the Ghana tests was to assess the 
ability of the prototype to perform in a resource-limited field setting, unique from the 
controlled laboratory environments in Boston, MA or Rockville, MD. Additionally, we 
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were also interested in getting user feedback from those who had not participated in 
developing or optimizing the prototype.  
6.2 MATERIALS AND METHODS  
6.2.1 Chip fabrication 
Microfluidics chips were fabricated using polydimethylsiloxane (PDMS) cast on 
an SU8 mold. The detailed protocol of chip fabrication process was provided in the 
chapter 7. The chips were bonded to Dolomite predrilled glass slides (Dolomite, United 
Kingdom) after O2 plasma exposure for 1 min using the PVA TePla M4L plasma asher. 
Chips were then incubated at 80°C for 6 h to deactivate plasma-activated surfaces (Ho et 
al., 2015). 
6.2.2 Probe preparation 
Two milligrams of hematin porcine (Sigma-Aldrich, H3281) and 2 mg of luminol 
(Sigma Aldrich, MI) were dissolved in 50 ml of 0.1 M NaOH prepared by dissolving 4 g 
of NaOH (Sigma, MI) in 1 L of distilled water using a stir bar for 30 min. A fresh probe 
solution was prepared at the beginning of each day of testing. 
6.2.3 Selectivity for artesunate, artemisinin, dihydroartemisinin, artemether, and quinine 
sulfate 
For samples preparation, 2 mg each of artesunate, artemisinin (ART), 
dihydroartemisinin (DHA), artemether (ATE), and quinine sulfate (QS) was measured 
and dissolve in 1 ml of acetonitrile. A mixture of 100 ul of each pharmaceutical and 100 
ul of detection probe was pipetted and measured in kinetically luminescent mode using a 
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spectrophotometer (Molecular Devices, CA). Eight replicates for each chemical 
compounds were prepared and measured. 
6.2.4 Artesunate reference standard preparation 
To eliminate the hazardous waste during field trial in Ghana, the reference 
standard at CePAT facility was prepared in PBS. Sixteen mg of ATS (Sigma-Aldrich, 
MI) was dissolved completely in 1 ml of 200-proof ethanol.  The solution was then 
diluted to 10 ml with 1X PBS to yield a final concentration of 1.6 mg/ml of artesunate. 
The 1X PBS was diluted from 10X PBS, which was prepared by dissolving 80 g NaCl 
(Sigma, MI), 2 g KCl (Sigma, MI), 14.1 g Na2HPO4 (Sigma, MI), 2.4 g KH2PO4 (Sigma, 
MI) in 800 ml of distilled water and adjusting pH to 7.4 with HCl 1M or NaOH 1 M. 
Later, in Boston, in the optimization tests of ATS samples from Ghana, the reference 
standard was dissolved in acetonitrile, since the results from Ghana showed that ATS was 
not dissolved completely in PBS. Four mg of ATS was dissolved in 2 ml of acetonitrile 
and diluted in 2 ml of PBS to achieve the final concentration of 1 mg/ml. The 1:1 ratio of 
acetonitrile and PBS was to help with the flow of the solution to the channels on chip 
since acetonitrile is an organic solvent, which is not capable of wetting PDMS surface. 
6.2.5 Tablet sample’s preparation 
The Lever® and Camosunate® tablet samples were prepared, filtered and run on 
the first day. In Ghana, sample tablets were individually wrapped in aluminum foil and 
crushed to a powder using a pestle. The tablet sample from the crushed powder was then 
dissolved in 30 ml container of 1X PBS to a final concentration of 1.67 mg/ml of ATS. 
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Solution was mixed by hands vigorously for 3 min and then allowed to settle for 5 min. 
Unfiltered samples were taken from the supernatant and transferred to 2 ml 
microcentrifuge tubes. Filtered tablet samples were prepared by injecting the sample 
solution through a 0.2 µm hydrophobic filter (Qosina, NY) using a syringe. The signals 
from the filtered and unfiltered samples were compared with each other to determine if 
the turbidity of the solution would interfere with the strength of the signal. 
In Boston, for the tests with acetonitrile, 5 tablets were weighed and crushed into 
a powder to provide consistency with the MiniLab protocol. The amount of ATS powder 
corresponding to 1 tablet was weighed and dissolved in acetonitrile to ensure complete 
dissolution of ATS in solution and achieve the final concentration of 2mg/ml. The 
solutions were left on a shaker for 15 minutes and left to settle for 15 minutes. The 
sample solutions were filtered to remove all the particulates from the excipients and 
diluted in PBS down to 1 mg/ml immediately prior to analysis.  
The concentration of the samples in Ghana was 1.67 mg/ml due to the availability 
of only 30 ml containers in testing facility. In Boston, the concentration of 1 mg/ml was 
chosen to ensure the ATS concentrations of samples to be in the linear range of the 
standard curve. 
6.2.6 Injection sample’s preparation 
Glunate® injectable samples were prepared as indicated on the packaging. The 
samples were dissolved in sodium bicarbonate provided by the manufacturer. After that, 
the solubilized sample was then diluted using 1X PBS to a final concentration of 1.67 and 
1 mg/ml of ATS in Ghana and Boston respectively.  
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6.2.7 HPLC preparation 
The HPLC analysis for the artesunate samples collected from Ghana was 
conducted at the USP laboratory in Rockville, MD and used as the reference to compare 
PharmaChk’s results. There were three solvents used for the mobile phase: water adjusted 
the pH to 3 by formic acid, acetonitrile, and methanol with 8:11:1 ratio. A Waters 
Alliance 2695 HPLC with a Photodiode Array detector was used to determine the 
concentration of ATS in both tablet and liquid forms. A Phenomenex Luna C18(2), 4.6 x 
250 mm, 5 um HPLC column and Thermo Fisher Scientific BDS Hypseril C18, 4.6 x 100 
mm, 3 um HPLC column were used for tablet and injectable assays, respectively. No 
calibration curves were used. Instead, the USP Medicines Compendium Artesunate 
Tablets monograph and the final Authorized Version 1.0 the International Pharmacopeia 
4th Edition Artesunate for Injection monograph was used to compare to tablet and 
injectable respectively (International conference on harmonisation of technical 
requirement for registration of pharmaceuticals for human use, 1994). For the tablets, 5 
tablets from the same batch were weighed and crushed into powder using the pestle. The 
amount of powder according to the weight of one tablet was measured and dissolved in 
acetonitrile. For the injectables, the samples were dissolved according to instructions on 
the package. The solutions were then filtered through 0.2 µm polypropylene filter (Fisher, 
03-276-229). For the HPLC run, the samples were run at a flow rate of 0.8 ml/min. The 
UV detection wavelength was at 216 nm. The injection volume was 20 µl. The injection 
time was 20 minutes (United States Pharmacopeia, 2012a). 
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6.2.8 Data Processing 
Luminescence values sampled at 16 Hz were saved to an SD card in the form of 
comma-separated values (CSVs). Plots of the resulting data provide a reaction profile of 
luminescence intensity over a capture period of 5 min. Peak value, as noted in previous 
studies, was determined to be the most reliable in comparison to curve area and signal 
rate of increase, and was used for all analysis (Ho et al., 2015). The linear range of 
luminescent signal from reaction of ATS with detection probe was 0-2 mg/ml in PBS and 
acetonitrile. 
6.2.9 Repeatability, intermediate precision, and reproducibility 
Validation of analytical procedures from the International conference on 
harmonization of technical requirements for registration of pharmaceuticals for human 
use was used as a guideline to confirm the performance of the platform (International 
conference on harmonisation of technical requirement for registration of pharmaceuticals 
for human use, 1994). The repeatability of the system was defined as the ability to 
provide consistent results using the same procedure. The intermediate precision is a 
measure of precision under a defined set of conditions. Prior to the Ghana field-testing, 
we tested the repeatability of the PharmaChk instrument in both the lab at Boston 
University and at the USP facility in Rockville, MD (Ho et al., 2015). From the field test 
in Ghana, we were able to demonstrate with PharmaChk that when the system was used 
on different days, the system produced consistent measurement for tablets and injectables 
from the same batch. After the Ghana field-test, we ran a set of repeatability and 
intermediate precision tests using acetonitrile as the new solvent to dissolve the 
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Camosunate® and Lever® tablets in order to improve the solubility of ATS in solutions in 
2 different days by 2 different users (i.e. Nga Ho and Lukas Roth) in the Boston 
University lab for Camosunate®, Lever® samples also re-ran Glunate® ATS samples. For 
each day, the user prepared a fresh ATS reference standard solution in PBS or acetonitrile 
depending on the types of samples tested. For Camosuante® and Lever® samples, three 
different tablets were crushed, dissolved in acetonitrile, and tested for each day. For the 
Glunate® samples, one liquid injection sample from three different dosage strengths (30, 
60, 120 mg) were dissolved in sodium bicarbonate and PBS and quantified on the first 
day. The 30 and 60 mg samples were measured on the second day, however the 120 mg 
sample was not as only one 120 mg sample was brought back from Ghana. 
6.2.10 The agreement of the measurement of API contents between HPLC and 
PharmaChk 
The averages of measurements from PharmaChk and HPLC were taken for both 
tablets and injectables. The differences between the two measurements from each method 
on the same samples were calculated and plotted over the average values of both HPLC 
and PharmaChk based on the statistical method presented by Bland et al (Bland & 
Altman, 1986). Two standard deviation of the differences was calculated and plotted to 
show the range where 95% confidence of the agreement between 2 methods in the plot of 
the differences versus the average.  
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6.3 RESULTS 
For selectivity test, our assay can selectively detect 3 antimalarials derived from 
ART, but not ATE and QS. They are artemisinin, artesunate, and dihydroartemisin. 
Based on Figure 6.2, ART, ATS, and DHA can be distinguished by looking at the time 
where the peak signal occurred in the curve of the luminescent reaction over time. 
Artemisinin had the peak signal immediately after the mixing with detection probe while 
ATS luminescent signal peaked at 4 minutes and 1 minute for DHA. From our previous 
paper, we demonstrated that our assay was specific for ATS, ART, and DHA, but not to 
other excipients in the tablets (Ho et al., 2015). As a proof-of-concept, we only tested 
ATS for our field trial in Accra, Ghana. 
In Ghana, tests at CePAT were completed with minimal chip failures (3 out of 60 
chips failed, less than 5%). Failed chips were considered ones in which the well did not 
fill completely in the allotted time due to channel blockages associated with chip 
fabrication.  
The relative standard deviation (%RSD), the percentage of one standard deviation 
compared to the mean value, for all samples tested only in Ghana, was found to be less 
than 5% on average (range 3% - 12%) from tablet to tablet, and injectable tests from the 
same brand also showed consistent results, with percent differences of less than 6% 
(Table 6.1). Plots of the data are presented in Figure 6.3.  
To illustrate the accuracy of the PharmaChk system, comparisons of the 
PharmaChk results to HPLC, the gold standard method, are provided in Figure 6.4. The 
HPLC results were done at USP in Rockville, MD. MinilabTM results confirm API 
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content of between 80-100% for both Lever® and Camosunate® (tablets). Those ranges 
are within the accuracy range of MiniLab that is unable to provide a finer range of 
accuracy beyond 80-100%. The Glunate® sample (injectable) was not tested using 
Minilab®, as a MinilabTM protocol for artesunate for injection does not currently exist. 
PharmaChk data showed inconsistent readings against the HPLC data for tablets 
dissolved in 1X PBS, showing errors of 8.58% and 30.98% for Lever® and Camosunate®, 
respectively. Further investigation into this issue in the lab in Boston attributed this 
variation to solvent interaction and performance, since overall solubility of both Lever® 
and Camosunate® was highly variable and unstable in aqueous solution like PBS 
(Agnihotri, Singh, & Bigonia, 2012; World Health Organization, 1995a). To address this 
issue and improve the accuracy of the system, acetonitrile was used as the solvent to 
dissolve the tablets. For tablets dissolved in acetonitrile, the percentage difference was 
reduced to only 3% between the results from PharmaChk and HPLC (Figure 6.4); 
Camosunate® API content was measured as 98% and 95% of the intended dosage for 
PharmaChk and HPLC, respectively. Lever® API content was measured as 91% and 
88%, respectively.  
Furthermore, to confirm the repeatability of acetonitrile, the repeatability and 
intermediate precision tests by two different users on two different days in Boston were 
conducted on Camosunate® and Lever® tablets in acetonitrile and Glunate® samples in 
manufacture-provided solvent as per the standard protocol for testing injectables. In those 
tests, there were 10% variations in the results of API quantification between the first day 
and the second day for Camosunate® (93% on the first day compared to 83% on the 
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second day on the same batch of ATS). The results from the first day showed consistent 
results with the HPLC results but with relatively high %CV, while the results from the 
second day were less consistent to the HPLC but with lower %CV (less than 5%) (Figure 
6.5-Top). For the Lever® tablets, the results were consistent from day to day with less 
than 4% difference compared to the HPLC results (Figure 6.5-Top). 
The bottom graph in Figure 6.5 presented results from the Glunate® injection 
samples, demonstrating very consistent readings between the first and second day as well 
as to HPLC results (less than 5% difference between 2 days compared to HPLC). This 
applied to all three dosage strengths (30, 60, 120 mg ATS). The percent difference was 
less than 4% for 30 and 60 mg samples for both days compared to the HPLC results and 
less than 10% for the 120 mg samples for the first day compared to the HPLC results. 
Finally, in Figure 6.6, the average of API percentage (%API) between HPLC and 
PharmaChk measurements were plotted against the difference in %API measurements 
between HPLC and PharmaChk. It showed that all the measurements of both HPLC and 
PharmaChk fell within 2 standard deviations (about 11%) from the mean value from the 
API content measurements of both tablets (Camosunate® and Lever®) and injectables 
(Glunate® 30, 60 ,and 120 mg) using both methods. 
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6.4 DISCUSSION 
In field testing, PharmaChk reliably tested samples with RSD of less than 6%. 
PharmaChk demonstrated relatively high precision during the field tests, even though 
there was a significant difference between PharmaChk and HPLC results (about 10-30% 
difference) in cases where the tablets were tested while the injectable showed consistent 
results between PharmaChk and HPLC.  This is further supported by tablet-to-tablet 
consistency, despite testing on different days using fresh probe solutions for each day. 
While MinilabTM and HPLC results indicated API content between 80-100% for both 
Lever® and Camosunate®, the Camsonunate® signal using PharmaChk initially gave a 
result of 65% using a PBS solvent. Given the consistency of the signal obtained for both 
tablets with and without filtering, the presence of any particles was ruled out as a cause. 
PBS was first chosen since it was not a hazardous chemical and would therefore be 
suitable for field testing. However, with further investigation in Boston after the field test, 
one possible cause for this inconsistency was that artesunate solubility was formulation-
dependent and was different for Lever® and Camosunate®. To test this hypothesis, 
samples of both Camosunate® and Lever® tablets were dissolved in acetonitrile instead of 
1X PBS and retested. Acetonitrile was our first choice after PBS since it was the solvent 
used in HPLC to dissolve the tablets and affordable (less than $2 per test) (Agnihotri et 
al., 2012). The luminescent signals from those tablets were normalized and compared to 
the ATS standard samples in acetonitrile. The percentage recovery of ATS from the 
tablets is shown in the top graph in Figure 6.5. By using acetonitrile as the solvent, the 
error in percent recovery between HPLC and PharmaChk was improved significantly 
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from 30.98% (with PBS) down to only 3% (with acetonitrile), indicating that the prior 
inconsistency in results was due to incomplete solubility of ATS in the PBS solution. In 
the tablets, there needs to be an extraction step that PBS is not able to facilitate. On the 
other hand, this issue was not present with the injectable, presumably because the 
artesunate API for the injectable could react with 5%(w/v) sodium bicarbonate to form 
sodium salt artesunate which is soluble in aqueous solution to be ready for injection 
(World Health Organization, 1995b).  Among the injectable samples, PharmaChk results 
for the 120 mg ATS sample was 9% higher than the HPLC results while they were less 
than 3% for the 30 and 60 mg samples. One of the possible causes was that not all the 
sodium bicarbonate solution provided by the manufacturer was transferred to ATS 
powder vial to dissolve ATS to inject to the patients. In addition, only one Glunate® 
injectable of 120 mg dose was tested on the first day since one package of Glunate® was 
brought back from Ghana. Additional testing on different batches of Gluante® 120 mg 
needs to be done to confirm if the variations depends on the dose. Finally from Figure 
6.6, it showed 95% confidence of the difference between HPLC and PharmaChk was less 
than 11% over difference brands and forms of antimalarials. 
Subsequent repeatability and intermediate precision testing from two different 
users on two different days also showed consistent measurements from day to day and by 
different users Furthermore, the relatively high RSD between the Camosunate® 
measurements (8%) was due to the misalignment of the reaction chamber on the chips 
compared to the photodiode position and the recycling of used chips from Ghana. The 
misalignment of the reaction chamber can cause the decrease in the chemiluminescent 
  144 
signal captured by the photodiodes while the recycling of used chip can cause the partial 
blockage of the chips due to the deposit of reagents in the channels or the deformation of 
the channel during the air-drying and heating step of the cleaning cycle. Currently, we are 
investigating into different chip fabrication methods to reduce the cost and the variations 
between chips such as: hot embossing, injection mold, etc. Finally, Figure 6.6 showed 
that there was a good agreement between the PharmaChk and HPLC in measuring the 
API content of both tablets and injectables forms of ATS with a standard deviations of 
the difference between 2 methods about 5.5%.   
For the next step, we plan to expand the list of pharmaceuticals tested by 
PharmaChk from ATS monotherapy to fixed-dose combination therapy for malaria and 
other medicines of public health importance in LMICs. We also plan to investigate the 
automation and user-friendliness of the PharmaChk interface platform and various chip 
fabrication methods to reduce the manufacturing cost, increase test reliability and 
accuracy, and allow for relative dissolution testing that was not carried out in the current 
study. For testing in field settings, the platform will be modified into low powered device 
(with the ability to operate with solar or battery power) with all the solvents pre-packed 
beforehand and containers to dispose the hazardous chemicals from the tests. In 
additions, the detection probes will be tested with other known impurities and excipients 
to determine its specificity and selectivity for different pharmaceutical brand of ATS. 
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6.5 TABLES 
 
Sample ID 
Day 1 Day 2 
Signal 
(V) 
Recovery 
percentage 
(%) 
%RSD Signal (V) 
Recovery 
percentage 
(%) 
%RSD 
Reference 
standard 3.34 100 2.05 3.47 100 2.93 
Camosunate® 2.45 70.2 4.93 2.36 65.1 5.66 
Lever® 3.54 101.5 3.99 3.44 94.9 2.07 
Glunate® 
30mg 
3.34 97.0 3.03 - - - 
 
Table 6.1: The summary of the ATS test in Ghana with reference standards, 
Camosunate® and Lever® tablets and Glunate® injectable liquid on the PharmaChk 
system 
 
The table demonstrated the day-to-day repeatability in Camosunate® and Lever® tablets 
and Glunate® injectable liquid on the PharmaChk system in Ghana. Comparisons showed 
a percent difference between days of less than 5%, which fell within the relative standard 
deviation of the individual data sets. Samples on day 1 were not filtered, while sample on 
day 2 were filtered through a 0.2 µm hydrophobic filter. The results indicated that the 
assay results were independent of the presence of particulate matter in solution. For each 
brand, an individual tablet was used per day and the measurements were repeated for 5 
times/day/tablet. 
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6.6 FIGURES 
 
 
Figure 6.1: The PharmaChk system and the CAD of the microfluidic chip  
 
Top: The picture of the PharmaChk prototypes. The prototype included the pressure 
pump, the optical chip nest where the chip was placed above the photodiode for 
detection, the LCD screen to show users the operation instruction, the SD card holder 
with power cord to supply electricity to the entire system. Bottom: The CAD draw of 
chip with the pressure drop channel.  The mixing channel (200 µm thick, yellow color) 
with herringbone patterns (40 µm thick, green color), and the reaction chamber (5 by 5 by 
3 mm, blue color) (C). 
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Figure 6.2: Selectivity test for artesunate, artemisinin, dihydroartermisinin, artemether, 
quinine sulfate, and negative control (acetonitrile) 
 
The luminescent signals from ATS, ART, DHA, ATE, QS, and acetonitrile were plotted 
over time when the antimalarials reacted with luminol under the presence of hematin as 
the catalyst and alkaline condition.  From the graph, ATS, ART, DHA could be detected 
distinguishably based on the luminescent peak signals at different time points 4, 0, 2 
minutes respectively while QS, ATE, and acetonitrile did not show significant change in 
signals. 
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Figure 6.3: The repeatability of the prototype on the detection of pure ATS standard 
(powder), Lever® (tablets), Camosunate® (tablets), and Glunate® (injectable liquid) 
samples from Ghana 
 
Top left: Plot of multiple replicates conducted of the artesunate reference solution (1.6 
mg/ml) over two days. Trial 3 was discarded from the 3/12 data due to a chip failure. The 
plot showed consistent peak values across the two days, although the peak width is 
greater for data obtained on 3/11 (n=2 samples and 3 measurements/sample/day). Top 
right: Plot of multiple replicates conducted of the Lever® tablets across two days. A 
different tablet was tested each day, but the plots showed consistent peaks across all tests. 
The RSD for replicates within a tablet was less than 5% for both (n=2 tablets and 5 
measurements/sample/day). Bottom left: Plot of multiple replicates conducted of the 
Camosunate® tablets across two days. A different tablet was tested each day, but the plots 
showed consistent peaks across all tests. The RSD for replicates within a tablet was less 
than 5% for both. Trial 5 of the Camosunate® tablet tested on 3/12 was discarded due to a 
chip failure (n=2 tablets and 5 measurements/sample/day). Bottom right: plot of multiple 
replicates conducted of the Glunate® injectable liquid from 1 day. Trial 4 of the Glunate® 
liquid tested was discarded due to a chip failure (n=1 injectable liquid and 3 
measurements/sample/day). 
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Figure 6.4 Comparison of PharmaChk results to HPLC from the Ghana tests 
 
API percentages for PharmaChk results were normalized to the pure artesuante reference. 
While the tablet results (Lever® and Camosunate®) in 1X PBS (n=2 tablets and 3 
measurements/sample/day) showed inconsistencies with the HPLC results, the Glunate® 
liquid injectable (n=1 injectable liquid and 3 measurements/sample/day) had only 3% 
difference compared to the HPLC data. Thus, the Camosunate® and Lever® tablets were 
re-tested in acetonitrile as the solvent. The graphs showed that the percentage different 
between HPLC and PharmaChk reduced to only 3% for the Lever® and Camosunate® 
tablets in acetonitrile.  
  150 
 
Figure 6.5: The summary of the repeatability and intermediate precision tests for the 
reference standard, the Camosunate®, Lever® tablets, and the Glunate® injectable liquid 
in Boston 
 
Top: For the Camosunate® tablets, there was 10% difference in the percentage of 
recovery between the first and second days and compared to HPLC while the percentage 
of difference for Lever® was less than 5% (n=3 for both Camosunate® and Lever® tablets 
with 1 measurements/tablet/day and n=2 for the standards with 5 
measurements/standard/day). Bottom: The results from two different days were 
consistent with the HPLC results for all three Glunate® samples (30, 60, 120 mg). The 
percentage of error was less than 4% (n=1 for Glunate® injectable liquid with 3 
measurements/liquid/day and n=2 for the standards with 5 measurements/standard/day). 
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Figure 6.6: the plot to show the agreement in API content measurement between 
PharmarChck and HPLC 
 
From the graph of the mean of API content measured by both methods versus the 
difference of the API content measurement between PharmaChk and HPLC, it showed 
that all the measurements for tablets and injectable fell within 2 standard deviations from 
the mean value of the difference between 2 methods that are represented by two blue 
lines crossing the y-axis at 11.4 and -11.4. The mean values are at the black line crossing 
the y-axis at 0. 
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Chapter 7 Microfluidic chip for multiplexing and real time testing of 2 API 
7.1 INTRODUCTION 
With the chip design in chapter 6, the chip can only test one API at a time and 
give a semi-quantitative answer. To improve the chip performance, a new versatile chip 
design is proposed. These features would allow a real time measurement of two different 
API contents in the tablets if the assays for API detection are in the solvent used to 
dissolve the tablets. The new chip design would help to create a standard curve on the 
chip to eliminate the errors from sample preparation from human and measurement from 
machine. The standard curve on the chip would prevent the variations of measured 
signals from different chips, imaging system, user, and environmental conditions. 
Moreover, the chip can give semi-quantitative answers on multiple tablets. With this chip 
design, 4 different tablets can be quantified simultaneously. Finally, the chip can 
potentially do dissolution profile in discrete manner by taking the sample at different time 
points (4 time points total) during the dissolution time of the tablet. 
As a proof of concept, we used the assay developed for the combination therapy 
of antimalarial (ATS and AQ) from the previous chapters to test the performance of the 
multiplex chips.  To quantify ATS in the presences of AQ, we had to modify the assay 
using different solvents since ATS is very sensitive to the acidic condition from AQ with 
HCl and can degrade rapidly in the acidic environment. Thus, ATS and AQ combination 
therapy was produced by bilayer co-formulation. Different solvents were used to dissolve 
the Winthrop tablet (one of the ACTs) for detection of either ATS or AQ. For the 
detection system, we have developed a bench top system that consists of CCD camera 
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with filter wheel and lenses, pressure pump with 6 outlets/inlets, Arduino system to 
control the pump, and a computer to record the images and analyze the data. The overall 
system has the potential to transform into a field deployable platform used in the 
resource-limiting regions. 
7.2 MATERIALS AND METHODS 
7.2.1 Modification of ATS detection assay 
7.2.1.1 Optimization of NaOH concentrations 
To neutral the acidic condition created from the HCl group in AQ, different 
concentrations of NaOH were used to dissolve ATS pure powder in the presence of AQ 
to determine the NaOH concentration at which the HCl was neutralized. Three 
concentrations of NaOH at 0.1, 0.5, 1 M was tested. The detection probe solution was 
made of 50 ml NaOH 0.1, 2 mg of hematin, 2 mg of luminol, and 2 mg of fluorescein and 
sonicated for 3 minutes. Three 50 ml tubes in which each had 1 Winthrop tablet (100 mg 
ATS and 270 mg AQ) were added 50 ml of NaOH at 0.1, 0.5, 1 M to achieve 2mg/ml of 
ATS. The solution was but on the shaker for 30 minutes and filtered through 0.45 
polypropylene membranes. One hundred of ATS solution was pipetted into 96-well plate. 
Immediately before the measurement, 100 µl of detection solution was pipetted to the 
well. The measurements were taken at 2 different wavelengths 425 and 530 nm over 4 
minute with 30second interval using the spectrophotometer. There were 2 replicates for 
each condition. 
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7.2.1.2 Characterization of different solvents – NaOH and Acetonitrile 
ATS has been known to be soluble in acetonitrile. Thus, NaOH at 0.1 M and 
acetonitrile (ACN) were used to dissolve ATS in the presence of AQ to compare the 
luminescent signals from two different solvents. Two stock solutions of ATS at 2mg/ml 
and 5.4 mg/ml of AQ were made in NaOH 0.1M and ACN. Each stock solution was 
serially diluted into 1.5, 1, 0.5 mg/ml of ATS. For each ATS concentration in either 
NaOH 0.1 M or ACN, a solution of 100 µl of ATS and 100 µl of detection probe solution 
were mixed together and measured at 2 different wavelengths (425 and 530 nm) using the 
spectrophotometer. Four replicates were created for each condition. 
7.2.1.3 Detection of ATS on Arsuamoon and Winthrop tablets 
The modified ATS assay was tested on Arsuamoon and Winthrop tablets. The 
Arsuamoon tablets (50 mg of ATS) were dissolved in 25 ml of NaOH 0.1 M while the 
Winthrop (100 mg of ATS) was dissolved in 50 ml to achieve a concentration of 2 
mg/ml. The mixtures was sonicated for 10 minutes and filtered through 0.45 µm 
polypropylene membrane. The ATS solutions were mixed with 100 µl of detection probe 
at equal volume immediately before the measurement with the spectrophotometer in 
luminescent mode at 530 nm. For each tablets, the measurements were repeated for 8 
times. 
7.2.2 Chip design 
The chip was designed based on the Hagen–Poiseuille law in non-ideal fluidic 
mechanic. Equation 7-1 below represented the law. 
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2  was for rectangular channel.  
By rearranging the equation, the resistance of the channel can be calculated: 
4
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µ
=  Eq. 7-3 
From equations above, we can treat the flow in the microchannel as the flow of 
current in the electrical circuit. The pressure drop ΔP was acted as the voltage. The flow 
rate Q was as the current. Thus, to make sure all flows of the API and detection probe 
would intersect and mix at certain points. The channel’s lengths were varied to adjust the 
resistance since the resistance changed proportionally with the length of the channel. In 
the multiplex chip design, there would be 4 different detection regions so the detection 
probe channel was divided into 4 sub-channels to mix with different API concentrations. 
To ensure the probe and API mix at the same time and pressure drop, the API channels’ 
lengths had to be 4 times the probe channel and the distance from each detection wells to 
the waste outlet had to be the same. After putting all those restriction into consideration, a 
chip design from Figure 7.1. There were 4 inlets for the API and pure known samples, 
one inlet for the detection probe, and 2 waste outlets for the reactions chambers. The 
mixing herringbones in the chips would be 40 µm high while the channel’s height was 
200 µm. The ratio between the channel and herringbones was to ensure the mixing 
between the API and detection probe. 
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7.2.3 Chip fabrication 
The chip mold was made using soft lithography with SU8 negative photoresist. 
The chip design was made in AutoCAD. The photomask was created using photomask 
blank plate with 0.090 inches thickness of positive photoresist AZTFP-650 on glass. The 
chip design was drawn on the photomask using laser mask writer Heidelbergh DWL 66. 
The mask was developed in MF319 for the photoresist and then in chrome developer to 
dissolve the chrome layer. Two masks were made for the channel and herringbones 
separately. After that, the silicon wafer was spun with 1ml of SU8-2100 photoresist at 
500 rpm with 100 rpm/s for 1 minute and 1300 rpm with 300 rpm/s for 2 minutes on the 
Headway Research CB-15 & PWM32 to achieve a 200 µm thick layer of photoresist. The 
wafer was soft-baked at 65 ºC for 5 minutes and at 95 ºC for 45 minutes to evaporate the 
solvents in the photoresist. Then, the wafer was exposed to UV light with the channel 
photomask on top for 45 seconds at 10 mW/cm2 and hard-baked at 65oC for 5 minutes 
and at 95 ºC for 15 minutes. After that, another layer of SU8-2025 with 40 µm thickness 
was spun on top of the exposed photoresist at 500 rpm with 100 rpm/s for 1 minute and 
2000 rpm with 300 rpm/s for 2 minutes. The wafer was soft-baked at 65 ºC for 2 minutes 
and at 95 ºC for 5 minutes and aligned with the herringbone photomask using the mask 
aligner Karl Suss MA6 to get exposed to UV light for 22 seconds. The wafer was hard-
baked again at 65 ºC for 1 minute and at 95 ºC for 3 minutes and developed in SU8 
developer for 45 minutes. Finally, it was washed with isopropanol for 15 seconds and air-
dried to be ready for casting PDMS over it. The PDMS was prepared by mixing 3 g of 
curing reagent with 30 g of base from the PDMS kit from Fisher Scientific and poured on 
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the mold. The PDMS and mold was cured at 80 ºC for 2 hours and cut out to bond to 
clean glass slides using plasma treatment. The schematic to summarize the entire 
fabrication process was in Figure 7.2. 
7.2.4 Chip characterization 
To measure the signal from the microfluidic chip, an optical bench top platform 
was built that included two pressure pumps, optical system (CCD camera, filter wheel, 
LEDs, optical box), and computer to record the data. The complete system was presented 
in Figure 7.3. All the tests were run in this platform. 
7.2.4.1 Flow rate 
The flow rates for 4 API channel and the detection probe were measured by using 
pressure pump and a scale. Five 2ml microcentrifuge tubes were filled with water and 
placed in the pressure pump. The chip was filled with water by pump at 12 psi. The tubes 
were weighed on the scale and record the amount of water in each tube before the flow 
rate test. After that, the water was pump at 12 psi for 1 minute. The tubes were weighed 
and the remaining weight of water in each tube was recorded. The flow rate in each inlet 
was calculated by subtracting the tube weight before to the weight after the flow rate 
measurement.  
7.2.4.2 Mixing ratio 
To test the mixing ratio, the detection probe tube was filled with fluorescein 
solution. The solution was made by dissolving 5 mg of fbiotin-4-fluorescein from 
Invitrogen in 25 ml of 1X PBS and diluted by a factor of 10 in PBS 1x. The chip was 
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filled with fluorescein solution and water by pumping at 12 psi. The image of the chip 
after pumping for 1 minute was taken with CCD camera at 500 ms exposure and 30dB 
gain. The results were analyzed using ImageJ. 
7.2.5 Standard curve on chip  
7.2.5.1 Artesunate 
The standard curve on chip of ATS included 4 different concentrations: 0, 0.5, 1, 
and 2 mg/ml. the stock solution of 2 mg/ml was prepared by diluting 10 mg of ATS 
powder in 5 ml of NaOH 0.1 M. The stock solution was diluted into 2 concentrations (1 
and 0.5 mg/ml) by adding 1000 and 500 µl of ATS stock solution in 1000 and 1500 µl of 
NaOH 0.1M respectively and mix by vortex.  Each concentration of ATS was aliquoted 
into 2 ml tubes and placed in the pressure vessel where the tubing to the API inlets was 
connected. The detection probe was prepared like described in previous chapter 6. The 
ATS reactions were run on the chip for 2 minutes and the CCD captured the images every 
30 seconds at 1.5s exposure time and gain of 30dB. ImageJ was used to analyze the 
results. There were 3 replicates for the standard curves 
7.2.5.2 Amodiaquine 
The standard curve for AQ was created with 4 points total: 0, 25%, 50%, and 
100%. The stock solution of 100% was prepared by dissolved 5 mg of AQ hydrochloride 
in 5 ml of water and diluted by factor of 40 in water. The solution of 25% and 50% of 
AQ was made by diluting 1000 µl and 500 µl of the stock solution in 1000 µl and 500 µl 
of water. The solutions of AQ was pipetted into 2ml tubes and placed in the pressure 
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vessel. The quenching reaction of AQ on EY was carried on chip for 2 minutes. The 
fluorescent signal was measured at 515 nm excitation and 545 nm emission and captured 
by CCD with long pass filter at 530 nm and 100 ms exposure time and 20dB gain. The 
analysis was run in ImageJ. Three replicates were repeated for the AQ standard curves. 
7.2.6 Quantification of unknowns and Winthrop tablets 
7.2.6.1 Artesunate 
A 3-point standard curve was created on chip for real time quantification of the 
ATS samples with unknown concentrations. The ATS unknown samples were prepared 
by a fixed amount of ATS stock solution of 2 mg/ml in NaOH 0.1M. The standard 
samples were 3 solutions of 0, 1, and 2 mg/ml of ATS powder. The API inlets were for 3 
standard solutions while the last API inlet was the unknown sample. The solutions were 
mixed with detection probe at constant flow rate for 2 minutes. The images of detection 
regions on chip were captured using CCD camera at 1.5 s exposure time and 30 dB gain. 
They were analyzed with ImageJ. There were 2 unknown samples. 
7.2.6.2 Amodiaquine 
Similarly to ATS, there were three AQ samples with unknown concentrations 
prepared by diluting the 100% stock solution in water. Three different standard curves of 
AQ at 0, 50%, and 100% concentrations from the 100% stock solutions were created on 
chip to quantify the amount of AQ in the unknown samples. The quenching reactions 
were run for 2 minutes. The CCD camera captured the images of the chip every 30 
seconds in the fluorescent mode with 515 nm excitation and 545 nm emission 
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wavelengths. The 530 nm long pass filter, 100 ms, and 30 dB gain were used. Image 
analysis was done in ImageJ. 
7.3 RESULTS AND DISCUSSIONS  
7.3.1 Modification of ATS assay 
To neutralize the hydrochloride acid in the fixed dose combination of ATS and 
AQ, sodium hydroxide at 0.1, 0.5, and 1 M was used to dissolve ATS in the presence of 
AQ.HCl compound. From Figure 7.4, NaOH helped to slow down the degradation of 
ATS in acidic conditions since the luminescent signal was more than 1 million relative 
luminescent units (RLU) while ATS dissolved in water in the presence of AQ.HCl was 
around 10,000 RLU. The signal increased by a factor of 100. Moreover, different 
concentration of NaOH had different effects on the luminescent signal. The solution of 
NaOH 0.1 M gave the highest signal immediately after the mixing of ATS with the 
detection probe while the peak signal of the reaction in NaOH 0.5 and 1 M was 2 and 10 
times less and at a later time than the one in NaOH 0.1M. The luminescent signal 
collected at 530 nm was 2 times more than the one at 425 nm at same concentration of 
NaOH 0.1 M. Thus, NaOH 0.1 M was chosen to dissolve ATS in the fixed dose 
combination tablets. Different solvent was used to confirm the hypothesis that the acidic 
condition degraded the amount of ATS in solutions. Acetonitrile, the solvent used to 
dissolve ATS in HPLC, was used to dissolve ATS in the presence of AQ.HCl. By 
comparing the top (acetonitrile) and bottom (NaOH) graph in Figure 7.5, it showed that 
the luminescent signal in ACN was 10 times lower than the one in NaOH. This concluded 
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that NaOH was the key factor to stop the degradation of ATS in acidic environment while 
the ACN slow down the dissolution of HCl in to the solution, but it was enough to 
decrease the presence of ATS or the luminescent signal during the reaction. 
To confirm further, a standard curve of ATS in AQ.HCl was created and 
measured immediately and after 1 hour incubation at room temperature. The results 
showed that the ATS were stable after 1 hour in NaOH 0.1 solution with AQ.HCl (Figure 
7.6) since the luminescent signals were similar between the two standard curves. 
Furthermore, the Arsuamoon and Winthrop tablets were tested using the new modified 
assay to detect ATS and AQ and the standard curve in Figure 7.6 was used to quantify the 
ATS in the tablets. For Arsuamoon, both tablets of ATS and AQ were dissolved in NaOH 
and the individual Winthrop tablet was dissolved in NaOH. From the HPLC results for 
Arsuamoon tablet in chapter 3 and the one in Table 7.1, we concluded that the new assay 
was able to measure the amount of ATS in combination therapy with high accuracy and 
precision. For the Winthrop tablets, the results showed that amount of ATS in the 
solution was the same as the amount stated in the packages, but the results needed to be 
confirmed with the HPLC, the gold standard method for chemical analysis. 
7.3.2 Chip characterization  
In the first test to measure the flow rate in detection probe and API channels, the 
results from Table 7.2 showed that flow rate in the API channel was approximately 24% 
higher than it was expected base on the flow rate of detection probe divided by 4 due to 
the inconsistency in the channel’s height across the chips. However, we could calibrate 
the different out by measuring the mixing ratio between the detection probe and the API 
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using fluorescein. Figure 7.7 showed how the mixing happened on chip using the 
herringbone. The fluorescein signal was uniform in the detection region. Based on the 
schematic of the chip in Figure 7.1, we derived a formula to calculate the flow rate from 
the mixing ratio. The equation was presented below: 
( )
RF
RFVV −= 112  Eq. 7-4 
The term of RF represented the ratio of fluorescent mixing. V1 was the volumetric 
flow rate of the detection probe channel while V2 was the volumetric flow rate of API 
channels. Based on equation 7-2, we could back-calculate the flow rate of the detection 
probe and API and mixing ratio of the flow rate. Using the mixing ratio of the flow rate, 
we could adjust the final calculation of the API based on graph of signal versus the 
percentage of API in the mixture of API and detection probe in Figure 7.8 and Figure 7.9. 
Polynomial equations were fitted through the points for ATS and AQ and called yATS_ratio 
and yAQ_ratio. The mixing factors of the calculation of ATS and AQ concentrations were 
labeled as mATS and mAQ. The equation to calculate mATS and mAQ were below: 
( )
( )RFy
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_ 5.0=  Eq. 7-5 
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ratioAQ
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AQ
_
_ 5.0=  Eq. 7-6 
Using the mixing factor, the final calculated concentration of ATS and AQ could 
be adjusted and calibrated out the errors from the manufacturing of chips and fluctuation 
of pressure during the measurements. 
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7.3.3 On-chip testing of Artesuante 
An ATS standard curve on chip with 4 different concentrations of ATS (0, 0.5, 1, 
and 2 mg/ml) was created and repeated for 3 times to determine the variation between 
runs on different chips. The image in Figure 7.10 showed that we were able to distinguish 
different concentrations of ATS on chip based on the brightness of the luminescent signal 
captured by the CCD camera. The repeatability of the ATS assay on chip was shown in 
the plot in Figure 7.10. There were less than 15% of variation between standard curves, 
but the linearity of the standard curve was retained. To quantify the unknown samples, 3-
point standard curve was created for each unknown. In the graph in Figure 7.11, we 
showed that 3-point standard curve was successfully created using the image captured by 
CCD camera and ImageJ software. Moreover, it was used to quantify the ATS unknown 
samples with less than 5% errors (Table 7.3) for 2 unknown samples in the middle and 
upper range of ATS dose used in the Arsuamoon and Winthrop tablets. 
7.3.4 On-chip testing of Amodiaquine 
Similarly to ATS tests, an AQ standard curve on chip with 4 different 
concentrations of AQ (0, 25, 50, 100%) was created and repeated for 3 times to determine 
the variation between runs on different chips. The 100% AQ solution equaled to 25 
µg/ml. The image in Figure 7.12 showed that different concentrations of AQ on chip had 
the different brightness since the fluorescent signal captured by the CCD camera. The 
graph in Figure 7.12 represented the repeatability of AQ standard curve on chip. There 
were less than 5% of variation between standard curves and the linearity of the standard 
curve was retained. To quantify the unknown samples, 3-point standard curve was 
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created for each unknown. In the graph in Figure 7.13, a 3-point standard curve was 
successfully created using the image captured by CCD camera and ImageJ softw. 
Moreover, we were able to use the fitted equation from the curve to quantify the AQ 
unknown samples with less than 5% errors Table 7.4 for 3 unknown samples in the 
middle and upper range of AQ dose used in the Arsuamoon and Winthrop tablets. 
Overall, we demonstrated that we were able to quantify the ATS and AQ samples 
with unknown concentration using 3-point standard curves on chip to eliminate the error 
from samples preparation and optical measurement. Moreover, all the measurements 
were captured in optical system we built and optimized in our own laboratory that can be 
potentially modified and compressed into a field-deployable device to be tested in the 
resources-limited testing. 
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7.4 TABLES 
 
 Arsuamoon  Winthrop 
Average signal (RLU) 10914879 11160900 
Standard deviation 341320 155138 
Concentration 
(mg/ml) Expected 2 2 
Calculated 1.98 2.06 
 
Table 7.1: The summary of the results of the luminescent ATS assay for both Arsuamoon 
and Winthrop tablets 
 
It included the expected and calculated concentration of ATS in the tablets, and the 
percentage of recovery of ATS compared to the expected concentrations. 
Channel ID Actual flow rate (ml/min) 
Fluorescein 
mixing  (RF) 
Calculated flow 
rate (ml/min) 
Upper left channel 0.295 0.448898 0.296805 
Upper right channel 0.313 0.474165 0.314012 
Lower left channel 0.291 0.449373 0.296235 
Lower right channel 0.324 0.477393 0.318474 
Detection probe 0.967 1 0.24175 
 
Table 7.2: The summary of the flow rate and mixing ration test on the multiplex chip 
 
It included the actual measured flow from weighing the water in the tubes before and 
after 1 minute running on the chip, the fluorescein mixing ratio from the image capture 
with CCD camera, and the calculated flow rate based on the mixing ratio. 
Sample ID Theoretical 
concentration 
(mg/ml) 
Measured 
concentration 
(mg/ml) 
% recovery 
Unknown 1 1.2 1.176099 98% 
Unknown 2 1.7 1.780695 104.7% 
 
Table 7.3: The summary of the measurement and calculation of the ATS unknown 
samples 
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It included the theoretical concentration and the measured concentration of the unknown 
samples, and the percentage of recovery of measured concentration to the theoretical 
concentration. There were 2 unknown samples. 
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Sample ID Theoretical 
concentration (%) 
Measured 
concentration (%) 
% recovery 
Unknown 1 87 88.1 101% 
Unknown 2 61 64.1 105% 
Unknown 3 108 111.6 103% 
 
Table 7.4: The summary of the measurement and calculation of the AQ unknown samples 
 
It included the theoretical concentration and the measured concentration of the unknown 
samples, and the percentage of recovery of measured concentration to the theoretical 
concentration. There were 3 unknown samples total. 
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7.5 FIGURES 
 
Figure 7.1: The AutoCAD draw of the multiplex chip with description 
The white features on the chip were the channel. The green features were the herringbone 
for passive mixing. The red regions were the detection region for the reaction. There were 
4 API inlets, 1 detection probe inlet, and 2 waste outlets. The solution from the detection 
probe inlet would be split into 4 channels to mix with each API channels in the 
herringbone region and the signal would be detected in the red channels. The field of 
view for CCD camera to capture the images was 3 cm in diameter around the detection 
region. 
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Figure 7.2: The schematic of how the chip was made using SU8 photoresist and PDMS  
1: The photoresist on silicon wafer was exposed under UV light with photomask on top. 
2: The part got exposed to UV light became hardened compared to the unexposed 
photoresist. 3: The silicon wafer was developed in SU developer to dissolve the 
photoresist that was not exposed to UV light and the mold was complete. 4: PDMS was 
poured on the silicon mold to form the chip pattern in the PDMS. After that, the PDMS 
would be bond to glass slide using oxygen plasma. 
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Figure 7.3: The components of the bench top system that has been developing in our 
laboratory  
The system consisted of the CCD camera with filter wheel and LED lights (right) in an 
optical box (left) to block the ambient light from interfering with the measurement and 
two pressure pumps with LCD (middle) for users to control the pressure. The 
microfluidic chip can connect with the pressure system to perform the detection assay on 
chip and the optical system can capture the images of the chip over time and record the 
data to the computer. 
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Figure 7.4: The graph of luminescent signal from the reactions of ATS in the presence of 
AQ with detection probe versus the time 
The signals were measured at 3 different concentrations of NaOH (0.1, 0.5, and 1 M) at 2 
different emission wavelengths (425 and 530 nm). 
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Figure 7.5: The detection of ATS in the presence of AQ in 2 solvents: NaOH and 
acetonitrile 
Top: The graph of the luminescent signal versus the concentrations of ATS at 425 and 
530 nm emission wavelengths and ATS was dissolved in acetonitrile. The peak signal 
was at 2 million RLUs. Bottom: The graph of the luminescent signal versus the 
concentrations of ATS at 425 and 530 nm emission wavelengths and ATS was dissolved 
in NaOH 0.1M. The peak signal was at 14 million RLUs. 
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Figure 7.6: The standard curve of ATS in the presence of AQ after 1 hour waiting at 
room temperature  
The graph of luminescent signal versus ATS concentration at 425 and 530 nm emission 
wavelengths for immediate measurement and 1 hour after mixing was plotted. 
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Figure 7.7: The image of the chip in the mixing ratio test to show how the mixing was 
carried and measured on chip using fluorescein  
The fluorescein solution from the top channel with brightest signal was mixed with water 
from the API channels which could not be seen under fluorescent measurement. The 
signals in the herringbone and detection regions were much lighter than the one in the 
detection channel.  
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Figure 7.8: The graph of the percentage of ATS in the mixture with detection probe 
versus the luminescent signal from the reaction 
A polynomial equation was fitted through the points. 
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Figure 7.9: The graph of the percentage of AQ in the mixture with detection probe versus 
the luminescent signal from the reaction  
A polynomial equation was fitted through the points. 
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Figure 7.10: The 4-point standard curve of ATS in the presence of AQ on a multiplex 
chip 
Top: The image of the chip with 4 different concentrations of ATS: 0 (upper right 
channel), 0.5 (lower left channel), 1 (upper left channel), and 2 (lower right channel) 
mg/ml. Bottom: The standard curve of ATS on chip with 4 different concentrations of 
ATS (0, 0.5, 1, and 2 mg/ml). There were 3 replicates for the standard curve. 
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Figure 7.11: The quantification of unknown samples using on chip ATS standard curves  
Top: The image of the chip with 1 unknown (lower left) and 3 known concentrations of 
ATS: 0 (upper right channel), 1 (upper left channel), and 2 (lower right channel) mg/ml. 
Bottom: The three-point standard curve on chip (0, 1, and 2 mg/ml) was used to calculate 
the ATS concentration of the unknown samples. There was one standard curve for each 
unknown sample. 
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Figure 7.12: The 4-point standard curve of AQ on a multiplex chip  
Top: The image of the chip with 4 different concentrations of AQ: 0% (upper left 
channel), 25% (lower left channel), 50% (lower right channel), and 100% (upper right 
channel). Bottom: The standard curve of AQ on chip with 4 different concentrations of 
AQ (0%, 25%, 50%, and 100%). The 100% AQ solution was at 25 µg/ml. There were 3 
replicates for the standard curve. 
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Figure 7.13: The quantification of unknown samples using on chip AQ standard curves  
Top: The image of the chip with 1 unknown (lower left) and 3 known concentrations of 
AQ: 0% (upper left channel), 50% (upper right channel), and 100% (lower right 
channel).Bottom: The three-point standard curve on chip (0%, 50%, and 100%) was used 
to calculate the AQ concentration of the unknown samples. The 100% AQ solution was 
at 25 µg/ml. There was one standard curve for each unknown sample. 
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Chapter 8 Conclusions and future works 
8.1 Assay development  
8.1.1 Major contributions 
In the assay development, there are two most important steps: to discover the 
reaction between the target and the detection molecule and to optimize the conditions at 
which the reaction would give out the maximum signal with high sensitivity and 
specificity to the target. My major contribution in the assay development for the detection 
of antimalarial was to optimize and validate all the factors required by the international 
guidelines. In addition, I identified the factor to distinguish the different antimalarials like 
ATS, ART, and DHA even though they have the O-O bonds that can be detected using 
luminol reaction. By capturing the entire curve of the luminescent signal over time for 
each antimalarial, I have been able to determine that the shapes of the curve were 
different and the peak signal was at different time point. The original signals from the 
luminol reaction with the antimalarials were not detectable using a photodiode since most 
of the photodiodes are only sensitive for wavelengths in the range of 500-650 nm and the 
emission wavelength of chemiluminescent reaction was 425-450 nm. Thus, I optimized 
the signal by shifting the emission wavelength to 530 nm using fluorescein based on the 
theory of FRET. This helped to increase the signal by a factor of 5 and make it sensitive 
to commercially available photodiode.  
Moreover, I have optimized the solvents to dissolve ATS tablets in monotherapy 
and fixed dose combination therapy with AQ. For monotherapy, acetonitrile was the best 
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solvent to dissolve most the ATS in the tablet to achieve comparable results with thin 5-
10% errors compared to the quantitative results from HPLC. In the case of fixed dose 
combination therapy, I discovered that NaOH 0.1 M was the solvent that helped to 
protect ATS from being degraded by HCl in AQ compound. With this modification, the 
assay can detect ATS in the presence of AQ.HCl without the need to extract ATS from 
AQ while HPLC requires an extraction step to separate ATS from AQ before it can 
quantify the mixture. Furthermore, I have validated the sensitivity, specificity, selectivity, 
thermal stability, repeatability, intermediate precision, and the accuracy of the luminol 
assay to quantify ATS in solutions according to the international guidelines. 
For the quantification of AQ, I developed a novel assay to detect AQ using the 
quenching effect of AQ on eosin Y. I ran optimization experiments on different 
concertation of EY and the emission and excitation wavelengths that give out the highest 
quenching effect with high specificity in the linear decrease in signal with different 
concentrations of AQ. Similarly to ATS, a series of validation tests was run on the AQ 
detection assay. 
  Overall, I successfully developed and validated the novel assay to detect 
ATS in the presence of AQ and vice versa. I was able to test the assay on the field 
deployable prototype, PharmaChk, with field samples collected from local 
pharmacies in Ghana. The results from the Lever, Camosunate, and Glunate brands 
showed that the assay was able to quantify ATS with high accuracy and precision 
compared to the gold standard method, HPLC, but in resources-limited setting with 
much higher quantitative power compared to field methods TLC. With these assay, 
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we believe that would the foundation to reach our ultimate goal is to build and 
validate the performance of an affordable, easy to use sensitive, robust, and 
portable platform that does real time quantification of antimalarials using 
luminescent signal in resource limited settings with high specificity and sensitivity. 
We hope that this would help to combat the spread of counterfeit and substandard 
antimalarial in the developing world and thus save million precious lives around 
the world. 
8.1.2 Future investigations 
At the moment, we have tested the assay on 5 different brands of ATS and AQ 
combination therapy for only ATS but other artermisinin’s derivatives like ART and 
DHA. For future investigations, we would like to use the assay to test other brand 
available in the market. The other goal is to focus on modifying the assay to detect 
different antimalarials (ART and DHA) and validate its performance with the 
international guideline. The final goal is to optimize the assay until it will show 
comparable results compared to HPLC with less than 5% errors. 
8.2 Portable platform for quantification of pharmaceuticals 
8.2.1 Major contributions 
I have developed and novel microfluidic chip to conduct the chemiluminescent 
reaction on chip including the mixing and incubation steps in the reaction chamber to 
minimize the human errors, decrease the reagents volume. On the detection system 
development, we developed PharmaChk, a novel luminescent-based system to quantify 
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active ingredient concentration in remote settings. We developed a luminescent assay to 
quantify Artesunate in monotherapies. Further, we field-tested PharmaChk in Ghana 
using Artesunate samples in both tablet (Lever and Camosuante) and powder for injection 
(Glunate) form and compared results to those obtained from USP’s HPLC-UV Medicine 
Compendium Artesunate tablets monograph. The initial results showed that the 
PharmaChk system quantified active pharmaceutical ingredient (API) content with high 
precision and a relative standard deviation of 5% or less but had shown high deviation 
from confirmatory HPLC-UV tests. The initial high variability was determined to be 
influenced by solvent selection. By using acetonitrile, instead of PBS solvent these 
variability issues were addressed and the average difference in results between 
PharmaChk and HPLC-UV was under 3% for Glunate® injectables, less than 4% for 
Lever® tablets, and less than 9% for Camosunate® tablets with tests in multiple locations, 
with multiple users, and over multiple days. Overall, our results from the field studies 
show high performance in measuring API content and substantial improvement over field 
based methods for API detection in precision, accuracy and ease-of-use and can help 
assure the quality of medicines in the field when used with other complementary 
technologies.  
In addition, I have developed a novel multiplex chip to create a standard curve of 
API of interest on a chip and used the curve to quantify the unknown samples in real 
time. The chip can be used to quantify multiple tablets simultaneously and create a 
discrete dissolution profile at 4 different time points during the dissolution of the API 
tablets. 
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8.2.2 Future investigations 
With the current assay and platform, our error compared to HPLC was about 
10%. We want to lower the errors to less than 5% by improving the errors occurring in 
the samples preparation and mixing step. In the samples preparation step, detection probe 
solution made on different days can cause the variations in both standard and unknown 
solutions. By making a 3-point standard curve on the chip, it would help to eliminate this 
error. In the mixing step, the source of errors was from the difference in channel’s height 
across the chip. There are two approaches to decrease the errors in the mixing. The first 
one is to improve the precision of photoresist spinning during the fabrication process or 
change to a different process with better feature control like inject mold, lase cut, 3D 
printing. The second approach is to develop a curve between the mixing ratio of API and 
detection probe and the reaction signal to calibrate out the error from the mixing step. 
The mixing ratio can be calculated by adding fluorescent tracer into detection probe 
solution and taking the image of the signal from the tracer during the reaction. 
Furthermore, to improve the accuracy of the system, an automated platform with 
minimal involvement of users would help to eliminate the variations from different 
people running the tests. In addition, for future testing on the APIs with different 
fluorescent dyes as tracers, a set of verification tests to determine the interference 
between those dyes and the API and detection probe should be conducted to compensate 
for the change in signal after the introduction of the dyes. All these experiments would 
help to improve the precision and accuracy and the user’s friendliness of the entire 
platform to be used in the resources-limiting settings. 
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8.3 Aptamer development for small organic molecules 
8.3.1 Major contributions 
Even though SELEX has been developed for more than 2 decades, there were 
very few aptamers for small organic molecules with the molecular weight less than 1000 
Daltons. There were two main SELEX developed for those targets: Capture-SELEX 
using magnetic beads and GO-SELEX using graphene oxide. I used both processes to 
develop an aptamer for TMP, but the initial aptamers from the first run using Capture-
SELEX did not show any specific binding to TMP. I identified the steps during the 
selection cycles that the good aptamers may be lost due to the binding and purification 
steps. A series of optimization steps was performed to ensure good recovery of aptamer 
after each cycle. I identified the sources of the loss of the aptamers and the methods to 
prevent them. All these optimization steps helped to increase the chance of finding 
aptamers bound specifically to the target by making at least 1015 random aptamers bound 
to the magnetic beads or graphene oxides in the firs cycles, successfully amplifying them, 
and recover them after the purification step. At the selection cycles, next generation 
sequencing (NGS) was used to identify the unique aptamer instead of the conventional 
Sanger sequences. NGS gave about 8 million reads from the aptamers pool which 
improves the chances to find the aptamers. With the optimized process, I was able to 
discover an aptamer to bind specifically to TMP, an antibacterial that hasn’t been 
developed before. 
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8.3.2 Future investigations 
For future direction, the optimized protocol to develop small-molecule aptamers 
can be used to develop aptamers for other types of targets: small peptides, water-
insoluble organic compounds. For small peptides, the challenge is that the peptides 
degrade rapidly at room temperature. A quality control step using HPLC to ensure the 
presence of the correct structure of peptides will be performed. In parallel, before and 
during the SELEX cycles, a selection step to isolate aptamers bound to counter/non-
targets like degraded structures of peptides. These counter-targets selection steps help to 
eliminate the aptamers specific to both correct and incorrect structure the peptide target. 
For water-insoluble targets, different solvent can be tried out to see: 1) in which solvent 
the target is soluble and 2) the solvent should interfere with the binding the aptamer of 
target at certain volume of the solvent. Then, normal SELEX cycles will be performed 
using the identified solvent. With these modifications, I hope to expand the aptamer 
library for small organic molecules and shift the quality control of different 
pharmaceuticals using the physical properties like HPLC to the chemical properties like 
binding reactions.  
8.4 Concluding Remarks 
In conclusion, I have developed assays to quantify the combination therapy for 
antimalarials (ATS and AQ) according to the international guidelines for analytical 
procedures. In parallel, I worked on building and validating the performance of several of 
the core features of a field-deployable medicines quality screening prototype, 
PharmaChk, by measuring the API content of ATS from different brands (Camosunate®, 
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Lever®, Glunate®) and forms (tablets and injectable liquid) in Accra, Ghana. We have 
demonstrated the ability of PharmaChk to quantify the API content of ATS tablets with 
high accuracy and precision. Moreover, I have developed and optimized a SELEX 
protocol for small organic molecules to screen for different water-soluble 
pharmaceuticals. As a proof of concept, I identified an aptamer specific to TMP, an 
antibiotic using the optimized SELEX protocol. This will be a foundation to build a 
library of aptamers for small pharmaceuticals and lead us to the final goal.  Our final goal 
is to build an affordable, robust, portable, and accurate platform that quantifies API 
content and release API kinetics over time using chemical reactions or binding effects. I 
believe that these assay and aptamer developments with the validation performance using 
PharmaChk prototype in Accra, Ghana are a significant and promising step further in that 
direction. 
  189 
REFERENCES 
Affum, A. O., Lowor, S., Osae, S. D., Dickson, A., Gyan, B. a, & Tulasi, D. (2013). A 
pilot study on quality of artesunate and amodiaquine tablets used in the fishing 
community of Tema, Ghana. Malaria Journal, 12(1), 220. 
http://doi.org/10.1186/1475-2875-12-220 
Agilent. (2011). HPLC system. Retrieved March 1, 2016, from 
http://www.primerasci.com/product/hplc_system 
Agnihotri, J., Singh, S., & Bigonia, P. (2012). Fomral chemical stability analysis and 
solubility analysis of artesunate and hydroxychloroquinine for development of 
parenteral dosage form. Journal of Pharmacy Research, 6(1), 117–122. 
Appleby, J. (2003). Fake drugs show up in US pharmacies. USA Today. Retrieved from 
http://www.usatoday.com/money/industries/health/drugs/2003-05-14-fakedrug-
cover_x.html 
Bate, R., Jensen, P., Hess, K., Mooney, L., & Milligan, J. (2013). Substandard and 
falsified anti-tuberculosis drugs: A preliminary field analysis. International Journal 
of Tuberculosis and Lung Disease, 17(3), 308–311. 
http://doi.org/10.5588/ijtld.12.0355 
Bianchini, M., Radrizzani, M., Brocardo, M. G., Reyes, G. B., Gonzalez Solveyra, C., & 
Santa-Coloma, T. A. (2001). Specific oligobodies against ERK-2 that recognize both 
the native and the denatured state of the protein. Journal of Immunological Methods, 
252(1-2), 191–197. http://doi.org/10.1016/S0022-1759(01)00350-7 
Bio-rad. (2016). Quantitative PCR using Taqman probe. Retrieved March 1, 2016, from 
http://www.bio-rad.com/en-us/applications-technologies/introduction-pcr-primer-
probe-chemistries 
Bland, J. M., & Altman, D. G. (1986). Statistical methods for assessing agreement 
between two methods of clinical measurement. Lancet, 1, 307–310. 
http://doi.org/10.1016/S0140-6736(86)90837-8 
Blind, M., & Blank, M. (2015). Aptamer Selection Technology and Recent Advances. 
Molecular Therapy—Nucleic Acids, 4(1), 223–229. 
http://doi.org/10.1038/mtna.2014.74 
Bowles, D., Olson, A., Hodges II, N., Heglund, D., Vargas, R., & Williams, S. (2012). 
Chemiluminescent identification and quantification of artemisinin and relevant 
sesquiterpene lactone derivatives. Applied Spectroscopy, 66(2), 175–179. 
  190 
CBS. (2015). Herbal supplements filled with fake ingredients, investigators find. 
Retrieved March 1, 2016, from http://www.cbsnews.com/news/herbal-supplements-
targeted-by-new-york-attorney-general/ 
Center for Disease Control and Prevention. (2014). Impact of Malaria. Retrieved March 
1, 2016, from http://www.cdc.gov/malaria/malaria_worldwide/impact.html 
Cheeseman, R. (1999). Direct sensitivity comparison of fluorescein and luminol 
bloodstain enhancement techniques. Journal of Forensic Identification, (49), 261–
268. 
Cockburn, R., Newton, P., Agyarko, K., Akunyili, D., & White, N. (2005). The Global 
Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate 
the Dangers. PLoS Medicine, 2(4), 302–307. 
Crecelius, A., Clench, M. R., & Richards, D. S. (2004). TLC–MALDI in Pharmaceutical 
Analysis. Current Trends in Mass Spectrometry, 19(12). 
Cui, L., Yan, G., Sattabongkot, J., Chen, B., Cao, Y., Fan, Q., & Parker, D. (2012). 
Challenges and prospects for malaria elimination in the Greater Mekong Subregion. 
Acta Tropica, 121, 240–145. 
Day, N. (2006). Counterfeit anti-infective drugs. Lancet Infectious Diseases, 6(9), 602–
613. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16931411 
Dinoop, K., Parija, S., Mandal, J., Swaminathan, R., & Narayanan, P. (2016). 
Comparison of nested-multiplex, Taqman &amp; SYBR Green real-time PCR in 
diagnosis of amoebic liver abscess in a tertiary health care institute in India. Indian 
Journal of Medical Research, 143(1), 49. http://doi.org/10.4103/0971-5916.178592 
Dondorp, A., Newton, P., Mayxay, M., Van Damme, W., Smithuis, F., Yeung, S., & 
Petit, A. (2004). Fake antimalarials in Southeast Asia are a major impediment to 
malaria control: multinational cross-sectional survey on the prevalence of fake 
antimalarials. Tropical Medicine and International Health, 9, 1241. 
Edomaruse, C. (2011). Life Imprisonment for Indians Shipping Fake Drugs to Nigeria. 
This Day Live. Retrieved from http://www.thisdaylive.com/articles/life-
imprisonment-for-indians-shipping-fake-drugs-tonigeria/88697/ 
Ellington, A., & Szostak, J. (1992). Selection in vitro of single-stranded DNA molecules 
that fold into specific ligand-binding structures. Nature, 355, 850–852. 
http://doi.org/10.1038/355850a0 
FDA. (1997). Guidance for Industry Dissolution Testing of Immediate. Retrieved from 
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070246.pdf 
  191 
Gandhi, S., Deshpande, P., Jagdale, P., & Godbole, V. (2010). A simple and sensitive 
RP-HPLC method for simultaneous estimation of Artesunate and Amodiaquine in 
combined tablet dosage form. Journal of Chemical and Pharmaceutical Research, 
2(6), 429–434. 
Global Pharma Health Fund. (2015). GPHF MiniLab. Retrieved March 1, 2016, from 
http://www.junglekey.fr/search.php?query=Minilab&type=image&lang=fr&region=
fr&img=1&adv=1 
Green, M., Mount, D., Wirtz, R., & White, N. (2000). A colorimetric field method to 
assess the authenticity of drugs sold as the antimalarial artesunate. Journal of 
Pharmaceutical and Biomedical Analysis, 24, 65–70. 
Hermann, T., & Patel, D. J. (2000). Adaptive recognition by nucleic acid aptamers. 
Science, 287(5454), 820–825. http://doi.org/10.1126/science.287.5454.820 
Ho, N. T., Desai, D., & Zaman, M. H. (2015). Rapid and specific drug quality testing 
assay for artemisinin and its derivatives using a luminescent reaction and novel 
microfluidic technology. The American Journal of Tropical Medicine and Hygiene, 
92(6), 24–30. http://doi.org/10.4269/ajtmh.14-0392 
Huang, Y. (2007). China State FDA Recommends Death Penalty for Drug Counterfeiters. 
PharmAsia News. Retrieved from http://fdcalerts.typepad.com/asia/2007/12/china-
state-fda.html 
International conference on harmonisation of technical requirement for registration of 
pharmaceuticals for human use. (1994). ICH HARMONISED TRIPARTITE 
GUIDELINE - VALIDATION OF ANALYTICAL P ROCEDURES. International 
Pharmaceutical Federation. 
Karunamoorthi, K. (2014). The counterfeit anti-malarial is a crime against humanity: a 
systematic review of the scientific evidence. Malaria Journal, 13, 209–221. 
Kaufman, M. (2007). FDA Scrutiny Scant in India, China as Drugs Pour into U.S. 
Washington Post. Retrieved from http://www.washingtonpost.com/wp-
dyn/content/article/2007/06/16/AR2007061601295.html 
Kelesidis, T., Kelesidis, I., Rafailidis, P. I., & Falagas, M. E. (2007). Counterfeit and 
substandard antimicrobial drugs a review of the scientific evidence. Journal of 
Antimicribial Chemotherapy, 6r, 214–236. 
Khan, P., Jee, R., Watt, R., & Moffat, A. (1997). The Identification of Active Drugs in 
Tablets Using Near Infrared Spectroscopy. Pharmaceutical Sciences, 447–453. 
 
  192 
Kirby, R., Cho, E. J., Gehrke, B., Bayer, T., Sok, Y., Neikirk, D. P., … Park, Y. S. 
(2004). Aptamer-Based Sensor Arrays for the Detection and Quantitation of Proteins 
Aptamer-Based Sensor Arrays for the Detection and Quantitation of Proteins. 
Analytical Chemistry, 76(14), 4066–4075. http://doi.org/10.1021/ac049858n 
Knox, R. (2013). Report: Action Needed To Wipe Out Fake And Substandard Drugs. 
Retrieved March 1, 2016, from http://www.npr.org/sections/health-
shots/2013/02/13/171923516/report-action-needed-to-curb-fake-and-substandard-
drugs 
Krishna, S., Uhlemann, A.-C., & Haynes, R. K. (2004). Artemisinins: mechanisms of 
action and potential for resistance. Drug Resistance Updates, 7(4-5), 233–44. 
http://doi.org/10.1016/j.drup.2004.07.001 
Kuzdralinski, A. (2011). Real-time PCR. Retrieved March 1, 2016, from http://www.e-
biotechnologia.pl/Artykuly/real-time-pcr 
Lacaze, C., Kauss, T., Kiechel, J., Caminiti, A., Fawaz, F., Terrassin, L., … Millet, P. 
(2011). The initial pharmaceutical development of an artesunate/amodiaquine oral 
formulation for the treatment of malaria: a public-private partnership. Malaria 
Journal, 10(1), 142. http://doi.org/10.1186/1475-2875-10-142 
Lanzhou Huaxi Science Equipment. (2016). Handheld Infrared Spectrometer. Retrieved 
March 1, 2016, from 
http://search.trade2cn.com/en/product/search.html?classes=21417 
Le Vaillant, Y., C, B., Grange, Y., Nicolas, A., Bonnet, P., Massing-Bias, L., … 
Chauvey, D. (2012). Simultaneous Determination of Artesunate and Amodiaquine in 
Fixed-Dose Combination by a RP-HPLC Method with Double UV Detection: 
Implementation in Interlaboratory Study Involving Seven African National Quality 
Control Laboratories. Chromatographia, 75(11), 617–628. 
Lee, C. Y., Chang, C. L., Wang, Y. N., & Fu, L. M. (2011). Microfluidic mixing: A 
review. International Journal of Molecular Sciences, 12(5), 3263–3287. 
http://doi.org/10.3390/ijms12053263 
Lelijveld, J., & Kortmann, H. (1970). The eosin colour test of Dill and Glazko: a simple 
field test to detect chloroquine in urine. Bulletin of the World Health Organization, 
42(3), 477–479. 
Lutgen, P. (2013). The problem of ACTs: Counterfeit or unstable? Malaria World. 
Retrieved from http://www.malariaworld.org/blog/problem-acts-counterfeit-or-
unstable 
 
  193 
Mann, D., Reinemann, C., Stoltenburg, R., & Strehlitz, B. (2005). In vitro selection of 
DNA aptamers binding ethanolamine. Biochemical and Biophysical Research 
Communications, 338(4), 1928–1934. http://doi.org/10.1016/j.bbrc.2005.10.172 
Markert, H., Ring, J., & Campbell, N. (2011). A Comparison of Four Commercially 
Available Portable Raman Spectrometers. National Forensic Science Technology 
Center, (727), 1–8. 
Martinez, L., Peinado, A., Liesum, L., & Betz, G. (2013). Use of near-infrared 
spectroscopy to quantify drug content on a continuous blending process: Influence 
of mass flow and rotation speed variations. European Journal of Pharmaceutics and 
Biopharmaceutics, 84(3), 606–615. http://doi.org/10.1016/j.ejpb.2013.01.016 
Myers, D. (2010). One European in five buys counerfeit medicine. Le Figaro. Retrieved 
from http://plus.lefigaro.fr/note/one-european-in-five-buys-counterfeit-medicine-
20100217-141835 
Nagy, A., Černíková, L., Vitásková, E., Křivda, V., Dán, Á., Dirbáková, Z., … 
Havlíčková, M. (2016). MeltMan: Optimization, Evaluation, and Universal 
Application of a qPCR System Integrating the TaqMan qPCR and Melting Analysis 
into a Single Assay. Plos One, 11(3), e0151204. 
http://doi.org/10.1371/journal.pone.0151204 
Nayyar, G. M., Breman, J. G., Newton, P. N., & Herrington, J. (2012). Poor-quality 
antimalarial drugs in southeast Asia and sub-Saharan Africa. The Lancet, 12(6), 
488–496. 
Nguyen, V.-T., Kwon, Y. S., Kim, J. H., & Gu, M. B. (2014). Multiple GO-SELEX for 
efficient screening of flexible aptamers. Chemical Communications, 50(72), 10513–
6. http://doi.org/10.1039/c4cc03953j 
Nikolin, B., Imamovic, B., Medanhodzic-Vuk, S., & M, S. (2004). High perfomance 
liquid chromatography in pharmaceutical analyses. Bosnian Journal of Basic 
Medical Sciences, 4, 5–9. 
Olsen, B. A., Borer, M. W., Perry, F. M., & Forbes, R. A. (2002). Screening for 
counterfeit drugs using NIR specrtoscopy. Pharmaceutical Technology, 62–71. 
Olsen, C. (2010). Using Promega ’ s CellTiter-Glo Luminescent Cell Viability Assay 
with SpectraMax L and SpectraMax M5 Microplate Readers. Molecular Devices. 
Park, J. W., Tatavarty, R., Kim, D. W., Jung, H. T., & Gu, M. B. (2012). Immobilization-
free screening of aptamers assisted by graphene oxide. Chemical Communications, 
48(15), 2071–2073. http://doi.org/10.1039/c2cc16473f 
  194 
Press Trust Of India. (2008). Fake Drugs Growing at 20-25%: Associated Chambers of 
Commerce and Industry of India. Business Standard. Retrieved from 
http://www.business-standard.com/india/news/fake-drugs-growing-at-20-25-
assocham/313278/ 
Putze, E., Conway, E., Reilly, M., & Madrid, O. (2008). The Deadly World of Fake 
Drugs. Foreign Policy, 168, 1–145. Retrieved from 
http://www.jstor.org/stable/25462337 
Qi, Q. (2008). Two-Thirds of Chinese Drug Stores Sell Counterfeit Medicine, Says 
Investigator. The Epoch Times. Retrieved from 
http://www.theepochtimes.com/n2/content/view/4973/ 
Ranieri, N. (2013). FDA Facts: FDA’s Counterfeit Detection Device CD-3. FDA 
Factsheet, 2013, 1–2. Retrieved from 
http://www.fda.gov/downloads/NewsEvents/Newsroom/FactSheets/UCM349286.pd
f 
Raymond, C. (2009). Cambodia Campaigns Against Counterfeit Medicines With Aid 
from USP Drug Quality and Information Program. Partnership for Safe Medecines. 
Retrieved from http://www.safemedicines.org/2009/10/cambodia-campaigns-
against-counterfeit-medicines-with-aid-from-usp-drug-quality-and-information-
program.html 
Sambria, J. (2013). Counterfeit drugs raise Africa’s temperature. Africa Renewal, 5. 
Retrieved from http://www.un.org/africarenewal/magazine/may-2013/counterfeit-
drugs-raise-africa%E2%80%99s-temperature 
Sanofi-Aventis. (2010). Artesunate Amodiaquine Winthrop ®. Retrieved from 
http://apps.who.int/prequal/WHOPAR/WHOPARPRODUCTS/MA058part1v1.pdf 
Shamsa, F., & Amani, L. (2006). Determination of Sulfamethoxazole and Trimethoprim 
in Pharmaceuticals by Visible and UV Spectrophotometry. Iranian Journal of 
Pharmaceutical Research, 31–36. 
Sigma Aldrich. (2016). Trimethoprim Lactate. Retrieved from 
http://www.sigmaaldrich.com/catalog/product/sigma/t0667?lang=en&region=US 
Sklamberg, H. (2014). Counterfeit Drugs: Fighting Illegal Supply Chains. FDA. 
Retrieved from http://www.fda.gov/NewsEvents/Testimony/ucm387449.htm 
Spiga, F. M., Maietta, P., & Guiducci, C. (2015). More DNA-aptamers for small drugs: A 
capture-SELEX coupled with surface plasmon resonance and high-throughput 
sequencing. ACS Combinatorial Science, 17(5), 326–333. 
http://doi.org/10.1021/acscombsci.5b00023 
  195 
Srisawat, C., Goldstein, I. J., & Engelke, D. R. (2001). Sephadex-binding RNA ligands: 
rapid affinity purification of RNA from complex RNA mixtures. Nucleic Acids 
Research, 29(2), E4. http://doi.org/10.1093/nar/29.2.e4 
Stoltenburg, R., Nikolaus, N., & Strehlitz, B. (2012). Capture-SELEX: Selection of DNA 
Aptamers for Aminoglycoside Antibiotics. Journal of Analytical Methods in 
Chemistry, 2012, 415697. http://doi.org/10.1155/2012/415697 
Stoltenburg, R., Reinemann, C., & Strehlitz, B. (2007). SELEX--a (r)evolutionary 
method to generate high-affinity nucleic acid ligands. Biomolecular Engineering, 
24(4), 381–403. http://doi.org/10.1016/j.bioeng.2007.06.001 
Summer, H., Grämer, R., & Dröge, P. (2009). Denaturing urea polyacrylamide gel 
electrophoresis (Urea PAGE). Journal of Visualized Experiments, (32), 3–5. 
http://doi.org/10.3791/1485 
Taylor, R. B., Shakoor, O., Behrens, R. H., Everard, M., Low,  a S., Wangboonskul, J., 
… Kolawole, J. a. (2001a). Pharmacopoeial quality of drugs supplied by Nigerian 
pharmacies. Lancet, 357(9272), 1933–6. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/11425415 
Taylor, R. B., Shakoor, O., Behrens, R. H., Everard, M., Low,  a S., Wangboonskul, J., 
… Kolawole, J. a. (2001b). Pharmacopoeial quality of drugs supplied by Nigerian 
pharmacies. Lancet, 357(9272), 1933–6. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/11425415 
Teddy Ehianeta. (2012). Quality survey of some brands of artesunate-amodiaquine in 
Lagos drug market. African Journal of Pharmacy and Pharmacology, 6(9), 636–
642. http://doi.org/10.5897/AJPP11.841 
The Associated Press. (2003). FDA uncoveres more fake Lipitor. USA Today. Retrieved 
from http://usatoday30.usatoday.com/news/health/2003-06-03-fake-lipitor_x.htm 
ThermoFisher Scientific. (2016). TOPO® TA for sequencing. Retrieved March 1, 2016, 
from https://tools.thermofisher.com/content/sfs/manuals/topotaseq_man.pdf 
Ulrich, H., Magdesian, M. H., Alves, M. J. M., & Colli, W. (2002). In Vitro Selection of 
RNA Aptamers That Bind to Cell Adhesion Receptors of Trypanosoma cruzi and 
Inhibit Cell Invasion. Journal of Biological Chemistry, 277(23), 20756–20762. 
http://doi.org/10.1074/jbc.M111859200 
United States Pharmacopeia. (2012a). Artesunate for injection. Retrieved March 1, 2016, 
from https://mc.usp.org/monographs/artesunate-for-injection-1-
0?destination=node/861 
  196 
United States Pharmacopeia. (2012b). Promoting the Quality of Medicines in Developing 
Countries, 3–4. Retrieved from 
http://www.usp.org/sites/default/files/usp_pdf/EN/aroundTheWorld/PQM/promotin
g_quality_medicines_2012-02_pqm059f_feb_2012.pdf 
United States Pharmacopeia. (2015). Tool for Visual Inspection of Medicines. Retrieved 
from https://www.fip.org/files/fip/counterfeit/VisualInspection/A tool for visual 
inspection of medicines EN.pdf 
University of Bristol. (2002). Mechanism of reaction of luminol. Retrieved March 1, 
2016, from http://www.chm.bris.ac.uk/webprojects2002/fleming/mechanism.htm 
University of Southern of Denmark. (2016). Systematic evolution of ligands by 
exponenetial enrichment. Retrieved March 1, 2016, from 
http://www.sdu.dk/en/Om_SDU/Institutter_centre/C_Evolna/Background 
Wang, Y., Li, Z., Zhang, Z., & An, D. (2004). [Applications of Raman spectroscopy in 
pharmaceutical analysis]. Yao Xue Xue Bao = Acta Pharmaceutica Sinica, 39(9), 
764–8. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15606032 
Waters. (2016). How Does High Performance Liquid Chromatography Work? Retrieved 
March 1, 2016, from http://www.waters.com/waters/en_US/How-Does-High-
Performance-Liquid-Chromatography-
Work%3F/nav.htm?cid=10049055&locale=en_US 
Wondemagegnehu, E. (1999). Counterfeit and Substandard Drugs in Myanmar and Viet 
Nam. World Health Organization. Retrieved from 
http://apps.who.int/medicinedocs/pdf/s2276e/s2276e.pdf 
World Health Organization. (1995a). WHO Model Prescribing Information – Drugs used 
in parasitic Diseases. Retrieved March 1, 2016, from 
http://apps.who.int/medicinedocs/en/d/Jh2922e/2.5.11.html 
World Health Organization. (1995b). WHO Model Prescribing Information – Drugs used 
in parasitic Diseases. Retrieved March 1, 2016, from 
http://apps.who.int/medicinedocs/en/d/Jh2922e/ 
World Health Organization. (1999a). Guidelines for the development of measures to 
combat couterfeit drugs. Retrieved from 
http://apps.who.int/iris/bitstream/10665/65892/1/WHO_EDM_QSM_99.1.pdf 
World Health Organization. (1999b). Guidelines for the development of measures to 
combat couterfeit drugs. Retrieved from 
http://www.who.int/medicines/publications/counterfeitguidelines/en/ 
  197 
World Health Organization. (2005). Counterfeit medicines: frequently asked questions. 
Retrieved March 1, 2016, from 
http://www.wpro.who.int/mediacentre/factsheets/fs_20050506/en/ 
World Health Organization. (2011a). Amodiaquine 150 mg /artesunate 50 mg tbl - 
Summary of product characteristics. World Health Organization. Retrieved from 
http://apps.who.int/prequal/whopar/whoparproducts/MA046part4v1.pdf 
World Health Organization. (2011b). Survey of the quality of selected antimalarial 
medicines circulating in six countries of sub-Saharan Africa. World Health 
Organization, 1–118. http://doi.org/WHO/EMP/QSM/2011.1 
World Health Organization. (2013a). 10 facts on malaria. Retrieved March 1, 2016, from 
http://www.who.int/features/factfiles/malaria/malaria_facts/en/index8.html 
World Health Organization. (2013b). Q&A on artemisinin resistance. Retrieved March 1, 
2016, from http://www.who.int/malaria/media/artemisinin_resistance_qa/en/. 
World Health Organization. (2013c). Substandard and counterfeit medicine. Retrieved 
March 1, 2016, from http://www.who.int/mediacentre/factsheets/2003/fs275/en/ 
World Health Organization. (2016). Substandard, spurious, falsely labelled, falsified and 
counterfeit (SSFFC) medical products. Retrieved March 1, 2016, from 
http://www.who.int/mediacentre/factsheets/fs275/en/ 
  198 
CURRICULUM VITAE 
 
EDUCATION 
Boston University College of Engineering                                                        May 2016 
Doctor of Philosophy in Biomedical Engineering                                             Boston, MA 
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SKILLS 
Histological, biochemical and molecular biology characterization: Illumina next 
generation sequencing (library preparation and data analysis); Sanger sequencing; 
multiplex real time RT-PCR; Isothermal PCR (LAMP); primer design; handling and 
processing human blood; flow cytometry; DNA/RNA and protein isolation and 
quantification; gel extraction; nucleic acid precipitation; 
Immunofluorescence/luminescence; ELISA; chromatin immunoprecipitation (ChIP); 
mammalian cell/bacteria culture; bacterial cloning 
 
Analytical techniques: HPLC, LC-MS/MS, spectrophotometer; UV/Vis spectroscopy, 
particles sizing (qNano); SDS-PAGE/Agarose gel electrophoresis of DNA, RNA and 
proteins; quartz crystal microbalance, functionalization/silanization of glass and plastic 
with nucleic acids and antibodies. 
 
Microfabrication/microfluidic training: 3D printing, soft lithography, thermal 
evaporator, chemical vapor deposition, deep reactive-ion etching , mask writer, plasma 
treatment, hot embossing, plotter cutter, laser cutter, injection mold. 
 
Microscopy: Inverted, upright, confocal, phase contrast imaging. 
 
Bioinformatics: SamTools, Genometools - Tallymer 
 
Programming: Matlab, Ampl, R 
 
Finite Element Analysis (FEA): COMSOL, NAMD, ADINA, 
 
Designing Software: AutoCAD, Adobe Illustrator, Origin Lab, FMEA. 
 
Office: Word, Excel, Powerpoint. 
 
Environment: Linux (Ubuntu). 
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Building a portable platform to detect counterfeit and substandard pharmaceuticals 
– PharmaChk - Prof. Muhammad Zaman’s lab 
Develop a Systematic Evolution of Ligands by Exponential Enrichment (SELEX) 
protocol to discover DNA aptamers bound to pharmaceuticals like antibiotics with high 
specificity and sensitivity from a DNA library of 1015 molecules. 
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pre-proposal award ($10,000)  
 
Global Health & Engineering Meet-up - symposium awards (2013) – Second place 
($150) 
 
LEADERSHIP ROLES 
Global Health and Engineering Meet-ups – Boston University         Jun 2014 - Present  
Organizer  
Invite speakers and organize monthly meet-ups and networking event; fundraise for 
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West End House Boys and Girls Club                                                 Apr 2014 - Present 
Mentor  
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technology 
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3. Sample Concentration and Purification for Point-Of-care Diagnostic 
34th Annual International Conference of the IEEE Engineering in Medicine & 
Biology Society, SanDiego, CA (2012) 
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4. Enhancing Point-Of-Care Infectious Disease Diagnostics With A Microfluidic 
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5. A Dual-Pore Microfluidic Device: A New Method For Leukemia Diagnosis 
The Biomedical Engineering Society Annual Fall Meeting, Pittsburgh, PA (2009) 
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